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THE ROLE OF COMPLEMENT IN SYNAPTIC DEGENERATION 
By Katya Malfa 
Synapse loss is an early event of many neurodegenerative diseases including 
Alzheimer‟s disease and Parkinson‟s disease. The causes and mechanisms that underpin 
synapse dysfunction and degeneration are poorly understood. Animal models that 
mimic the major disease pathologies can be used to investigate possible pathways 
involved. This work describes the use of two models based on the prion disease and 
genetic deletion of CSPα both of which are characterised by synaptic degeneration. 
  The ME7 model of prion disease is characterised by accumulation of misfolded prion 
protein, microglia activation and astrocytosis at 8 weeks post disease initiation (p.i), 
synaptic degeneration in the CA1 of the hippocampus at 13 weeks p.i, and neuronal loss 
at 16 weeks p.i.  Complement proteins have been shown to be upregulated in brains of 
patients with a neurodegenerative disease. It has been suggested that C1q is involved in 
synaptic degeneration by „tagging‟ synapses for selective removal. qRT-PCR of 18 
week p.i. hippocampus from ME7-animals reveals a >5 fold induction of C1q mRNA. 
This was confirmed by quantitative western blotting of 18 week hippocampus showing 
a disease-associated increase in C1q protein. Although C1q is induced, the time course 
and spatial expression do not coincide with the initiation of synapse loss in the CA1. 
The induction is restricted to the later stages of the disease suggesting that C1q and 
complement does not direct synapse loss but may contribute to the removal of the 
cellular debris associated with neuronal loss and/or the accumulation of misfolded prion 
protein.  
  In the second model, Cysteine String Protein α (CSPα) knockout mice were 
investigated at time points beyond the P15, when they show synapse loss, but before 
they show premature death at P40. This model allows investigation of synaptic 
degeneration in the absence of accumulated misfolded protein. We investigated this in 
the context of the hippocampus but failed to show synapse loss at the time points 
investigated. In contrast we identified a robust astrogliosis consistent with an emerging 
neuronal dysfunction. This is likely related to the loss of parvalbumin-positive 
interneurones, and synapses, previously shown to be lost at this time point.   This 
astrocytic response, in contrast to the ME7 model, occurs without the associated 
induction of C1q and other markers of the neuro-immune response. 
  Together the data show that C1q is not selectively „tagging‟ synapses as previously 
suggested, and does not contribute to the progression of prion disease. It is more likely 
that C1q is upregulated in the late stages of disease to aid in the clearance of cellular 
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Chapter 1:  Introduction 
1.1  Chronic Neurodegeneration 
Neurodegeneration is an umbrella term for the progressive loss of structure 
and/or function of neurons, leading to cell loss (Simonian and Coyle, 1996; Ross and 
Poirier, 2004). Neurodegenerative diseases are characterized by the selective loss of 
neurons, often due to aggregation of intra- or extracellular proteins (Sanghera et al., 
2008; Arendt, 2009; Rozas et al., 2010). The most common neurodegenerative diseases 
are listed in Table 1.1. 
 Degeneration of neurones is often a late-stage event which occurs after 
dysregulation of neuronal processes, and could involve the degeneration of one or more 
neuronal compartments (Jeffrey et al., 2000; LaMonte et al., 2002; Rozas et al., 2010).  
 
1.1.1  Events which Contribute to Neuronal Dysfunction 
Multiple mechanisms have been implicated in the dysfunction of neurones. 
Below I discuss some key processes that have been implicated, or shown to play a key 
role, in the neurodegenerative process. 
 
1.1.2  Mitochondrial Dysfunction 
Substantial evidence indicates that mitochondrial dysfunction is a unifying fundamental 
mechanism involved in neuronal degeneration (Beal, 1998). Mitochondrial dysfunction 
has widespread deleterious effects on cellular function including impaired energy 
production, impaired cellular calcium buffering, activation of proteases and 
phospholipases, activation of nitric oxide synthase, and generation of free radicals 
(Beal, 1998). These processes may then lead to apoptotic or necrotic cell death. 
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Table 1.1. Common neurodegenerative diseases 
Neurodegenerative diseases are characterised by neuronal degeneration and loss. 
However, this is often a late-stage event which is preceded by synaptic and neuronal 
dysfunction.  
   
Disease  Protein misfolding/ 
accumulation?  Neuronal loss  Synaptic 
loss 
Alzheimer‟s 
disease 
Aβ  Yes  Yes 
Prion disease  Prion protein  Yes  Yes 
Parkinson‟s 
disease 
α-synuclein  Dopaminergic neurons 
in the substantia nigra 
(Dauer and 
Przedborski, 2003) 
Yes 
Huntington‟s 
disease 
Huntingtin protein  Striatal medium spiny 
neurones and cortical 
pyramidal neurones 
(Rozas et al., 2010) 
Yes 
Multiple 
sclerosis  -  Lower motor neurones 
(Vogt et al., 2009)  Yes 
Glaucoma 
- 
Retinal ganglion cells 
(Garcia-Valenzuela et 
al., 1995) 
Yes 
Motoneurone 
Disease/  
amyotrophic 
lateral sclerosis 
Ubiquitin, and generally 
incorporate one of the 
ALS-associated proteins: 
SOD1, TAR DNA binding 
protein (TDP-43, or 
TARDBP), or FUS 
Upper and lower 
motor neurons in the 
motor cortex of the 
brain, the brain stem, 
and the spinal cord 
(Kerman et al., 2010) 
Yes  
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1.1.3  Excitotoxicity 
Excitotoxicity of neurones is an early stage event that may contribute to 
neuronal degeneration. Excitotoxicity is a pathological process in which excitatory 
amino acid receptors become excessively activated (Doble, 1999). Excitatory amino 
acid transmitters (EAAs), such as glutamic or aspartic acids, normally play a crucial 
role in a variety of physiological processes related to neuronal plasticity. However, 
overactivity of this EAA system can result in excitotoxic damage to neurones. This 
excitotoxic damage has been identified in the pathologies associated with epilepsy, 
ischemia, hypoxia, hypoglycemia, trauma, stroke, and Alzheimer's disease (Scallet and 
Ye, 1997; Doble, 1999). 
 
1.1.4  Oxidative Stress 
Growing evidence also points to the involvement of free radicals in mediating 
neuronal death in neurodegenerative diseases (Simonian and Coyle, 1996). Reactive 
oxygen species (ROS) are normal by-products of cellular aerobic metabolism. The main 
cellular free radicals are superoxide (O2
-) and hydroxyl (OH) that result from the 
cellular redox process from both mitochondria and other metabolic pathways. ROS can 
be both toxic and beneficial, and the delicate balance between their two antagonistic 
effects is an important aspect of life (Pham-Huy et al., 2008). At low to medium 
concentrations, ROS exerts a beneficial effect on cellular responses and immune 
function. However, at high concentrations, ROS generates oxidative stress, a deleterious 
process that can damage all cell structures (Pham-Huy et al., 2008). Oxidative stress can 
occur when the production of free radicals increases, the scavenging of free radicals 
decreases, or the repair of oxidatively modified macromolecules decreases, or a 
combination of the three. This imbalance results in the build-up of oxidatively modified 
molecules that causes cellular dysfunction, and for post-mitotic cells such as neurons, 
cell death (Simonian and Coyle, 1996). 
 
1.1.5  Abnormal Protein Handling 
Many late-onset neurodegenerative diseases are caused by the aggregation of 
proteins, and are known as proteinopathies. Protein aggregates can form in multiple cell 
compartments, including in the cytosol (e.g. Parkinson‟s and Huntington‟s disease), in 
the nucleus  (e.g. Spinocerebellar ataxia type 1 (SCA1)), within the endoplasmic 
reticulum (e.g. neuroserpin mutations that cause familial encephalopathy with  
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neuroserpin inclusion), and secreted extracellularly (e.g. accumulation of amyloid-β 
(Aβ) in Alzheimer‟s disease) (Rubinsztein, 2006).  
The primary mechanism by which proteins are degraded is via the ubiquitin-
proteosome system. Protein ubiquitination is a key step in the degradation of many 
proteins that cause proteinopathies including polyQ expansions and α-synucleins. 
Evidence suggests that proteosome enzymes may not be able to correctly cleave the 
aberrant proteins, which could cause an increase in toxic species (Rubinsztein, 2006). 
Evidence suggests that these represent early stage events that lead to dysfunction 
and eventual degeneration in a process that contributes to pathology. For example, 
mitochondrial dysfunction and oxidative stress occur in the early stages of Alzheimer‟s 
disease, which may alter APP processing, leading to an increase in Aβ accumulation. In 
addition, free radical stress increases cellular Aβ42 levels. Oxidative stress can also 
increase the activity of alpha-secretase; the enzyme responsible for N-terminal cleavage 
of β-amyloid from APP. Dysfunction of multiple processes could contribute to the 
neurodegeneration seen in the later stages (Eckert et al., 2003; Bobba et al., 2010). 
Recent data suggests that prior to neuronal degeneration, compartmental dysfunction of 
the axons, and, or synapses occurs, which contribute to the progression of chronic 
neurodegenerative diseases (Cunningham et al., 2003; Li et al., 2003; Arendt, 2009; 
Rozas et al., 2010).   
    
5 
 
1.2  Compartmental Degeneration of a Neurone 
The death of a neurone is a compartmental process, in which the degeneration of 
one or more neuronal compartments eventually causes the death of the whole neurone. 
Recent data shows that disruption of axonal transport, or synaptic transmission, are 
early stage events that occur prior to neuronal cell death (Beal, 1998; Coleman and 
Ribchester, 2004; Calabrese et al., 2005; Butler et al., 2007; Dawson et al., 2010). 
Examples of how compartmental dysfunction contributes to neuronal dysfunction and 
loss are reviewed below.  
 
1.2.1  Axonal Dysfunction and Degeneration 
In order to survive and function, cells need the appropriate localisation of 
organelles, enzymes and cytoskeletal components. This is of greater importance for 
neurones because of their extended cellular  processes which are fundamental to 
neuronal specialization and function (Guzik and Goldstein, 2004). Neurones rely on a 
long-range microtubule-dependent transport system to ensure their continued function, 
and to deliver cellular components from the cell body to the dendrites and synapses. The 
basic components of this transport system are motor proteins (dynein and kinesin) and 
the polarised microtubule tracks along which the motor proteins carry their cargo 
(Guzik and Goldstein, 2004). Axonal transport can be disrupted in multiple ways 
including damage to kinesin and cytoplasmic dynein, microtubules, cargoes, and 
mitochondria (De Vos et al., 2008), leading to disruption of intracellular processes such 
as intracellular transport, metabolism, mRNA trafficking, protein sorting and targeting 
(Buée et al., 2000; Dawson et al., 2010).  
Many major human neurodegenerative diseases, including Alzheimer's disease, 
Parkinson's disease, Huntington‟s disease and amyotrophic lateral sclerosis (ALS), 
display axonal pathologies including abnormal accumulations of proteins and 
organelles. Axonal pathology can also lead to Wallarian degeneration, as is seen in 
multiple sclerosis (Dziedzic et al., 2010). Such pathologies highlight damage to the 
axon as part of the pathogenic process (Guzik and Goldstein, 2004; De Vos et al., 
2008).  
 
1.2.2  Synaptic Dysfunction and Degeneration 
Synaptic dysfunction and degeneration  has emerged over the last 10 years as a 
key feature in many neurodegenerative diseases, such as Alzheimer‟s disease (Arendt,  
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2009), prion diseases (Cunningham et al., 2003), and Huntington‟s disease (Li et al., 
2003). Table 1.2 lists some common neurodegenerative disorders which manifest with 
synaptic dysfunction. Studying the mechanisms which lead to synaptic dysfunction in 
these diseases, could lead to the generation of therapeutic interventions which could 
prevent, or at least delay, disease progression in multiple diseases (Gillingwater et al., 
2006).  
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Table 1.2. Common neurodegenerative diseases which manifest with synaptic 
dysfunction and loss before loss of the cell body. 
Increasing evidence suggests that synaptic degeneration is an early event in many 
neurodegenerative disorders, and occurs before neurone cell body death. The 
complement system has been implicated in these neurodegenerative disorders, as a 
possible contributing factor to synaptic degeneration.  
Disease 
Does synaptic loss/ 
dysfunction precede cell body 
loss? 
Complement involvement in disease 
Alzheimer‟s disease  Yes (Lee et al., 2004; Arendt, 
2009) 
C1q decorates Aβ plaques and MAC 
formation on neurones (Alexander et 
al., 2008) 
Prion disease  Yes (Cunningham et al., 2003)  C1q decorates PrP plaques and MAC 
formation on neurones (Kovacs et al., 
2004). Complement thought to 
mediate early PrP pathogenesis (Klein 
et al., 2001; Flores-Langarica et al., 
2009) 
Parkinson‟s disease  Yes (Dauer and Przedborski, 
2003) 
Early- and late-stage complement 
proteins on Lewy bodies in the 
substantia nigra. Complement 
activation was also detected on 
melanised neurone cell bodies and 
axons (Loeffler et al., 2006) 
Huntington‟s disease  Yes (Li et al., 2003; Rozas et 
al., 2010) 
Classical complement activation is 
thought to lead to neurone death and 
clearance of cellular debris (Singhrao 
et al., 1999) 
Multiple sclerosis  Yes (Centonze et al., 2009)  Complement activation has multiple 
roles in the EAE inflammatory 
lesions, causing demyelination, axonal 
damage, and oligodendrocytes injury 
(Ingram et al., 2009) 
Glaucoma  Yes (Stevens et al., 2007)  Complement C1q upregulated and 
localised to synapses to aid their 
removal (Stevens et al., 2007) 
Motoneurone Disease/  
amyotrophic lateral 
sclerosis 
Yes (Nagao et al., 1998)  C1q is unpregulated in the activated 
microglia and neurones in the spinal 
cord and motor cortex (Sta et al., 
2011)  
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1.3  Animal Models to Investigate Synaptic Degeneration 
Human tissue available for analysis of neurodegenerative disease pathways is 
procured from post-mortem brains of patients often in the later stages of disease. This 
makes it very difficult to study the initial triggers of disease, and therefore difficult to 
find therapeutic interventions which could ameliorate the disease (Dunckley et al., 
2005). Animal models that mimic clinical and pathological components of human 
diseases provide an invaluable route for analysis of key mechanisms in the earlier stages 
of disease, and allow the investigation of therapeutic interventions (Rosenthal and 
Brown, 2007; Jucker, 2010). 
The ME7 model of prion disease is a model of a protein misfolding disorder that 
allows the investigation into the pathways that contribute to neuronal degeneration in 
the hippocampus. It is hoped that any mechanistic insights gained by studying murine 
models of protein misfolding disorders will provide an insight into the pathways which 
cause neuronal degeneration in protein misfolding diseases such as Alzheimer‟s disease, 
Parkinson‟s disease and Huntington‟s disease. Genetic models can allow the 
investigation of mechanisms that cause synaptic dysfunction, without the added 
complications of the effect of protein aggregation. A genetic deletion of cysteine string 
protein-alpha (CSPα) in mice causes a synaptic degeneration of selective synapses 
(Fernández-Chacón et al., 2004), and therefore, studying this model could provide 
insight into how and why selective synapses degenerate in neurodegenerative diseases.  
 
1.3.1  Prion Diseases 
Prion diseases, also known as transmissible spongiform encephalopathies 
(TSEs) are a family of fatal, progressive, neurodegenerative diseases that affect the 
brain and central nervous system of humans and animals alike. A defining feature of 
prion diseases is their ability to be transmitted to healthy animals (Bueler et al., 1993). 
These disorders include Creutzfeldt-Jakob disease, fatal familial insomnia, and kuru in 
humans, as well as scrapie in sheep and bovine spongiform encephalopathy (BSE) in 
cattle (Fornai et al., 2006).  
Prion diseases are characterised by vacuolation (spongiform change), neuronal 
loss, activation of microglia, proliferation of astrocytes, and the accumulation of the 
misfolded, protease-resistant prion protein (PrP
Sc), formed from the conversion of the 
normal cellular prion protein (PrP
C) (Harris and True, 2006). Clinically, prion diseases  
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are characterised by dementia and motor dysfunction (Bell and Ironside, 1993; Soto and 
Castilla, 2004; Aguzzi et al., 2008).  
Although prion diseases are uncommon, they share many disease processes with 
more common protein misfolding diseases, and therefore researching their pathology 
could aid the understanding of the mechanisms behind the more common protein 
misfolding diseases such as Alzheimer‟s disease (Fonseca et al., 2004b).  
 
1.3.2  ME7 Model of Prion disease 
The ME7 model of prion disease is an animal model of a chronic protein 
misfolding neurodegenerative disease. There is a significant synaptic loss (30%) that 
occurs before any neuronal cell death is detected (Cunningham et al., 2003). The 
temporal separation facilitates the separate investigation of mechanisms which cause 
synaptic degeneration and cell loss, and how the two may be linked. 
The ME7 scrapie prion strain is a commonly used prion agent, which principally 
targets the hippocampus (CA1) (Betmouni et al., 1999). This strain has been developed 
for use following intrahippocampal injection of prion-infected brain homogenate (ME7) 
into the dorsal hippocampus of C57BL/6 mice (section 2.1). This results in a 
progressive neurodegenerative disease with a duration of about 25 weeks post-injection 
(p.i) (Betmouni et al., 1996; Betmouni et al., 1999).  Figure 1.1 shows the location of 
the hippocampus within a mouse brain. 
The ME7 model of prion disease exhibits an innate inflammatory response at 8 
weeks p.i (post-injection), characterised by microglia activation and hypertrophied 
astrocytes around the injection site in the dorsal hippocampus, both of which increase 
with the progression of pathology. At 12 weeks p.i  microglial activation can be 
detected in the whole of the dorsal hippocampus (Betmouni et al., 1996). At 12-13 
weeks p.i there is also a loss of synapses from the stratum radiatum (Cunningham et al., 
2003). By 20 weeks p.i neuronal loss can be detected in the CA1 region of the 
hippocampus (Betmouni et al., 1999). The appearance of clinical symptoms occurs 
around 20 weeks p.i and includes a reduction in mobility, hunched posture, poor coat 
condition, and weight loss (Betmouni et al., 1996; Betmouni et al., 1999). PrP
Sc 
deposition and plaque formation can be detected in the hilus of the dentate gyrus from 8 
weeks p.i, spreading to the CA3 and CA1 regions of the hippocampus by 20 weeks p.i 
(Cunningham et al., 2003).  Disease progression of mice infected with the ME7 prion 
agent can be monitored by non-invasive behavioural assays, which are associated with  
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the functioning of the intact hippocampus (section 2.3). It has been previously shown 
that at 12 weeks p.i there is a significant increase in open field activity and a significant 
decrease in burrowing and glucose consumption (Cunningham et al., 2003).  The ME7 
model of prion disease allows the investigation of disease mechanisms in the context of 
chronic neurodegenerative diseases. 
 
1.3.3  Cysteine String Protein-Alpha 
The synaptic vesicle protein cysteine-string protein alpha (CSPα) is an essential 
synaptic chaperone present on synaptic vesicles and secretory organelles (Arnold et al., 
2004; Fernández-Chacón et al., 2004; Swayne et al., 2006).  CSPα accounts for 1% of 
total vesicle proteins, with about eight CSPα monomers per vesicle. The role of CSPα in 
synaptic function emerged with the generation of Drosophila CSP null mutants. 
Inactivation of CSP in Drosophila severely reduces viability, with only 4% of mutant 
flies reaching adulthood. The surviving adults have a paralytic phenotype, displaying 
uncoordinated, sluggish movements, spasmic jumping, and intense shaking. In addition 
the flies develop a temperature-sensitive phenotype; adult mutant flies survive 4-5 days 
at 22
oC and only one hour at 30
oC. This observation demonstrated that CSPα is 
essential for Drosophila viability, and the phenotypic abnormalities indicate a role for 
CSPα in neurotransmission.   
 
1.3.4  Genetic Deletion of CSPα  
CSPα may play a central role in some neurodegenerative diseases since genetic 
deletion of CSPα in mice and flies leads to neurodegeneration (Fernández-Chacón et al., 
2004). This suggests that CSPα function is essential for the maintenance of synaptic 
function, and that disruption of the function of CSPα leads to neurodegeneration, 
possibly through the accumulation of misfolded SNARE proteins having a neurotoxic 
effect (Chandra et al., 2005). Sequestration of CSPα by polyQ stretches of the 
huntingtin protein, blocks CSPα inhibition of N-type calcium channels, and this could 
be a factor that contributes to synaptic degeneration in polyQ-induced diseases (Miller 
et al., 2003).  
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Figure 1.1. Image of a mouse brain showing the location of the hippocampus 
Coronal section of a mouse brain showing the hippocampus and the three main 
hippocampal regions labelled; the Cornu Ammonis area 1 (CA1), the Cornu Ammonis 
area 3 (CA3), and the dentate gyrus (DG).  
Image acquired from the Mouse Brain Library, 
http://www.mbl.org/atlas170/atlas170_frame.html , section number 23. 
http://www.mbl.org/atlas170/large_plain/20.jpg was accessed on 8th October 2011.    
CA1 
CA3 
DG  Hippocampus  
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1.3.5  CSPα -/- Model 
Mice with a genetic deletion of CSPα (CSPα -/-) develop a progressive lethal 
neurodegenerative disorder. CSPα-/- mice develop normally from birth until postnatal 
day 14 (P14), when compared to heterozygous (CSPα+/-) and wildtype (CSPα+/+) 
littermate controls.  From P15, CSPα-/- mice stop gaining weight, develop progressive 
muscle weakness, synaptic degeneration, and become lethargic at P30. Knockout (KO) 
mice began to die from postnatal week 3 and no mice survive beyond 3 months of age. 
CSPα+/- and CSPα+/+ mice develop normally and show no difference in mortality or 
weight gain indicating that decreased levels of CSPα in CSPα+/- mice does not cause a 
disease phenotype (Fernández-Chacón et al., 2004). All synapses are not equally 
sensitive to degeneration, and synaptic degeneration in the CSPα knockout model 
occurs in a use-dependent fashion.  The photoreceptor ribbon synapses degenerate first 
followed by the neuromuscular junction (NMJ) and Calyx of Held synapses (Fernández-
Chacón et al., 2004; Garcia-Junco-Clemente et al., 2010). This suggests that the role of 
CSPα is more important at synapses that experience high synaptic activity, and therefore 
have a greater need for synaptic vesicle recycling. Recently, it has been shown that in 
the hippocampus, synaptic degeneration occurs in a subset of GABAergic inhibitory 
inter-neurones, the parvalbumin positive (PV+) inter-neurones (Garcia-Junco-Clemente 
et al., 2010). PV+ inter-neurones make up about 20% of total GABAergic inter-
neurones within the hippocampus, which in turn make up about 10% of total cells in the 
hippocampus (Freund and Buzsaki, 1996; Jones and Yakel, 1999; Fuchs et al., 2007) 
and are extremely fast firing, therefore consistent with the role of CSPα as a co-
chaperone at the synapse. The high synaptic activity of GABAergic interneurones 
makes them selectively more vulnerable to synaptic degeneration, when compared to 
glutamatergic synapses, which are slower firing, and do not seem to degenerate (Garcia-
Junco-Clemente et al., 2010). These recent data reinforce the suggestion that sub-sets of 
neurones are selectively vulnerable. 
 
1.4  Pathways Implicated in Synaptic Dysfunction 
Despite the increased realisation and interest, the exact mechanisms that lead to 
synaptic dysfunction, degeneration and loss during chronic degeneration are not yet 
known. In the following section, I outline several biological processes that contribute to 
synaptic degeneration. 
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1.4.1  Neuroinflammation 
There is a non-neuronal response to synaptic degeneration, characterised by the 
activation of astrocytes and microglia (McGeer and McGeer, 1995; Cunningham et al., 
2003; Liu and Hong, 2003; D'Andrea et al., 2004; Frank-Cannon et al., 2009). 
Astrocytes are a subtype of glial cell in the central nervous system (CNS), and their 
many processes envelop synapses, forming a „tripartite‟ synapse between a presynaptic 
element, a postsynaptic element, and the glial element (Araque et al., 1999). Microglia 
are a resident macrophage of the brain and spinal cord, and are the first and main 
immune defence in the CNS. Glial cells respond to very subtle changes in their 
microenvironment, for example changes in ion homeostasis, that precede pathological 
changes, as well as changes in the brain‟s structural integrity (Kreutzberg, 1996). The 
idea that microglia activation is involved in neurodegenerative diseases was initially 
based on post-mortem analysis of brains from Alzheimer‟s disease (AD) and 
Parkinson‟s disease (PD) sufferers. Reactive microglia were found to co-localise with 
neuritic plaques in the cortical regions of AD brains (Liu and Hong, 2003). Astrocytes 
also become activated in response to many CNS pathologies including stroke, trauma, 
and neurodegenerative diseases, in a process known as reactive gliosis (Pekny and 
Nilsson, 2005; Maragakis and Rothstein, 2006). 
Activation of microglia and astrocytes occur at a very early stage in response to 
disease and injury (Cunningham et al., 2003; Liu and Hong, 2003). In an inflammation-
mediated rat model of PD, maximal activation of microglia in the substantia nigra (SN) 
occurred between 1-2 weeks after the start of LPS infusion, whereas degeneration of 
nigral dopaminergic neurones did not begin until 3-4 weeks after the peak of microglial 
activation (Liu and Hong, 2003). In a mouse model of ME7 prion disease, activation of 
microglia and astrocytes can be detected 8 weeks after  i.c. injection of ME7 brain 
homogenate, synaptic degeneration occurs around 12 weeks post injection (p.i) and 
CA1 pyramidal neurone degeneration occurs around 16 weeks p.i (Cunningham et al., 
2003). 
It is thought that in neurodegenerative diseases, glial cells are able to detect early 
dysfunctional changes in the neurone and become activated in response to this 
(Kreutzberg, 1996). Synapses dysfunction at an early stage in the disease process and 
this eventually leads to the degeneration of the whole neurone (Heinonen et al., 1995; 
Cunningham et al., 2003; Wishart et al., 2006; Gray et al., 2009).  
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1.4.2  Activation of Apoptotic Pathways in Synaptic Degeneration 
Many different neurodegenerative disorders involve excessive activation of 
caspases and calpains including Alzheimer‟s, Parkinson‟s, Huntington‟s diseases and 
stroke (Mattson and Duan, 1999; Mattson, 2000; Mattson and Chan, 2002). An 
increasing number of proteins are implicated in neuronal apoptosis including caspases 
1, 2, and 3, the Bcl-2 family members Bax and Bad, prostate apoptosis response-4 (Par-
4), p53, cytochrome C, and Apaf-1 (Mattson and Duan, 1999). However recent data 
implicates the local activation of these cascades in synaptic degeneration. 
Tg2576 transgenic mice, with the human APPswe mutant allele, that is linked to 
familial Alzheimer‟s disease, develop synaptic deficits by three months of age, before 
the development of amyloid plaques and dystrophic neurites (D'Amelio et al., 2011). 
Data from whole cell extracts and synaptosomal fractions of the hippocampi revealed an 
increase in caspase-3 activity (D'Amelio et al., 2011), a mediator of programmed cell 
death (Porter and Janicke, 1999). The increased caspase-3 activity in hippocampal 
synapses led to a permanent activation of calcineurin, dephosporylation of AMPA 
receptor GluR1 subunit, and its removal from the postsynaptic density. This resulted in 
a reduction of spine density in CA1 pyramidal neurones, and an alteration in 
glutamatergic transmission, indicating that increased caspases-3 activity in Tg2576 
mice is a cause of early synaptic dysfunction (D'Amelio et al., 2011).  
 
1.4.3  Ubiquitin-Proteasome System 
The ubiquitin-proteasome system (UPS) is a major pathway for protein turnover, 
responsible for removing denatured, misfolded, damaged or improperly translated 
proteins, and for regulating turnover of normal proteins to ensure correct function of 
typical cell processes ranging from cell division to axon guidance (Wang and 
Maldonado, 2006). In the nervous system, ubiquitination plays a role in neuronal 
signalling, synapse formation and function, and may be involved in different diseases of 
the nervous system (Hegde and DiAntonio, 2002). Defects in the UPS can lead to many 
disorders, including malignancies, neurodegenerative diseases and possible systemic 
autoimmunity (Nalepa et al., 2006). 
There is increasing evidence that altered activities of the UPS are crucially 
involved in the pathophysiology of Parkinson‟s disease, Huntington‟s disease, and in 
spinocerebellar ataxia (Korhonen and Lindholm, 2004; Rubinsztein, 2006). For 
example, α-synuclein, which is mutated in some familiar forms of PD, is highly  
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enriched in presynaptic terminals and Lewy-bodies, possibly caused by a failure of its 
clearance (Spillantini et al., 1997).  
 
1.4.4  Microtubule Disorganisation 
Proteins and oligomers with a tendency to accumulate intracellulary can disrupt 
the transport mechanisms responsible for replenishing supplies to synapses. The 
disruption of microtubule integrity has been implicated in synaptic pathology related to 
early stage AD (Heinonen et al., 1995). An obvious candidate for this is the 
microtubule-associated protein tau, whose expression is altered in the aged brain and 
AD (Ballatore et al., 2007). Altered behaviour of tau, including neurofibrillary tangles, 
has been linked to decreased expression of synaptic markers in age-related diseases and 
in models of protein accumulation (Butler et al., 2007). A hippocampal slice model that 
reproduces protein accumulation, in response to lysosomal degradation, revealed that 
the induced protein accumulation is associated with transport failure and progressive 
synaptic decline, leading to a reduction in the number of synapses per neurone (Hall et 
al., 2000; Butler et al., 2007). In addition, administration of TX67, a taxol compound 
known to promote microtubule stabilisation, to hippocampal slices protected against the 
synaptic pathology associated with the lysosomal disturbance and protein accumulation 
(Butler et al., 2007). These findings indicate that disruption of the microtubule network 
can cause synaptic dysfunction.  
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1.5  Mechanisms of Synaptic Loss 
As discussed above, defects in neuronal processes contribute to synaptic 
dysfunction. How these dysfunctioning synapses are eliminated is not yet fully 
understood, and multiple mechanisms have been suggested for the physical loss of a 
synapse. 
 
1.5.1  Synaptic Stripping 
Synaptic stripping was first shown after axotomy of facial nerves. Following 
axotomy, microglia become activated and spread on the surface of motoneurones and 
are believed to actively denervate facial nerve neurones by physically separating pre- 
and postsynaptic components (Trapp et al., 2007; Yamada et al., 2008). Synaptic 
stripping is reversible because once reconnection to the target muscle is achieved, 
boutons reappear on the motoneurones and the microglia processes are withdrawn 
(Yamada et al., 2008).  
 
1.5.2  Selective Presynaptic Degeneration and Engulfment  
In the ME7 model of prion disease (section 1.3.2) synaptic degeneration occurs 
prior to cell body loss (Cunningham et al., 2003). Between weeks 12-21 after disease 
initiation there is a decrease of proteins associated with synaptic vesicles (Gray et al., 
2009). This indicates a selective loss of the presynaptic inputs that synapse onto 
otherwise intact post synaptic terminals (Gray et al., 2009).  
Siskova et al. observed a progressive curvature of the post synaptic density 
(PSD) of spines on CA1 pyramidal cells around the dark degenerating pre-synaptic 
Schaffer axon boutons during prion disease progression, and an almost complete 
envelopment of the presynaptic terminal by the PSD. It is not yet known what happens 
to the enveloped presynaptic terminal, but it appears to be a neurone autonomous 
process, with no direct involvement of glia (Siskova et al., 2009).  
 
1.5.3  Tagging of Synaptic Terminals by Complement Proteins 
During development, the formation of mature neural circuits requires the 
pruning of excess synapses. Whatever the mechanism by which they are lost either in 
development or degenerative disease, there is an important requirement for a molecular 
mechanism to ensure that only the dysfunctional and/or degenerating synapses are lost. 
The signals mediating this are poorly understood but important clues may come from  
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looking in development. A classic model of this is synapse elimination in the mouse 
retinogeniculate system (Figure 1.2); neurones in the dorsal lateral geniculate nucleus 
(dLGN) undergo synaptic refinement. Initially the dLGN neurones are innervated by up 
to ten retinal ganglion cell (RGC) axons, but by three weeks of age, each dLGN 
neurones receives only one or two inputs from RGC axons (Hooks and Chen, 2006; 
Stevens et al., 2007). It has been shown that components of the classical complement 
cascade (section 1.6), for example C1q, are present during this period, and are 
synthesised and secreted by the ganglion cells, and tag synapses for removal, possibly 
by phagocytosis by microglia, as has been proposed for synaptic stripping. C1q is also 
upregulated in the glaucomatous eye, where it could be mediating synaptic 
degeneration, and contributing to disease progression (Stasi et al., 2006; Stevens et al., 
2007).  
Accumulating evidence suggests that components of the complement cascade 
are involved in the pathogenesis of many neurodegenerative (Fischer et al., 1995; 
Singhrao et al., 1999; Klein et al., 2001; Fan and Tenner, 2004; Fonseca et al., 2004b; 
Kalliopi Stasi, 2006; Stevens et al., 2007; Flores-Langarica et al., 2009; Ingram et al., 
2009) and as such provide an attractive route through which instructive synapse loss 
may occur. 
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Figure 1.2. The role of C1q in developmental retinogeniculate segregation 
Initially the dLGN neurones are innervated by up to ten retinal ganglion cell (RGC) axons, but by three weeks of age, each dLGN neurones receives 
only one or two inputs from RGC axons. C1q is synthesised and secreted by the RGCs, and tags synapses for removal, possibly by phagocytosis by 
microglia. In C1q knockout mice, there is a lack of retinal ganglion axon refinement. 
20 
 
 
 
    
21 
 
1.6  Complement Cascade 
The complement cascade is a major component of the innate immune system 
involved in the recognition and elimination of pathogenic and unwanted host material, 
and can bind to cells undergoing apoptosis to aid in the elimination of these cells 
(Walport, 2001). It is comprised of more than forty soluble and cell surface associated 
proteins, including the complement proteins themselves, their regulators and cell 
membrane receptor targets. Complement proteins are synthesised primarily by the liver 
and are found in all body tissues and fluids. In the CNS, microglia, astrocytes, neurones, 
and oligodendrocytes can synthesise complement proteins (Alexander et al., 2008). 
However, astrocytes and microglia are the main source of complement behind an intact 
blood–brain barrier (Alexander et al., 2008).  
The complement cascade can be activated by three distinct routes; the classical, 
the alternative and the lectin pathway, depending on the specific recognition molecules 
that are activated. All three pathways converge on the assembly of the C3 convertase 
and subsequent C3 cleavage, ultimately leading to the formation of the membrane-
attack complex (MAC) (Figure 1.3). The MAC inserts itself into target membranes 
causing osmotic lysis (Avirutnan et al., 2008). Immune complexes, apoptotic cells, non-
self tissue and microbial infections are all able to activate the complement cascade, 
leading to the clearance of immune complexes and cell debris, degranulation of mast 
cells, cytokine induction, enhancement of immune responses, cell activation, lysis of 
microbes, opsonisation for phagocytosis, and chemotaxis (Woof and Burton, 2004; 
Paul, 2008). 
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Figure 1.3. The complement cascade 
The Classical Complement Cascade; C1q forms the C1 complex with C1r2 and C1s2 to 
activate the classical complement cascade, which results in the cleavage of C4 and C2 
to form C3 convertase (DeFranco et al., 2007). The Alternative complement pathway is 
activated by a low-grade cleavage of C3 in plasma. Covalent binding of C3b to 
hydroxyl groups on cell-surface carbohydrates and proteins, leads to the formation of 
the alternative pathway C3 convertase (C3bBb) (DeFranco et al., 2007). The Mannose-
binding lectin pathway is activated by the binding of the mannose-binding lectin, MBL, 
MASP-1 and MASP-2 complex to mannose groups on the surface of bacterial cells, 
leading to the formation of the C3 convertase (DeFranco et al., 2007). The membrane 
attack complex (MAC) showing the arrangement of the five complement proteins, C5b-
9. The MAC inserts itself into target membranes causing osmotic lysis. 
(http://www.bio.davidson.edu/Courses/Immunology/Students/spring2006/Dresser/YFIP
_CD59.html. Accessed on 16th March 2009). 
 
D 
A  B  C  
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1.6.1  Complement Activation and Inflammation 
Complement activation at the site of tissue damage or injury can cause damage 
via the deposition of the membrane-attack complex, and C4b and C3b which activate 
leukocytes with complement receptors on their surface. C3a and C5a can amplify tissue 
damage via the influx and activation of inflammatory cells (Walport, 2001). 
Once the complement cascade is activated, the complement proteins also have 
the ability to activate other extracellular, and eventually intracellular, signalling 
pathways. For example, activation of C3 can cause the release of tumour necrosis 
factor-alpha (TNFα). TNFα is a cytokine involved in systemic inflammation and 
stimulates the acute phase reaction. The primary role of TNFα is to regulate immune 
cells, but it is also able to induce cell death by apoptosis, and inflammation. Binding of 
TNFα to its receptors, TNF-R1 (expressed on most tissues) and TNF-R2 (expressed on 
immune cells), causes synthesis of downstream proinflammatory cytokines such as IL-1 
and IL-6, which can cause an upregulation of complement protein synthesis, and IL-18, 
facilitating and amplifying inflammation (Wajant et al., 2003). Activation of the 
complement cascade can lead to cell death either through the assembly of the MAC 
complex and opsonisation by C3a and C5a, or through cytokine signalling leading to the 
activation of caspase 3, the effector protein responsible for the downstream function of 
apoptosis (Alexander et al., 2008). 
   
1.6.2  Complement and Alzheimer's Disease 
AD is characterised by accumulated extracellular amyloid-β (Aβ) plaques, 
intracellular neurofibrillary tangles (NFT) composed of hyperphosphorylated tau, 
synaptic dysfunction and neuronal loss (Fonseca et al., 2004a; Fonseca et al., 2004b; 
Alexander et al., 2008; Arendt, 2009). The presence of morphologically activated 
microglia and astrocytes suggests the development of a local, chronic inflammatory 
response, which could involve the complement system (Fonseca et al., 2004b). 
Since the 1980‟s, studies of  complement proteins in AD brains have found them 
in association with Aβ plaques, and in vitro studies have shown that β-sheet fibrils of 
Aβ are able to activate the classical and alternative complement cascades, through the 
interaction of C1q in the C1 complex, and directly through C3 (Fischer et al., 1995; Rus 
et al., 2006). Synthesis of all complement proteins are upregulated in AD, as well as in 
animal models of AD. In addition, NFT have been shown to be „coated‟ or opsonised 
with C1q (Salminen et al., 2009). Activation of the complement cascade leads to the  
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generation of C3a and C5a, which are chemotactic for microglia and astrocytes, and 
both glial cells have been shown to be associated with Aβ plaques (Tenner and 
Pisalyaput, 2008). This is consistent with a role for complement proteins in the 
inflammatory event associated with AD, which could exacerbate cognitive decline and 
neuronal loss. 
Several mouse models have shown that C1q and C3 are found associated with 
fibrillar Aβ plaques (Shen and Meri, 2003; Fonseca et al., 2004b; Alexander et al., 
2008). APP transgenic mice crossed with mice containing a targeted deletion of C1q 
(Botto et al., 1998) had similar total amyloid and fibrillar Aβ in the frontal cortex and 
hippocampus when compared to C1q sufficient mice. However, C1q deficient mice had 
significantly less (~50%) astrocyte and microglia activation, and showed a 50-65% 
decrease in the loss of synaptophysin, indicating a reduction in the synaptic loss, in the 
CA3 region (Fonseca et al., 2004b; Alexander et al., 2008). In addition, the MAC has 
been found in association with plaques, and dysfunctional neurones (McGeer and 
McGeer, 1995). These observations are consistent with a detriment role of C1q and 
complement activation in a mouse model of AD (Figure 1.4). However, there is also 
evidence to suggest that C1q could provide a protective effect in the earlier stages of 
disease. 
C1q has been shown to bind to apoptotic cells or neuronal blebs for rapid 
removal by microglia, therefore preventing the release of neurotoxic levels of 
intracellular components, for example glutamate. Furthermore, addition of C1q to the 
media of primary rat and mouse neurones protects neurones against toxicity induced by 
Aβ and serum amyloid protein (Alexander et al., 2008). This demonstrates that C1q 
could play a protective role in the early stages of disease by enhancing the clearance of 
both fibrillar proteins and cellular debris. 
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Figure 1.4. Complement activation in Alzheimer's disease. 
Complement (C‟) activation by Aβ plaques and NFT leads to the activation of microglia 
and astrocytes, and the insertion of the MAC in neurones, leading to neuronal damage 
and death. Adapted from (Tenner and Pisalyaput, 2008). 
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1.6.3  The Role of Complement in other Neurodegenerative Diseases 
Complement has been involved in the pathogenesis of many neurodegenerative 
diseases (Table 1.2). In PD, multiple complement proteins have been found associated 
with Lewy bodies (Loeffler et al., 2006). 
Activated components of the classical complement pathway have been observed 
in the serum, cerebrospinal fluid and neuronal tissue of individuals suffering from 
motoneurone disease. In addition, motor neurons and spinal cord tissue from SOD1 
transgenic mice show an upregulation of C1q mRNA transcript and protein, in some 
cases prior to disease onset (Saxena et al., 2009; Woodruff et al., 2009). 
There is a growing list of cellular and soluble immune mediators that have been 
shown to contribute to the pathogenesis of MS, or its experimental mouse model, 
experimental autoimmune encephalomyelitis (EAE) (Nataf et al., 2000; Alexander et 
al., 2008; Tenner and Pisalyaput, 2008). 
Stevens et al (2007) have shown that C1q is significantly upregulated in the 
retinas of DBA/2J (a mouse model of glaucoma) mice at the early stages of glaucoma, 
before significant RGC loss (Stasi et al., 2006; Alexander et al., 2008). Consistent with 
these findings, C1q mRNA and protein are upregulated in the retina of mouse, primate 
and human glaucomatous eyes (Stasi et al., 2006). This locally induced C1q could then 
bind to the RGCs causing cell death (Stasi et al., 2006). 
The above shows a clear role for complement proteins in the pathological 
process of many neurodegenerative diseases. This suggests a mechanism whereby 
synaptic dysfunction causes activation of astrocytes, and possibly microglia, causing 
them to express a signal which causes induction of complement proteins in neurones. 
Complement proteins could then „tag‟ the synapses for elimination by activated 
microglia (Alexander et al., 2008), as well as aiding in the clearance of debris and 
misfolded proteins (Nauta et al., 2004; Blanquet-Grossard et al., 2005; Alexander et al., 
2008; Erlich et al., 2010). 
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1.7  Aims 
The aim of this project was to investigate possible mechanisms that are involved 
in synaptic degeneration. This will focus on the role of the innate immune system and 
the complement cascade. Here we use two mouse models to examine possible 
involvement of the complement system. The ME7 model of prion disease that has a well 
defined synaptic loss associated with premature death of the neurone, and the CSPα 
model in which mice are genetically induced to develop synaptic degeneration resulting, 
in premature death.  
The complement system has been implicated in many neurodegenerative 
diseases and could provide a conserved mechanism of disease progression. The project 
will focus on establishing and characterising these two. Following this, the temporal and 
spatial expression of cellular and molecular components of the innate immune system, 
with a particular focus on complement, will be characterised and compared to the 
synaptic loss seen in these two models. Finally, the hypothesis that C1q and the 
complement cascade initiate and/or drive synaptic loss and other degenerative processes 
will be investigated with the use of C1q knockout mice.   
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Chapter 2:   General Methods 
2.1  Surgery 
All procedures were carried out under a UK Home Office licence and in 
accordance with the Animals (Scientific Procedures) Act, 1986. For the prion 
experiments, mice were purchased from Harlan Ltd (UK) and were housed in groups of 
5 or 10 at an ambient room temperature of 21±2
oC on a standard 12 hour:12 hour light-
dark cycle. Food (RM-1, Special Diet Services, UK) and water were provided ad 
libitum. Mice were allowed to acclimatise for two weeks prior to undergoing any 
surgical procedure. 
C57BL/6 and BALB/C mice, between 8-10 weeks were intra-cranially (i.c) 
injected with either ME7 prion homogenate (ME7) or normal brain homogenate (NBH). 
Each mouse was anaesthetised with 0.1ml/10g body weight of a ketamine/xylazine mix, 
and placed in a heated chamber until no pedal withdrawal reflex was detected. The 
mouse was then mounted in a stereotaxic frame (David Kopf Instruments, USA); the 
scalp cut open and the skull exposed. Burr holes were drilled on either side of the 
midline at coordinates -2.0mm from Bregma, ±1.7mm bilateral, and -1.6mm deep, to 
allow the injection of 1µl of brain homogenate (10% w/v in sterile PBS) of either 
normal brain homogenate (NBH) or ME7 scrapie infected brain (ME7). Injections were 
made using a 10µl Hamilton syringe. The scalp was stitched up (Ethicon, USA) and the 
mouse was placed in a heated recovery chamber at 37
oC. When mice had regained their 
righting reflex they were re-housed in groups of 5 or 10. 
Mice which had been injected with ME7 brain homogenate will be referred to as 
ME7-animals and mice injected with NBH will be referred to as NBH-animals. Mice 
which had not undergone any surgery will be referred to as naive animals. 
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2.2  Animal Husbandry 
CSPα wildtype (WT) and heterozygous (HZ) mice were bred in-house to obtain 
CSPα knockout (KO) mice. Litters resulting from CSPα heterozygous crosses were 
separated by sex at postnatal day 21 (P21) and housed according to Home Office 
regulations on a 12 hour light:dark cycle. Mice were given water and food (RM-1, 
Special Diet Services, UK) ad libitum. Mice were identified by ear punches (Appendix 
7.6). 
 
2.3  Behavioural Tests 
From week 9 post surgery, the behaviour of groups of NBH- and ME7-animals 
(C57BL/6 and BALB/C) were tested weekly. Burrowing was measured after two hours 
and/or overnight, and glucose consumption was measured overnight. 
 
2.3.1  Burrowing Behaviour 
Plastic burrowing tubes, with an elevated „foot‟ at the open end, were filled with 
200g of normal food pellets. A tube was placed in each individual mouse cage, and the 
amount left after the experimental period was weighed and recorded. Training was 
required for two weeks prior to the start of the testing period, allowing mice to explore 
the burrowing tubes and become accustomed to digging out the food pellets. Each 
training week, two burrowing tubes, each filled with 200g of food pellets, were placed 
overnight into a cage containing between 5-10 mice. To assess the burrowing 
behaviours, mice were placed individually in cages and were given one burrowing tube 
each, containing 200g of food pellets. After approximately 16 hours, the food remaining 
inside the burrowing tube was weighed. The weight of the food removed from the 
burrowing tube, or burrowed, was recorded as a measure of a mouse‟s burrowing 
behaviour. The changes in the amount burrowed was tracked on a weekly basis to 
determine disease progression (Cunningham et al., 2003). Mice were then re-housed to 
their original cage if female, or re-housed separately if male. 
 
2.3.2  Glucose Consumption Test 
Normal drinking water was substituted for pre-weighed bottles containing 5% 
glucose. The bottles were re-weighed the following morning and the amount of glucose 
consumed was recorded, and tracked on a weekly basis. The glucose consumption test 
was performed at the same time as the overnight burrowing.  
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2.3.3  Inverted Screen Test 
The inverted screen test was performed after the overnight burrowing test. Mice 
were placed back into their home cages and left to habituate for 30 minutes before the 
test was conducted. Mice were placed on a 30 x 30 cm wire mesh screen elevated 80cm 
above the floor. A tray with flat sponges was placed underneath to protect mice if they 
fell off. The screen was inverted by 180
o and the length of time the mouse held on, up to 
60 seconds, was recorded.  
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2.4  Breeding of CSPα Heterozygous mice to produce CSPα Knockout 
Mice 
CSPα +/- male and female mice were received as a generous gift from Rafael 
Fernández Chacón, Spain. Heterozygous male/female pairing should produce 50% 
heterozygous pups (+/-), 25% wild-type pups (+/+) and 25% knockout pups (-/-) in a 
Mendelian pattern; however, this was rarely observed and some litters were born with 
no CSPα -/- mice. This implies that a genetic deficiency of CSPα prenatally is lethal in 
some pups or puts them at a severe disadvantage to other pups. Trio pairings of two 
female CSPα +/- and one male CSPα +/- were mated to produce litters. The genetically 
different mice have no discernable phenotypic differences at birth, however, CSPα-/- 
mice can be distinguished from CSPα +/+ and CSPα +/- mice after P16 as they fail to 
gain weight (Figure 2.1). Litters were genotyped before tissue was collected. CSPα -/- 
mice develop progressive muscle weakness and display a typical leg position of 
“inverted champagne bottles” (Fernández-Chacón et al., 2004). CSPα -/- become 
increasingly lethargic and disabled, therefore litters which have CSPα -/- pups were 
given high protein food pellets soaked in water to make it easier for the CSPα -/- mice 
to eat, and were given water bottles with longer nozzles so that the CSPα -/- mice did 
not need to reach as far to drink, allowing them to maintain their body weight for 
longer. CSPα-/- mice were kept until their weight fell to below 80% of their littermates 
(as stated in the project and personal licences). 
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Figure 2.1. Characterisation of weight gain of CSPα wildtype, heterozygous and 
knockout mice. 
Body weights of CSPα wildtype (WT), heterozygous (HZ), and homozygous knockout 
(KO) mice. CSPα WT and HZ mice gain weight at the same rate. CSPα KO mice 
initially gain weight at the same rate as CSPα WT and HZ mice, however, after P14-P15 
CSPα KO mice fail to gain weight (Fernández-Chacón et al., 2004). 
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2.5  Tissue Harvesting 
2.5.1  Perfusion and Tissue Fixation 
Mice were terminally anaesthetised with 300μl rat avertin (2,2,2-tri-bromo-
ethanol in tertiary amyl alcohol). Once the pedal reflex disappeared, the mice were 
pinned ventral side up, the abdomen and thoracic cavity where exposed, and the 
diaphragm cut. A butterfly needle (27-gauge, Venisystems, Eire) was inserted into the 
left ventricle and the right atrium was cut. The mice were perfused with heparinised 
saline (0.9% saline containing 5000U/L heparin, 14ml/min) until the perfusate ran clear. 
If required, mice were then perfusion-fixed with 10% neutral buffered formalin. Organ 
samples were collected, if needed, then the skull was cut open and the brain removed. 
All non formalin-fixed samples collected were kept at -20
oC for short-term or -80
oC for 
long-term storage. 
 
2.5.2  Post Fixation 
Formalin-fixed brains were post-fixed in fresh 10% formalin for 2-3days at 4
oC. 
The tissue was then dehydrated through a series of increasing ethanol concentrations 
(70%, 70%, 80%, 90%, absolute ethanol x 3, each for 2 hours), immersed in histoclear 
(National Diagnostics, UK) for 8 hours, then submerged in paraffin wax (Polywax, UK) 
at 60
oC for 4 hours. Brains were then embedded in fresh wax and allowed to cool. Wax 
blocks were stored in an airtight box at room temperature. 
 
2.5.3  Hippocampal Collection 
Post-perfusion and formalin fixation, the top of the skull was opened by cutting 
along the midline of the skull and peeling the skull away from the brain, and the whole 
brain removed. The cerebellum and forebrain were removed; the cortices were folded 
down towards the olfactory bulb, exposing the hippocampus. Incisions were made at the 
outer ends of the hippocampus, allowing it to be rolled out away from the cortex and 
detached. Tissue was snap frozen and stored at -80
oC until use. 
 
2.5.3.1  Hippocampus Microdissection 
In order to microdissect the hippocampus into CA1, CA3 and dentate gyrus, the 
hippocampus was removed from the brain as described in section 2.5.3. The dentate  
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gyrus and CA1 were removed and the remaining tissue was taken as CA3. All 
microdissected tissues were snap-frozen and kept at -80
oC until use. 
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2.6  Tissue Processing 
2.6.1  RNA Extraction 
Total RNA extraction was carried out using Qiagen RNeasy Minikit (Qiagen, 
UK), according to manufacturer‟s instructions. The RNA was eluted in 55μl nuclease 
free water (Ambion, USA).  
 
2.6.1.1  Quality of Extracted RNA 
Total RNA was analysed using a NanoDrop spectrophotometer (ThermoFischer 
Scientific, UK) to determine the concentration and quality. 1μl of RNA was placed on 
the NanoDrop pedestal and its absorbance measured. The NanoDrop was „blanked‟ 
using nuclease free water. The ratio of the absorbance at 260nm and 280 nm was used 
to assess RNA purity. Pure RNA has an A260/A280 of ≥ 2.0. 
 
2.6.2  cDNA Synthesis 
800ng of total RNA (section 2.6.1) was reverse transcribed into cDNA using the 
iScript Select cDNA Synthesis Kit (Bio-Rad) in a 40μl reaction, according to 
manufacturer‟s instructions, as follows: 
 
 
 
 
 
 
The reactions were incubated on a thermocycler (GeneAmp PCR System 9700, 
Applied Biosystems) at the following conditions and the cDNA product was kept at -
20
oC. 
   
5x iScript Select Reaction Mix  8µl 
Oligo(dT)20 Primer   4µl 
iScript Reverse Transcriptase  2µl 
RNA sample (1pg to 1µg total RNA)  Variable 
Nuclease-free Water  Variable 
60 minutes  42
oC 
5 minutes  85
oC 
Hold  4
oC  
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2.7  Polymerase Chain Reaction 
2.7.1  Primer Design 
Forward and reverse primer sequences (Table 2.1) were designed and then 
ordered from Sigma Aldrich, UK. Primers were designed using the following criteria; 
17-25 bases in length, a GC% between 50-60%, melting temperatures of between 55-
80
oC, no self- complementarity, and avoiding runs of three or more Cs or Gs at the 3'-
end of primers. Genes of interest were aligned using Kalign (European Bioinformatics 
Institute) to determine the position of the introns. Short, 18-23 nucleotides, forward and 
reverse sequences were designed to amplify a fragment of at least 100 base pairs and 
where possible spanned at least one intron. Preferred sequences were entered into 
OligoCalc, (http://www.basic.northwestern.edu/biotools/oligocalc.html), to calculate the 
melting temperature, GC% content, and self-complementarity (hairpin structures etc), to 
ensure each set of primers had similar melting temperatures and GC% content. Primers 
which had a GC% which was too high or low, with an incorrect melting temperature or 
had hair-pin or secondary structures were rejected. Forward and reverse primer pairs 
were only accepted if their melting temperatures were within 3
oC of each other.  
In order to determine the cycling parameters of each primer pair a test PCR was 
conducted using the primers. The annealing temperature, extension time, and cycle 
numbers were determined for each primer pair. A standard curve using primer specific 
plasmids (section 2.10.8) was generated. If the standard curve was robust and 
reproducible then the cycling parameters were accepted. 
The annealing temperature (TA) for a specific primer pair depends on the length 
and composition of the primers. On average, an annealing temperature about 3°C below 
the lowest melting temperature (TM) of the pair of primers was used. To calculate the 
extension time, the general rule of one minute per kb was adopted. For products less 
than one kb, an extension time of 30–60 seconds was used depending on the outcome of 
the optimisation PCRs. Table 2.2 lists the optimised cycling parameters for each primer 
pair used.  
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Table 2.1. Forward and reverse sequences of the oligonucleotide primers showing 
the difference in mRNA and genomic DNA product size.Gene and mRNA sequences 
for each gene were aligned using Kalign (NCBI) to find the position of the introns. 
Short sequences, 16-23 nucleotides in length, were chosen either side of an intron to 
ensure that the amplification product was not a result of contamination. Suitability of 
the primer sequence was determined using Oligo Calc. 
   
Primer 
mRNA 
product 
size 
Genomic 
DNA 
product 
Size 
C1qA  
FWD  5‟-TCAAAGGAGAGAGAGGGGAG-3‟ 
163  1109 
REV  5‟-TGCCTGGATTGCCTTTCACG-3‟ 
C1qB 
FWD  5‟-CCAGGGATAAAGGGGGAGAA-3‟ 
177  1434 
REV  5‟-TTCTGTGTAGCCCCGTAGTC-3‟ 
C1qC 
FWD  5‟-ATGTGGACTTTGCCTGCTGC-3‟ 
185  1964 
REV  5‟-CTCGCCCTTCTGACCCTT-3‟ 
GAPDH 
FWD  5‟-TGAACGGGAAGCTCACTGG-3‟ 
307 
REV  5‟-TCCACCACCCTGTTGCTGTA-3‟ 
C1r 
FWD  5‟-GCAACTACAGCATCCGGGTG-3‟ 
176  384 
REV  5‟-GGTGTCAAGGTCTGGAGGCCT-3‟ 
C1s 
FWD  5‟-GGGAGATGGGTAAATGACCAGC-3‟ 
210  1010 
REV  5‟-AACGTGAGCAGCCGTCAGCAC-3‟ 
IL-1ß 
FWD  5‟-CAGACCCACCCTGCA-3‟ 
68  789 
REV  5‟-ACCGTTTTTCCATCTTCTTCTT-3‟ 
IL-6 
FWD  5‟-CGCTATGAAGTTCCTCTCTGC-3‟ 
135  300 
REV  5‟-GGTCTGTTGGGAGTGGTATC-3‟ 
TNFα 
FWD  5‟-CTCCAGGCGGTGCCTATG-3‟ 
149  665 
REV  5‟-GGGCCATAGAACTGATGAGAGG-3‟ 
IL-10 
FWD  5‟-GTGGAGCAGGTGAAGAGTGA-3‟ 
231  1852 
REV  5‟-CGAGGTTTTCCAAGGAGTTG-3‟  
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Primer  Primer 
TM (
oC) 
PCR TA 
(
oC) 
Product 
Size (bp) 
Extension 
Time (s) 
Cycle 
Number 
C1qA FWD  62.5 
61  163  30  35 
C1qA REV  70.5 
C1qB FWD  66.0 
61  177  30  40 
C1qB REV  61.7 
C1qC FWD  67.6 
61  185  30  35 
C1qC REV  64.4 
GAPDH FWD  66.5 
58  307  60  35 
GAPDH REV  66.6 
C1r FWD  67.8 
65  176  30  35 
C1r REV  68.8 
C1s FWD  67.5 
65  210  30  35 
C1s REV  72.1 
IL-1β FWD  60.4 
62  68  30  35 
IL-1β REV  61.7 
IL-6 FWD  63.0 
61  135  30  40 
IL-6 REV  60.9 
TNFα FWD  66.9 
62  149  30  35 
TNFα REV  65.8 
IL-10 FWD  63.2 
59  231  30  40 
IL-10 REV  63.5 
Table 2.2. PCR primer specific cycling parameters. 
Each primer pair was optimised to determine the appropriate cycling parameters. As an 
indication, an annealing temperature (TA) of 3
oC below the lowest melting temperature 
(TM) of the primer pair was used, and an extension time of either 30seconds (below 
300bp) or 60seconds (above 600bp). A cycle number of 35 was used unless the 
optimisation PCR identified a need for a higher cycle number. 
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2.8  REDTaq PCR 
REDTaq ReadyMix PCR Reaction (Sigma, UK) was used as supplied by the 
manufacturer in 25µl reactions as follows: 
REDTaq ReadyMix  12.5µl 
Forward Primer (0.1-1.0µM, 15-30 bp)  1µl 
Reverse Primer (0.1-1.0µM, 15-30 bp)  1µl 
Nuclease-free Water  9.5µl 
Template cDNA  1µl 
The reaction was incubated (GeneAmp PCR System 9700, Applied Biosystems) 
using the following cycling parameters. Cycling parameters indicated in bold were 
adjusted, as indicated, in order to optimise conditions for the primers in Table 2.1. 
 
 
 
 
 
 
PCR products were stored at 4
oC short-term and -20
oC long-term, and were 
separated by agarose gel electrophoresis (section 2.9), if required and to check for 
genomic contamination (Figure 2.2). 
 
2.8.1  PCR Product Purification 
PCR products were purified using QIAquick PCR Purification Kit (Qiagen, 
UK), according to manufacturer‟s instructions. The PCR products were not confirmed 
by sequencing until they were inserted into plasmids (Section 2.10) 
   
Initial denaturation  2 minutes  94
oC 
Denaturation   40 seconds  94
oC 
Annealing  30 seconds  61
oC 
Extension  40 seconds  72
oC 
Final Extension  10 minutes  72
oC 
35 cycles  
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Figure 2.2. C1qA, C1qB and C1qC REDTaq PCR products separated on a 2% 
agarose gel showing the band sizes for each of the amplification products.  
cDNA was amplified using REDTaq (section 2.8) and 12.5µl of the product products 
was separated on a 2% agarose gel along with 5µl 1kb+ Standard Ladder (Biorad, UK) 
(see section 2.9). The bands are clean and no primer dimers can be seen. In addition, no 
high molecular weight bands are visible, which indicates there was no amplification of 
contaminating genomic DNA. 
A. C1qA FWD and REV primers 
B. C1qB FWD and REV primers 
C. C1qC FWD and REV primers 
M: 1kb+ Standard Ladder 
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2.8.2  Quantitative Real Time Polymerase Chain Reaction 
Quantitative real time PCR (rt-PCR) was performed using iQ SYBR Green 
(Biorad, UK). Direct detection of PCR products was monitored by measuring the 
increase in fluorescence caused by the binding of SYBR Green dye to dsDNA. iQ 
SYBR Green Supermix was used as supplied by the manufacturer, in 25µl reactions as 
follows: 
 
 
 
 
 
 
Standard curves were constructed using 10
14-10
9 plasmids/µl, see section 2.10, 
and were sampled alongside cDNA derived from mRNA of either NBH or ME7-
injected animals. The reactions were incubated in a Chromo 4 DNA Engine 
thermocycler (Bio-Rad), running Opticon Monitor v3.1.32 software, using the following 
cycling conditions: 
Initial denaturation  10 minutes  94
oC 
Denaturation   1 minute  94
oC 
Annealing  30 seconds  61
oC 
Extension  30 seconds  72
oC 
Final Extension  10 minutes  72
oC 
PCR products were stored at 4
oC short-term and -20
oC long-term, and were 
separated with agarose gel electrophoresis; see section 2.9, if required. Figure 2.3 shows 
the raw data obtained from the Opticon Monitor software. The sigmoid curves for each 
duplicate dilution should overlap each other, and in the case of a standard curve the 
spacing between the curves for each dilution should be even indicating a good serial 
dilution of the plasmids. For SYBR Green based amplicon detection it is important to 
run a melting curve after the real time PCR. This is because SYBR Green will detect 
any double stranded DNA including primer dimers, contaminating DNA, and PCR 
products from mis-annealed primers, as well as the desired amplification product. 
Looking at the melting curve ensures that only the desired product was detected. A 
single peak on the melting curve indicates that only the desired product has been 
amplified. A typical melting curve is shown in Figure 2.4. 
iQ SYBR Green Supermix  12.5µl 
Forward Primer (100nM-500nM)  1µl 
Reverse Primer (100nM-500nM)  1µl 
Nuclease-free Water  9.5µl 
Template DNA  1µl 
40 cycles  
46 
 
To ensure that the quantification of the cDNA sampled was within the linear 
range of calculations, samples are compared to the standard curve. This required that the 
standard curve shows a linear relationship between Ct value and cycle number. This was 
determined by plotting the log of the number of plasmids/µl versus the Ct value. A 
linear regression line was fitted and the r
2 value calculated. Standard curves were 
considered linear as long as the r
2 ≥ 0.95 (Figure 2.5). The Ct value is the cycle number 
at which the florescence crosses the threshold (normally one standard deviation) and 
indicates the amount of mRNA of the gene of interest, present in the original sample. 
The higher the Ct values the lower the amount of mRNA in the original sample. 
 
2.8.2.1  Data Preparation and GAPDH Normalisation 
All samples analysed by rt-PCR were normalised to GAPDH reference gene 
(Figure 2.6), as the levels of GAPDH are not altered with disease, to correct for sample 
to sample variations in rt-PCR efficiency and errors in sample quantification, allowing 
for direct comparison of samples from different mice.  
Data obtained from the Opticon Monitor software was copied into Excel 
(Microsoft, USA), and then the average Ct number of each duplicated value was 
calculated. Firstly, a graph was plotted of log10(plasmid number) versus the average Ct 
values from the standard curve. A linear regression line was fitted to find the equation 
of the line (y=mx + c) and the r
2 value. Using the equation from the linear regression 
line, arbitrary units for each of the sample Ct values were calculated using the following 
calculation: AU = (Ct – c)/m. The data is then transformed to find the power, 10
AU. 
Data can be normalised by dividing the power of the chosen gene by the power of 
GAPDH for each sample. 
 
2.8.2.2  Quantification 
After GAPDH normalisation, the values for each sample were plotted on a graph 
to determine whether any changes could be seen between the samples being analysed.  
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Figure 2.3. Raw data readout from qt-PCR of C1qA plasmid standard curve using 
1x10
14–1x10
9 plasmid/µl. 
The Ct value is the cycle number at which the florescence crosses the threshold (dashed 
line), and indicates the amount of mRNA in the original sample. The higher the Ct 
values the less mRNA in the original sample. The readout showed duplicate sample 
values were very similar and the equal spacing between the sigmoid curves shows that 
the dilutions of the plasmid standard curve were good.  
 
 
 
 
Figure 2.4. Melting curve for C1qA plasmid standard curve. 
Typical melting curve from a rt-PCR. It is apparent from the single, neat peak, that there 
were no contaminating products present in the reaction. Contaminating DNA or primer 
dimers would produce an additional peak separate from the desired amplicon peak. 
 
 
 
Sigmoid curves from left to 
right represent the following 
plasmid numbers: 
1x10
14, 1x10
13, 1x10
12, 1x10
11, 
1x10
10, And 1x10
9. The lines 
running under the threshold are 
blanks, containing no plasmids. 
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Figure 2.5. Linear regression line showing the reliability of a C1qA plasmid 
standard curve. 
Plasmids were generated as described in section 2.10 and after plasmid numbers were 
calculated, a standard curve was generated using 10
14-10
9 plasmids/µl. These are 
amplified by qt-PCR and the Ct values, calculated by the Opticon Monitor software, are 
plotted against log10(plasmid number). A linear regression line is fitted and the r
2 value 
noted. A r
2≥0.95 indicates a reliable standard curve. 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.6. Raw data obtained from Opticon Monitor showing Ct values for 
GAPDH rt-PCR on 13week p.i NBH and ME7 mice. 
Hippocampal cDNA from 13 week p.i NBH and ME7 mice, a time point at which the 
disease is well established and synaptic degeneration is occurring, shows that the Ct 
values for both NBH and ME7 mice are very similar indicating that GAPDH levels do 
not change depending on the disease status of the mouse. 
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2.9  Agarose Gel Electrophoresis 
Agarose gels, containing ethidium bromide, were used to separate PCR 
products, from NBH- or ME7-animals, based on size. Agarose gels were made by 
dissolving agarose (Sigma, UK) in either 50ml Tris acetate (TAE-1X)(small gel), or 
150ml TAE-1X (large gel), and heating in a microwave until molten. The TAE was 
diluted from a 50X stock (Appendix 7.2.1). The molten agarose was allowed to cool 
slightly before addition of 2.5µl or 7.5µl ethidium bromide (10mg/ml, Sigma, UK) 
respectively, and was then poured into a casting mould and allowed to set before 
placing into an electrophoresis chamber containing 1X TAE. Samples were mixed with 
6x loading buffer (Appendix 7.2.2) to obtain a 1X final concentration and 12µl of each 
sample was loaded into the wells along with a molecular marker (Trackit 1kb plus DNA 
ladder, Invitrogen, UK).  Small gels were run at 80V and large gels were run at 100V 
for one hour. 
 
2.10 Generation of Plasmids Containing the Gene of Interest 
Purified PCR products (section 2.8.1), were cloned into a PCR-II vector and 
transformed into chemically competent TOP10 Cells, allowing the generation of 
plasmid standard curves with specific plasmid numbers to be used during rt-PCR 
(section 2.8.2). 
Two different methods were used to clone the PCR fragment into the PCR-II 
vector. One makes use of blunt end PCR products whereas the second method requires 
PCR products with A-overhangs. 
 
2.10.1 TA Dual Promoter Kit for Cloning 
TA Dual Promoter Kit (Invitrogen, UK) was used according to manufacturer‟s 
instructions. This method requires PCR products with A-overhangs. A stock of inserts 
was generated by amplifying cDNA containing the gene of interest, then purifying the 
PCR reaction with QIAquick PCR Purification kit (Qiagen, UK) according to 
manufacturer‟s instructions (section 2.8.1).  
 
2.10.2 Ligation 
Each 10μl ligation reaction contained the following kit reagents. The ligation 
reaction was incubated at 14
oC in a water bath (JB aqua 5, Grant) for 4 hours.  
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2.10.3 Zero Blunt TOPO PCR Cloning Kit 
The Zero Blunt TOPO PCR Cloning Kit (Invitrogen, UK) was used according to 
manufacturer‟s instructions. This kit requires PCR products with blunt ends. 
 
2.10.3.1 Ligation 
Each 6μl reaction will contain the following kit reagents. After gently mixing 
the reaction was incubated at room temperature (22-23
oC) for 5 minutes. 
 
 
 
 
 
 
 
2.10.4 Transformation into Chemically Competent TOP10 cells 
The eppendorfs containing the ligation reactions were briefly centrifuged 
(Eppendorf, UK) and 3μl ligation solution was added to a vial of chemically competent 
TOP10 cells, and incubated on ice for 20minutes. The cells were then heat shocked at 
42
oC for 30 seconds and returned immediately to ice. 250μl pre-warmed (37
oC) LB 
broth was added to each vial, followed by incubation at 37
oC for 1 hour with shaking. 
50μl of the resultant broth is streaked onto LB agar plates (containing 50μg/ml 
kanamycin (Sigma, UK) and 40mg/μl X-gal (Fisher Scientific, UK). The plates were 
incubated overnight at 37
oC and placed at 4
oC for a few hours to allow for colour 
development. 
 
2.10.5 Colony Selection  
Ten white or light blue colonies were picked and allowed to grow up overnight 
in 4ml LB broth containing 50μg/ml kanamycin, shaking at 37
oC. Miniprep was then 
performed to retrieve the plasmid and determine whether it contained an insert. 
 
10x Ligation Buffer  1µl 
PCRII Vector  2µl 
Purified Insert  3µl 
Nuclease-free Water  3µl 
PCR Product  0.5-4μl 
Salt Solution  1μl 
Water  Up to 5μl 
pCRII-Blunt-TOPO  1μl  
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2.10.6 Miniprep 
All reagents were purchased from Qiagen, UK, unless otherwise stated. 1.5ml of 
overnight culture was centrifuged at 13,000rpm for 1 minute. The bacterial pellet was 
resuspended in 100μl P1 buffer, and then 200μl P2 buffer was added. The reaction was 
mixed gently by inverting five times. 150μl P3 buffer was added, after inverting 5 
times, the reaction was centrifuged at 13,000rpm for 5 minutes. 900μl 100% ethanol 
was added to a clean 1.5ml eppendorf, and 450μl of the centrifuged supernatant was 
pipetted into the ethanol before centrifugation at 13,000rpm for 5 minutes. The 
supernatant was discarded and the pellet was washed with 100μl 70% ethanol, followed 
by centrifugation at 13,000rpm for 5 minutes. The ethanol was removed from the pellet 
using a pipette and the pellet was allowed to air dry (covered lightly with blue roll to 
prevent contamination) for about one hour. The plasmid DNA pellet was then 
resuspended in 20μl nuclease free water (Ambion, USA). 
 
2.10.7 Plasmid Digestion with EcoRI 
Digestion of the DNA plasmid harvested from the miniprep (see above) with 
EcoRI (Promega, UK) excises the insert, if present. Figure 2.7 shows the position of the 
EcoRI cut sites. Each 10μl digestion contained the following:  
 
 
 
 
 
 
The digestions were incubated at 37
oC for 2 hours. The EcoRI digested plasmids 
were separated by gel electrophoresis (section 2.9) to determine the presence of an 
insert of the correct size. Digest controls were used to show the size of the undigested 
(circular) plasmid using a reaction lacking the EcoRI enzyme. A previously prepared 
GAPDH plasmid was digested as a positive control of digestion to ensure the digestion 
worked, and a plasmid-only digest was also included to determine the size of the 
digested (linear) plasmid which contained no insert. Figure 2.8 shows an example of 
digested plasmids separated on a 2% agarose gel. 
 
 
EcoRI  1µl 
BSA  0.1µl 
10X Buffer H  1µl 
DNA (from miniprep)  2µl 
Nuclease-free Water  5.9µl  
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Figure 2.7. PCR-II vector map showing the position of the insert and the flanking 
EcoRI cut sites.The positioning of the EcoRI cut sites is similar for A-overhang and 
blunt end vectors. Purified PCR products were ligated to the vector then added to 
TOP10 cells which were heatshocked to enable uptake of the vector. After overnight 
growth the TOP10 cells were pelleted and the plasmid DNA harvested and digested 
with EcoRI to confirm the presence of the insert. Image adapted from the Invitrogen 
website http://products.invitrogen.com/ivgn/product/K460001?ICID=search-
product#manuals accessed on 8
th October 2011. 
 
 
 
 
 
 
 
 
 
 
Figure 2.8. Digestion of constructed plasmids with EcoRI to determine presence or 
absence of an insert of the appropriate size. 
C1q plasmid digests (lanes 1, 3, and 7) contained the appropriate sized insert (Table 
2.1). The digestion was successful as shown by the positive control GAPDH plasmid 
digestion (lane 5). Lanes 2, 4, 6, 8 and 10 shows the size of the undigested plasmids, 
and lane 9 shows the size of the linearised plasmid containing no insert.  
M. 1kb+ Standard Ladder 
1. C1qA plasmid digestion 
2. C1qA minus EcoRI 
3. C1qB plasmid digestion 
4. C1qB minus EcoRI 
5. GAPDH control digestion 
6. GAPDH minus EcoRI 
7. C1qC plasmid digestion 
8. C1qC minus EcoRI 
9. Plasmid only digestion 
10. Plasmid only minus EcoRI 
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2.10.8 Generation of a Plasmid Standard Curve for rt-PCR 
To ensure that the standard curve used in rt-PCR was as robust as possible, 
plasmids containing the gene of interest being investigated were used to construct a 
standard curve. The plasmids were generated as described in section 2.10.8. The 
concentration of the plasmids was found by using the NanoDrop (see section 2.6.11) 
and this was used to calculate the number of plasmids/µl of plasmid solution (Appendix 
7.1). Following this the plasmids were diluted with nuclease-free water to achieve 10
17 
– 10
3 plasmids per µl. A PCR was run using all dilutions, and it was found that plasmid 
copies of 10
14 – 10
9/µl gave best results. The use of a plasmid standard curve instead of 
a cDNA dilution standard curve does not affect the normalised results (data not shown). 
 
2.10.9 Sequencing of Plasmids 
To ensure that the correct insert was present in the plasmid, each plasmid was 
sent away for sequencing (Eurofins MWG Operon). The sequenced plasmid was 
aligned with the appropriate insert sequence to ensure the insert was correct. A typical 
alignment of plasmid sequence containing the forward and reverse primers with correct 
insert can be seen in appendix 7.5. 
 
2.11 Genotyping CSPα Pups 
In order to produce CSPα knockout (KO)  mice,  male and female CSPα 
heterozygous (HZ) mice were mated to produce litters containing a mixture of CSP 
wildtype (WT), HZ and KO mice in a 1:2:1 respectively (section 2.4). Pups were 
genotyped around postnatal day 14 (P14), using tail tips. Mice were identified by ear 
punched at the same time as tissue was collected for genotyping (Appendix 7.6). 
 
2.11.1 Tissue Collection 
P14 pups were ear punched for identification, and then ≤2mm of tail was 
removed using a clean, sharp scalpel blade. The tail tip, and/or piece of ear from 
identification, was placed in a 1.5ml eppendorf ready for digestion and DNA extraction. 
Mice were only ear punched after P14 due to their ear size. Mice which required 
genotyping before P14 were identified with coloured marker pen lines to the tail 
(markings were replaced twice a day to prevent fading). 10-15 minutes before the tail 
tip was taken, lidocaine (BioRex Laboratories) was applied to the tail end to numb the 
tail. The same protocol was used to extract DNA from ear punches and tail snips.  
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2.11.2 Proteinase K Digestion of Tail Tips 
Tails were digested in 100µl digestion buffer (10mM TRIS pH8 (Fisher 
Scientific, UK), 10mM EDTA (Sigma, UK), 100mM NaCl (Fisher Scientific, UK), and 
0.5% SDS (Sigma, UK)) containing 0.4µl proteinase K (100mg/ml, Promega, UK). 
Digests were incubated at 55
oC until the tails were fully digested, about 1 hour 30 
minutes.  Reactions were flicked every 20-30 minutes to aid the complete digestion of 
the tail.  
 
2.11.3 DNA Extraction 
After the tail tips were fully digested (see above) they were centrifuged for 10 
minutes at 12,000rpm to pellet the debris (cartilage and hair), undigested material 
formed a pellet at the bottom of the tube leaving the DNA in the supernatant. The 
supernatant was transferred to a clean eppendorf, ensuring no part of the pellet was 
disturbed, and 1 volume of isopropanol (Sigma, UK) was added to precipitate the DNA. 
The supernatant and isopropanol were mixed by flicking until the DNA was visible as 
white strands. The reaction was centrifuged for 5 minutes at 10,000rpm before 
removing the supernatant from the DNA pellet. The pellet was washed twice in 70% 
ethanol (Fisher Scientific, UK) followed by centrifugation at 10,000rpm for 5 minutes. 
The pellet was centrifuged a final time for 1 minute at 10,000rpm to remove residual 
ethanol and then left to air dry. Pellets were resuspended in 50µl nuclease-free water 
(Ambion, USA). DNA in solution was stored at 4°C. 
 
2.11.4 Amplification of DNA and Identification of Genotype 
The extracted DNA was amplified using REDTaq polymerase chain reaction 
(section 2.8). The PCR products were separated on a 1% agarose gel (section 2.9), to 
separate the product size and identify the genotype. Bands at 1200bp and 900bp 
identified the mice as heterozygous (+/-), a single band at 1200bp identified the mouse 
as homozygous wildtype (+/+), and a single band at 900bp identified the mouse as 
homozygous knockout (-/-) (Figure 2.9). 
CSPα primers were used to distinguish between CSPα +/+, +/- and -/- mice. The 
primers were the same as those documented in Fernández-Chacón et al (2004). Primers 
were named A (TGGTAGACTAACCTAACATGGCCG), B 
(TTGGCCCACCAGCTGGAGAGTAC) and C 
(GAGCGCGCGCGGCGGAGTTGTTGAC). Forward primer A binds to exon 1of the  
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CSPα wild-type gene, whilst forward primer C binds to the neomycin insert of the 
targeted gene of CSPα -/- mice, which was not present in CSPα+/+ and CSP+/- mice. 
Reverse primer B binds to exon 2 and forms the reverse primer for both the forward 
primers A and C (Figure 2.10). The product from the amplification using primer A and 
B was 1.2kb, the product from the amplification reaction using primers B and C was 
0.9kb. If the mouse was deficient in CSPα then primers C and B will bind to the DNA, 
if the mouse had both wild-type genes then primers A and B will bind, and if the mouse 
is heterozygous then both primer pairs (A+B and C+B) will bind to the extracted DNA. 
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Figure 2.9. Example of REDTaq PCR used to genotype CSPα litters.  
Pups at P14 were ear tagged for identification and a tail tip taken for genotyping. The 
tail tips were digested with proteinase K, the DNA extracted, a PCR performed, and 
products separated on a 1% agarose gel. CSPα HZ mice were identified by bands at 
1200bp and 900bp, CSPα KO mice by a single band at 900bp, and CSPα WT mice by a 
single band at 1200bp. 
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Figure 2.10. Schematic representation of the wild-type CSPα gene, the targeting 
vector, and the resulting CSPα -/- gene.  
In the targeted gene, giving rise to CSPα -/- mice, exon 1 was replaced with a neomycin 
resistance gene (neo). The positions of CSPα A, B and C primers are shown for the 
wild-type and targeted gene.    
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2.12 Western Blots 
2.12.1 Tissue Extraction 
Hippocampi were removed as described in section 2.5.3. They were then 
homogenised using a Kontes Pellet Pestle (Anachem, UK) in 10% weight/volume of 
homogenisation buffer [Hepes 20mM pH7.4, NaCl 125mM, 2% SDS, 1 tablet complete 
protease inhibitor (Roche, UK)]. Hippocampal protein samples were centrifuged at 
14,000rpm for 20 minutes and the protein-containing supernatant transferred to a clean 
eppendorf. Samples were stored at -20
oC until required. 
 
2.12.2 Protein Assay 
Protein concentration was assessed using the Bio-Rad Dc protein assay kit (Bio-
Rad, UK) according to manufacturer‟s instructions. In brief, a protein concentration 
curve was prepared using serial dilutions of BSA (20mg/ml) at 5mg/ml, 2.5 mg/ml, 1.25 
mg/ml, 0.0625 mg/ml, 0.0312 mg/ml diluted with homogenisation buffer. Hippocampal 
protein samples were prepared by diluting samples 1:5 and 1:10 using homogenisation 
buffer to a final volume of 25µl. 10µl of each hippocampal protein sample dilution and 
BSA standard curve were pipetted into a 96well plate in duplicate, and 25µl of protein 
assay reagents A* added. After the addition of 200µl of reagent B, the samples were 
incubated for 5 minutes before the absorbance was measured at 630nm (Dynex 
Technologies, using Revelation software).  
 
2.12.3 SDS-Polyacrylamide Gel Electrophoresis (SDS-PAGE) 
After determining the concentrations of the hippocampal protein homogenates, 
they were prepared by the addition of 5x sample buffer to a final concentration of 1x 
(100µl of 5x sample buffer were added per 400µl of hippocampal protein homogenate). 
Hippocampal protein homogenates were separated through a stacker and resolving gel 
alongside a standard protein ladder.  
The stacker and resolving gel solutions (Appendix 7.3.1, Table 7.1) were 
prepared minus the addition of TEMED, in a 50ml falcon tube. The front plate, with 
5mm spacing, and back plate were cleaned with ethanol and allowed to air dry before 
being assembled and placed into their holders. TEMED (Sigma Aldrich, UK) was added 
to the resolving gel solution immediately before casting, and poured between the glass 
plates, and then overlaid with isopropanol. After the resolving gel had polymerised and 
set, the isopropanol was removed using Whatman filter paper, and the stacking gel was  
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cast, immediately after the addition of TEMED, onto the resolving gel. A 5mm comb 
was inserted into the stacking gel, avoiding any bubble formation. Once the stacking gel 
had set, the gel cassettes were placed in a gel tank containing 1X Laemmli buffer 
(Appendix 7.3.3) and the combs removed. Hippocampal protein samples, containing a 
final concentration of 1x sample buffer, were boiled (if necessary) at 95
oC for 5 minutes 
before centrifugation at 14,000rpm for 1 minute. 15-20µg of each hippocampal protein 
sample was loaded onto the gel along with 5µl Precision Plus Protein Standards ladder 
(Bio-Rad, UK). The gel was run at 100V for 1 hour 30 minutes to allow the 
hippocampal protein samples to separate.  
 
2.12.4 Coomassie Staining 
If required, gels containing the separated hippocampal protein samples, were 
soaked overnight in Coomassie stain (1 part methanol to 4 parts Coomassie stain) 
(Sigma Aldrich, UK), then placed in destain (Appendix 7.3.4) for 15 minutes, followed 
by 25% methanol washes until the protein bands were clearly resolved above 
background. The gel was imaged with an Odyssey Infrared Imaging Scanner (Licor, 
UK) at 700nm and analysed using the Odyssey software program v1.2.  
 
2.12.5 Protein Transfer 
The separated hippocampal proteins were transferred from the polyacrylamide 
gel to a nitrocellulose membrane (Amersham, UK), either at 30V for ~16-17 hours 
(overnight) at 4
oC, or at 250mA for 2 hours at 4
oC. Table 2.3 states the transfer 
conditions of different primary antibodies. Whatman blotting paper and nitrocellulose 
were immersed in the appropriate buffer (Appendix 7.3.5 and 7.3.6), and the gel was 
sandwiched between the nitrocellulose and Whatman filter paper (Figure 2.11). The 
nitrocellulose membrane was placed closest to the positive anode.  
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Table 2.3. Primary and secondary antibodies used for western blotting detailing the transfer conditions and incubation times 
After blocking in 5% non-fat milk for one hour at room temperature, the nitrocellulose membranes (containing the hippocampal proteins) 
were incubated in the primary antibody, made with 2.5% non-fat milk, and incubated as required. The membrane was then washed in TBS-
T, 3 x 5minute washes, before incubation in the secondary antibody, made up in 2.5% non-fat milk. 
Antibody  Species  Dilution   Company  Type  Transfer 
Condition 
Incubation Time 
Anti-Glial Fibrillary Acidic 
Protein (GFAP) 
Rabbit  1:5000  Dako  1
o  Overnight  1hr room temperature 
Anti-Glial Fibrillary Acidic 
Protein (GFAP) 
Mouse  1:5000  Sigma  1
o  Overnight  1hr room temperature 
Anti-PrP 6H4  Mouse  1:5000  Prionics  1
o  Overnight  1hr room temperature 
Polyclonal Antiserum to 
Human C1q Protein 
Goat  1:1000  Quidel  1
o  2hr  Overnight 4
oC 
Anti-Synaptophysin (SY38)  Mouse  1:1000  Millipore  1
o  Overnight  Overnight 4
oC 
Anti-Syntaxin 10H5  Mouse  1:1000  Gift from Dr. M. Takahashi 
(Mitsubishi Kasei Institute of 
Life Sciences) 
1
o  2hr  Overnight 4
oC 
Anti-NL1  Rabbit  1:1000  Synaptic systems  1
o  Overnight  Overnight 4
oC 
Anti-NL2  Rabbit  1:1000  Synaptic Systems  1
o  Overnight  Overnight 4
oC 
Donkey anti-Mouse 800  Donkey  1:10000  Invitrogen  2
o  -  1hr room temperature 
Rabbit anti-Goat 680  Rabbit  1:10000  Invitrogen  2
o  -  1hr room temperature 
Goat anti-Rabbit 800  Goat  1:10000  Invitrogen  2
o  -  1hr room temperature  
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Figure 2.11. Organisation of the protein gel and nitrocellulose membrane used to 
transfer hippocampal proteins from a SDS-PAGE gel to a nitrocellulose 
membrane.  
Whatmans blotting paper and nitrocellulose were pre-soaked in transfer buffer (section 
2.12.5). Each layer was carefully constructed and any air bubbles removed. The 
sandwich was placed in the transfer tank so that the protein gel was closest to the 
cathode (negative) and the membrane was closest to the anode (positive). The tank was 
filled with transfer buffer and proteins were transferred either at 30V for ~16-17 hours 
(overnight) at 4
oC, or at 250mA for 2 hours at 4
oC. The arrow indicates the migration of 
the hippocampal proteins samples from the cathode to the anode.  
Whatmans blotting paper 
Whatmans blotting paper 
Nitrocellulose membrane 
Protein gel  
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2.12.6 SYPRO Ruby Staining 
After transfer of proteins onto the nitrocellulose membrane, the membrane was 
fixed in 10% methanol, 7% acetic acid (Appendix 7.3.7) for 10 minutes, followed by 
four 1 minute washes with distilled water. The membrane was then incubated with 10ml 
of SYPRO Ruby protein blot stain (Bio-Rad, UK) for 15 minutes. Excess stain was 
removed by four 1 minute washes with distilled water. The membrane was then imaged 
under UV light and the intensity of the protein fluorescence calculated using the 
Quantity One programme v4.4.1 (Bio-Rad, USA). 
 
2.12.7 Antibody Labelling 
The nitrocellulose membrane, containing the transferred hippocampal proteins, 
was blocked in 5% non-fat milk (Tesco, UK) in TBS-Tween (TBS-T) (Appendix 7.3.8) 
for 1 hour with shaking, followed by incubation with the primary antibody, made in 
2.5% non-fat milk, under the appropriate conditions (Table 2.3). Following the 
incubation with the primary antibody the membrane was washed three times in TBS-T, 
each for 10 minutes. Fluorescent secondary antibodies (Table 2.3) were incubated with 
the nitrocellulose membrane for 1 hour at room temperature with shaking. The 
nitrocellulose membrane was washed three times in TBS-T, each for 10 minutes, before 
imaging with an Odyssey Infrared Imaging Scanner (Licor, UK) running the Odyssey 
software v1.2, at 700nm and/or 800nm.  
 
2.12.8 Quantification of Protein Expression 
The Odyssey software v1.2 allows quantification of protein expression. A box 
was drawn round each hippocampal protein sample and the intensity of the signal was 
quantified relative to the background (Figure 2.12). The box size was kept the same for 
each protein sample on the membrane. The signal intensity was proportional to the 
amount of protein detected within the sample.    
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Figure 2.12. Quantification of florescent bands using Odyssey software v1.2. 
NBH- and ME7-hippocampal protein samples were separated on a 10% resolving gel 
and probed using an anti-GFAP antibody. A box was drawn round each protein band 
(A), and was used for quantification. The Details View button was selected to ensure 
that the whole protein of interest was quantified (B). The Details View button zooms 
into the quantification box and using an intensity curve shows whether the full band has 
been included within the box. In this example the first box has been enlarged in Details 
View and it can be seen that the full band had been quantified. 
   
A 
B  
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2.13 Immunocytochemistry 
2.13.1 Tissue Sectioning 
Brains from CSPα WT (n=3), HZ (n=3) and KO (n=3) mice were removed and 
fixed (section 2.5.1), and embedded in wax (section 2.5.2). A microtome (Leica 
RM2255) was used to section each wax block. Each brain-containing wax block was 
mounted onto the pedestal. 30µm thick coronal sections were cut through the forebrain 
until the beginning of the hippocampus could be seen. 10µm serial sections were cut 
through the hippocampus (usually 20-25 sections) and the brain slices were allowed to 
float on a water bath (52
oC) until the wax had expanded allowing the brain slice to 
stretch out. Sections were then transferred to a glass slide (Superfrost Plus, Fischer 
Scientific) and allowed to dry in an incubator set to 37
oC. The hippocampal sections 
were stored at room temperature. 
 
2.13.2 DAB Staining of Hippocampal Sections 
Hippocampal sections were de-waxed by heating in an oven at 60
oC for 30 
minute before rehydration using decreasing ethanol concentrations. The hippocampal 
sections were immersed in two xylene washes, each for 10 minutes, followed by 5 
minute immersions at the following ethanol concentrations; 100%, 100%, 95%, 80% 
and 70%. The sections were washed in PBS-Tween (PBS containing 0.05% Tween-20), 
and incubated in 1% hydrogen peroxide (diluted with PBS) for 15 minutes before 
washing in PBS-Tween for 5 minutes. Sections were immersed in citrate buffer and 
heated in a microwave for 3 minutes, transferred to cool distilled water for 3 minutes, 
returned to citrate buffer and heated for a further 3 minutes before cooling in distilled 
water for 3 minutes. The hippocampal sections were then washed in PBS-Tween for 
3x5minute washes. A hydrophobic barrier pen (ImmEdge, Vector Labs, UK) was used 
to draw individual wells round each brain section to ensure there was no cross-
contamination between the different primary and secondary antibodies used. The 
hippocampal sections were blocked with 5% BSA in PBS for 1 hour at room 
temperature in a humid chamber, to ensure the sections did not dry out. Sections were 
then incubated in the appropriate primary antibody (Table 2.4). Sections were washed 3 
times in PBS-Tween for 5 minutes each before incubating with the secondary antibody 
(Table 2.4) for 1 hour at room temperature in a humid chamber. Whilst the hippocampal 
sections were incubating in the secondary antibodies, the avidin-biotinylated 
horseradish peroxidise complex (ABC) was prepared; 2 drops of reagent A and 2 drops  
66 
 
of reagent B were added to 5ml PBS, vortexed, and incubated for 30 minutes on the 
bench top. 
Following the incubation with the appropriate secondary antibody, the 
hippocampal sections were washed in PBS-Tween, 3x5 minute washes. Sections were 
incubated in ABC for 30 minutes at room temperature in a humid chamber, before 
washing in PBS-Tween, 3x5minute washes. Hippocampal sections were developed in 
3,3'-Diaminobenzidine (DAB) (5ml DAB (25mg/ml) in 250ml 0.1M Phosphate buffer 
with 0.0015% H2O2) for an initial 15 seconds. Reactions were halted by immersion in 
PBS. Hippocampal sections were counterstained with Harris haematoxylin for 5 
seconds, rinsed under tap water until the water ran clear, before destaining in 1% acid 
alcohol for 10 seconds, and rinsing in Scott‟s tap water for 30 seconds. Sections were 
dehydrated using increasing alcohol concentrations; 2 minutes at the following ethanol 
concentrations, 70%, 80%, 95%, 100%, and 100%, followed by two immersions in 
xylene for 10 minutes each. Sections were coverslipped using DePex and left to air dry 
overnight in a fume hood. 
Images of astrocyte and microglia staining were captured using a Leica 
microscope (Leica DCF 300 FX) and a computer running Leica QWin software for 
image capture. Representative images from the CA1, CA3 and DG were captured at X5, 
X10, X20, X40 and X63 magnification using the same microscope settings for Tomato 
Lectin (Appendix 7.7) and GFAP (Appendix 7.8) at each magnification.   
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Table 2.4. Primary and secondary antibodies used for staining of CSPα WT, HZ, 
and KO hippocampal brain sections 
Hippocampal sections were stained for astrocytes and microglia using the antibodies 
and incubation conditions in the above table. 
   
Primary 
Antibody 
1
o Antibody 
Buffer 
Incubation 
Conditions 
Secondary 
Antibody 
2
o Antibody 
Buffer 
Tomato Lectin 
(Lectin from 
Lycopersicon 
esculentum 
(tomato) Biotin 
Conjugate 
(Sigma, UK, 
L0651) 
25mM Na-
TRIS pH7.4 
0.1mM MgCl2 
0.1mM CaCl2 
0.1mM MnCl2 
1% Triton X-
100 
1:100 dilution 
4
oC overnight 
No 2
oAb 
required for 
DAB staining as 
the Tomato 
lectin is already 
biotinylated. 
25mM Na-
TRIS pH7.4 
0.1mM 
MgCl2 
0.1mM 
CaCl2 
0.1mM 
MnCl2 
1% Triton 
X-100 
Polyclonal 
rabbit anti-
GFAP (Dako, 
UK) 
1% BSA in 
PBS 
1:1000 dilution 
4
oC overnight 
Anti-rabbit 
biotin 
1:200  
4
oC overnight 
1% BSA in 
PBS  
68 
 
2.13.3 Quantification of Astrocyte and Microglia Numbers 
The total number of astrocytes and microglia was quantified to determine 
whether there was an upregulation in CSPα knockout mice. 10µm hippocampal sections 
(section 2.13.1) were stained as described above. Glial numbers were counted in the 
CA1, CA3, and DG regions of the hippocampus of P23, P25 and P28 mice, in different 
CSPα genotypes. 
In order to quantify the number of astrocytes and microglia, images (X20 
magnification) were imported into Microsoft Office Visio 2007, and the program used 
to superimpose boxes over the areas of interest (CA1, CA3 and DG), all boxes were of 
identical size. Five boxes were drawn for each hippocampal region (Figure 2.13 A, B, 
C). The images were then imported into Microsoft Paint to aid with quantification. All 
astrocytes and microglia were identified with a red dot, and cell nuclei with green dots 
(Figure 2.13 D). In order to ensure that there was no bias in the quantification a criteria 
was drawn up as follows. For each brain region, the total number of astrocytes or 
microglia for each box was normalised to the total cell count for the box, and an average 
of the five boxes taken. 
1.  Each astrocyte or microglia, and their processes, within each box was counted as 
one entity.  
2.  Nuclei in the box were only counted if easily distinguishable from the 
background staining.  
3.  Any GFAP positive or Tomato Lectin positive processes, from a single glial 
cell, to cross the box boundary from outside the box were counted as one cell. 
4.  Any cell nucleus which was found on the box boundary was counted as one cell. 
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Figure 2.13. Example images from a CSPα KO mouse used for the quantification 
of astrocyte and microglia numbers 
Images taken at X20 magnification were imported into Microsoft Office Visio and 5 
boxes were superimposed onto each hippocampal region, CA1 (A), CA3 (B), and DG 
(C), as shown above. Images were then saved and imported into Microsoft Paint and 
each astrocyte or microglia was identified by a red dot, and cell nuclei by green dots 
(D). The total number of glial cells was normalised to the total cell count for each box. 
A  B 
D  C  
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Chapter 3:  The Use of SYPRO Ruby in Western Blotting to 
Account for Differences in Protein Loading 
3.1  Introduction 
The western blotting technique involves the transfer of resolved proteins to a 
solid phase that allows the presence and abundance of individual proteins to be 
quantified. The format of the technique, originally developed by Towbin and co-
workers (Hagiwara et al., 2009), has been widely used to identify and quantify protein. 
When the method is extended to quantify antigens in complex mixtures the loading of 
the samples is normalised. This normalization can be relative to cell number, relative 
expression to a known unchanging protein, or to the total protein loaded. When 
investigating protein expression in tissue with a pathological or degenerating disease, 
normalisation is vital to account for variations between the proteins of interest due to 
differences in protein loading (technical variation), rather than the disease process 
(biological change). This is especially important on brain tissue where the experimental 
protocol will usually involve the comparison of the levels of a given protein, and its 
modifications within disease (Greer et al., 2010). It is therefore essential that differences 
in total protein loading are accounted for before the data is analysed. There are several 
methods used to normalise for variable loading in complex protein extracts (Hagiwara et 
al., 2009). 
An established method of normalising for differential  protein loading is to 
probe for housekeeping genes such as β-actin or glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH), which are generally considered to be expressed at a constant 
level within a given tissue type (Ferguson et al., 2005). This is a convenient method to 
use, since the housekeeping genes can usually be probed for on the same membrane as 
the protein of interest. However, during disease many commonly used housekeeping 
genes are known to change (Benn et al., 2008), therefore any housekeeping genes 
chosen for normalisation should be independently shown not to change in disease.  The 
issue of sample normalization when investigating progressive degeneration associated 
with prion disease (section 1.3.2) required some consideration because preferred 
housing keeping proteins, including tubulin and actin, appeared to change expression 
across disease (data not shown). This was manifested in both immunohistochemical and 
western blots. Both the ensuing degeneration and the associated cellular activation  
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indicated that these proteins were not adequate controls (Gray et al., 2009). To 
circumvent this, colloidal Coomassie Blue staining of duplicate gels was used. The 
intensity of each band correlates to the amount of protein loaded. Although this is a very 
simple method of normalisation, it requires multiple gels to be run, which may not be 
possible if only small quantities of samples are available. Although the correlation of 
relative protein levels between the normalizing gel and the transferred gel is very good, 
it may fail to take into account transfer issues.  
Berggren et al (1999) and Hagiwara (2009) suggested SYPRO ruby staining of 
the solid phase after transfer, but prior to antigen detection.  This normalises for 
changes in protein loading and is recommended when the use of housekeeping proteins 
are unsuitable. Further, it overcomes the limitation of normalizing for sample load 
independent of the transfer step. SYPRO Ruby dye is a non-covalent ruthenium-based 
florescent dye which interacts with basic amino acids, including lysine (K), arginine 
(R), and histidine (H) (Simpson, 2006). It is fully compatible with colorimetric, 
florescent and chemiluminescent detection techniques that are used to detect 
immunoreactivity, allowing membranes to be subsequently probed with antibodies with 
no reported alteration in signal detection (Berggren et al., 2002). 
Despite its increase in use, recent evidence has shown that SYPRO Ruby dyes 
significantly affect the efficiency of protein mass detection. This has emerged from 
mass spectrometry studies where decreased signal/noise ratios and reduced number of 
peptides were detected following florescent staining in mass spectrometry (Lanne and 
Panfilov, 2005). 
In this chapter, we describe the use of the SYPRO Ruby in sample normalization 
of studies in which western blotting is used to determine protein expression. We 
highlight the potential of SYPRO ruby and compare it to the established use of 
Coomassie Blue staining. The work from our comparative approach indicates a reduced 
sensitivity of SYPRO Ruby, less pronounced linearity in protein normalization, and a 
modification of antigenicity of transferred proteins in immunoblotting when the 
nitrocellulose membrane harbouring the immobilized proteins are subjected to staining 
with SYPRO ruby. Most striking is the large decrease in immunoreactivity towards both 
PrP
c and PrP
Sc in samples subjected to SYRPO Ruby pre-treatment.             
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3.2  Methods 
3.2.1  Western Blot 
Hippocampal protein homogenates (6.25-50 µg) from naïve, NBH- or ME7-
animals were separated through 10% resolving gels (section 2.12.3). Figure 3.1 outlines 
how the gels were separated for each different treatment, to determine what effect, if 
any, SYPRO Ruby normalisation had on antibody detection. Following transfer, one 
section was blocked in milk (control membrane) (section 2.12.7), one section was 
SYPRO Ruby stained (SYPRO Ruby treated membrane) and the third section was 
blocked with methanol but not SYPRO Ruby stained (methanol treated membrane) 
(section 2.12.6). Both these membranes were then blocked in 5% milk and antibody 
labelling was carried out as described in section 2.12.7.  Following blocking, the 
membranes were incubated in the appropriate primary and secondary antibodies (Table 
3.1). The immunoreactivity of each membrane was quantified as described in section 
2.12.8. Each antibody investigated was quantified on two separate membranes (n=2), 
unless otherwise stated, and each membrane was quantified once per condition. The 
antibody signal intensity detected for each protein sample was proportional to the 
amount of protein detected within the sample. All data was analysed by One-Way 
Analysis of Variance (one – way ANOVA) using GraphPad Prism 5.  
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Figure 3.1. Diagrammatic representation of the pair of resolving gels used to determine the effect of SYPRO Ruby on quantification of the 
antibody signal intensity from different antibodies. Two 10% resolving gels were prepared for each antibody. After the gels were run, half of one 
gel was Coomassie stained (section 2.12.4) (A), the remaining gel and a half were transferred (section 2.12.5). Following transfer, B and C were 
blocked in 5% milk (control membranes) and then incubated in the appropriate antibodies. D and E were methanol fixed before blocking in 5% milk 
(methanol treated membranes) and F and G were methanol fixed and SYPRO ruby stained before blocking in 5% milk (SYPRO Ruby treated 
membranes). 
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Table 3.1. List of primary and secondary antibodies used during the SYPRO Ruby experiment. 
After membranes were differentially treated; no treatment, methanol fix only or methanol fixation and SYPRO Ruby staining, membranes were 
blocked in 5% milk for one hour before incubating in the appropriate primary antibody, followed by 3x 5 minute washes in TBS-T, and finally 
incubated in the appropriate secondary antibody
Antibody  Antigen Location  Species  Dilution  Company  Type  Transfer Condition  Incubation Time 
Anti-Glial Fibrillary Acidic 
Protein (GFAP) 
Astrocytes  Rabbit  1:5000  Dako, Germany  1
o  Overnight  1hr, room temperature 
Anti-PrP 6H4  Prion protein  Mouse  1:5000  Prionics, Eire  1
o  Overnight  1hr, room temperature 
Anti-PrP SAF32  Prion protein  Mouse  1:5000    1
o  Overnight  1hr, room temperature 
Anti-PSD95  Postsynaptic scaffold 
protein 
Mouse  1:1000  Millipore, UK  1
o  Overnight  Overnight, 4
oC 
Anti-SY38  Synaptic vesicle membrane 
protein 
Mouse  1:1000  Prionics, Eire  1
o  Overnight  Overnight, 4
oC 
Anti-Syntaxin 10H5  Neuronal membrane protein  Mouse  1:1000  Gift from  Dr. 
M. Takahash 
1
o  Overnight  Overnight, 4
oC 
Anti-NR1  Subunit of NMDA receptor 
on postsynaptic membrane 
Goat  1:1000    1
o  Overnight  Overnight, 4
oC 
   
Donkey anti-Mouse 800  -  Donkey  1:10000  Invitrogen, UK  2
o  -  1hr, room temperature 
Rabbit anti-Goat 680  -  Rabbit  1:10000  Invitrogen, UK  2
o  -  1hr, room temperature 
Goat anti-Mouse 680  -  Goat  1:10000  Invitrogen, UK  2
o  -  1hr, room temperature  
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3.3  Results 
3.3.1  Differences in the Efficiency of Coomassie and SYPRO Ruby in 
Quantification of Protein Loading 
Comparing the Coomassie stained gel and the SYPRO Ruby stained membrane 
of naïve hippocampal protein showed a decrease in sensitivity of SYPRO Ruby 
compared to Coomassie stain (Figure 3.2). Measurement of the serial protein 
homogenate dilution by Coomassie staining shows a proportional decrease of signal 
intensity with the decrease in protein loaded. The graph in Figure 3.2A shows a linear 
relationship between the intensity of Coomassie staining and the amount of 
hippocampal protein homogenate loaded. This linearity holds for between 50µg to 
6.25µg, as evidenced by the R
2 = 0.996. These amounts are consistent with the amount 
of protein normally loaded with most gel systems. Comparing this to the quantification 
of proteins based on the fluorescence from the SYPRO Ruby stained membrane shows 
that the SYPRO Ruby staining intensity does not halve when the amount of 
hippocampal protein homogenate loaded halves. Figure 3.2B shows that the gradient of 
the protein fluorescence intensity plot is less steep compared to Coomassie staining. In 
addition, there is a non-linear relationship between the quantity of protein loaded and 
the SYPRO Ruby florescence detected (R
2 = 0.892), highlighting the decreased 
sensitivity of SYPRO Ruby and its ability to quantify proteins. This result shows that 
Coomassie staining is a more sensitive, and likely accurate, technique of accounting for 
differences in total protein loading.  
 
3.3.2  SYPRO Ruby Differentially Affects Antibody Binding 
Parallel gels of equivalent samples (Figure 3.1), were transferred onto 
nitrocellulose membranes and differentially treated prior to immunodetection with 
antibodies. One treatment involved blocking membranes in 5% milk with no prior 
treatment (control), the second treatment involved methanol fixation of membranes to 
mimic the pre-treatment that precedes SYPRO Ruby treatment, and the third method 
involved methanol fixation followed by SYPRO Ruby staining. Several antibodies, to 
different antigens, were used to assess whether SYPRO Ruby had any effect on the 
quantification of protein expression.  All antibody incubations were carried out in 
parallel and membranes were scanned at the same time and with the same laser 
intensity. Overall the results show that SYPRO Ruby differentially affects the antibody  
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staining intensity of different proteins when compared to methanol and control 
membranes (Figure 3.3 and Figure 3.4). Methanol treatment of the nitrocellulose 
membrane affects the signal intensity of the scanned membrane, although this is not 
usually to the extent of SYPRO Ruby stained membranes. This indicates that the 
treatment of nitrocellulose membranes with methanol and SYPRO ruby has a complex 
and unpredictable effect on antibody binding, causing either an increase or decrease in 
the antibody signal staining intensity compared to non SYPRO Ruby stained 
membranes.  In order to address this issue, we investigated several different antigens to 
determine whether SYPRO Ruby affected their quantification. We concentrated on 
antigens which are routinely used for the analysis of disease progression, and 
presynaptic and postsynaptic integrity that have been used to show correlative changes 
in disease. A full list of the antigens analysed can be found in Table 3.1. 
There was a marked decrease (64%) in the immunoreactivity associated with PrP 6H4 
antibody when comparing the effect of SYPRO Ruby treated, methanol treated and 
control membranes (Figure 3.3 A-C). Results showed that treatment of membranes with 
SYPRO Ruby and methanol caused a reduction in PrP (6H4) antibody signal. One-Way 
ANOVA with Bonferroni‟s Multiple Comparison test revealed that SYPRO Ruby 
treatment caused a significant decrease in PrP 6H4 antibody staining intensity 
(p=≤0.05), whereas methanol treatment did not cause a significant decrease in PrP 6H4 
antibody staining intensity (p≥0.05).   
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Figure 3.2. Example of a Coomassie stained gel and SYPRO Ruby stained 
membrane of hippocampal protein homogenate of naive animals. 
A – Coomassie stained gel of naïve hippocampal protein homogenate (50µg – 6.25µg). 
The graph shows a linear relationship (R
2 = 0.996) between the intensity of Coomassie 
staining and the amount of hippocampal protein homogenate loaded. 
B – SYPRO Ruby stained membrane of naïve hippocampal protein homogenate (50µg – 
6.25µg). There was a non-linear relationship (R
2 = 0.892) between the intensity of 
SYPRO Ruby florescence and the amount of hippocampal protein homogenate loaded.
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Further analysis investigated the immunoreactivity of distinct antigens that are 
abundant markers of other neural types, and to distinct sub-cellular localisations. GFAP, 
an astrocyte specific marker (Brahmachari et al., 2006), is a widely  used marker of 
prion disease progression. Treatment of the nitrocellulose membrane, containing 
homogenates of neural proteins, with SYPRO Ruby caused an increase in GFAP 
antibody staining intensity (Figure 3.3G-I). Subsequent analysis revealed a 150% 
increase in the antibody staining intensity when the membrane was pre-treated with 
SYPRO Ruby (Figure 3.4). Statistical analysis revealed that the increase was not 
significant (F(2,3) = 1.560, p= 0.34). Synaptophysin is a synaptic vesicle glycoprotein 
found in all synapses of the CNS (McMahon et al., 1996). The effect of SYPRO Ruby 
on the antibody staining intensity of anti-synaptophysin (SY38), a commonly used 
antibody for the quantification of synapses, was investigated. Treatment of membranes, 
with either methanol or SYPRO Ruby, caused a significant decrease in the SY38 
antibody staining intensity (F(2, 3) = 78.56, p= 0.003) (Figure 3.4). PSD95 is a 
postsynaptic scaffolding protein, expressed at all postsynaptic membranes of 
glutamatergic synapses (Lee et al., 2000). Results revealed a non-significant 75% 
reduction in PSD95 antibody staining intensity (Figure 3.4) between control and 
SYPRO Ruby treated membranes (F(2, 3) = 4.861, p= 0.11). SYPRO ruby had a 
negligible effect on the detection of NR1 antibody staining intensity (F(2 ,3) = 0.465, p= 
0.67). NR1 is a subunit of the NMDA receptor found on the postsynaptic membrane of 
glutamatergic synapses. Lastly, the effect of SYPRO Ruby staining on the staining 
intensity of an anti-syntaxin (10H5) antibody was investigated. Syntaxin is a neuronal 
membrane protein involved in exocytosis. The treatment of membranes with SYPRO 
Ruby had no effect on the syntaxin antibody staining intensity (F(2, 3) = 2.937, p= 0.20) 
(Figure 3.3 and Figure 3.4).  
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Figure 3.3. Example of membranes from non-treated, methanol fixed and SYPRO Ruby stained membranes. 
Homogenates of neural proteins were separated by gel electrophoresis and transferred to nitrocellulose membranes. The membranes were either left 
untreated or treated with either methanol or methanol and SYPRO Ruby. 
Top row – non-treated            middle row – methanol treated          bottom row – SYPRO Ruby 
A-C: SYPRO Ruby causes a loss of prion 6H4 antibody signal. D-F: SYPRO Ruby does not affect the intensity of syntaxin 10H5 antibody signal. G-I: 
SYPRO Ruby causes an increase in GFAP antibody detection.  
Untreated 
Methanol 
Treated 
Methanol + 
SYPRO Ruby 
Treated  
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Figure 3.4. Quantification of band intensity from non-treated (control), methanol and SYPRO Ruby treated membranes. 
SYPRO Ruby causes a decrease in PrP 6H4, SY38 and PSD95 antibody staining, an increase in GFAP staining and no difference in NR1 and syntaxin 
10H5 staining. All data was analysed by one-way ANOVA using GraphPad Prism 5 (* P≤0.05).  
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3.3.3  Effect of SYPRO Ruby on Diseased and Non-Diseased Samples 
The effect of SYPRO Ruby on the detection of proteins in diseased and non-
diseased hippocampal protein homogenates was assessed to determine whether there 
were any differences. 50µg, 25µg, 12.5µg, and 6.25µg of hippocampal protein  
homogenate from naive and ME7-animals were loaded onto parallel gels (Figure 3.1), 
these four gels were then probed with an anti-PrP (6H4) antibody, and differences in 
antibody staining intensity determined. In view of the restricted epitope of the PrP 6H4 
antibody, we investigated whether the prion antibody exhibited a loss of 
immunoreactivity by investigating PrP 6H4 antibody staining intensity in control, 
methanol fixed and SYPRO Ruby stained membranes using hippocampal protein 
homogenates from naive and ME7-animals.  
Representative gels (Figure 3.5) showed the expected increase in PrP antibody 
immunoreactivity in the protein homogenate from ME7-animals relative to naive 
animals (Jeffrey et al., 2001). A threefold induction of the prion protein was seen in 
ME7-animals compared to naive animals, even though the same amount of hippocampal 
protein homogenate was loaded (50µg, 25µg, 12.5µg, and 6.25µg) for naive and ME7-
animals. Regardless of the increase in PrP 6H4 antibody staining intensity between 
naive and ME7-animals, there was a similar relative decrease in PrP immunoreactivity 
in both hippocampal protein homogenates from naive and ME7-animals.  
Figure 3.5 shows the decrease in antibody signal intensity relative to the control 
membranes. As described in section 3.3.2, in hippocampal protein homogenate from 
naive animals, when compared to control membranes, PrP 6H4 antibody staining 
intensity shows a 30% reduction in signal when the membrane was methanol fixed only, 
and a >50% reduction in signal when the membrane was stained with SYPRO Ruby 
(F(2, 6) = 10.81, p= 0.01). In comparison, PrP 6H4 antibody staining of hippocampal 
protein homogenates from ME7- animals showed a 30% reduction of signal in methanol 
treated membranes and a 70% reduction in SYPRO Ruby treated membranes. This 
indicates that SYPRO Ruby had a more profound effect on PrP antibody staining 
intensity in ME7-animals compared to naive animals. The implications of this are 
important when SYPRO Ruby is used to normalise data from prion infected animals 
since SYPRO Ruby decreased the antibody staining intensity of PrP (6H4) to a greater 
extent in ME7-animals compared to naïve animals. 
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Figure 3.5. Graphical representation of the difference in PrP 6H4 antibody 
staining intensity between hippocampal protein homogenates from naive and 
ME7-animals. 
Equivalent protein samples (50µg, 25µg, 12.5µg, and 6.25µg) of hippocampal protein 
homogenates from naive and ME7-animals (n=1) were loaded onto gels in parallel. 
After transfer, the membranes were differentially treated (section 3.2.1), then incubated 
in PrP 6H4 antibody under the conditions set out in Table 3.1 (*p≤ 0.05). 
Representative gels from hippocampal protein homogenates from naive and ME7-
animals (control membrane) showed a 3 fold induction of PrP.
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3.3.4  Effect of SYPRO Ruby on Different Antibody Epitopes 
Lastly, the effect of SYPRO Ruby on the antibody staining intensity of two 
different antibody epitopes, to the same protein, was investigated.  This was to 
determine whether SYPRO Ruby had an epitope-specific or a global effect for a given 
protein.  
Two different prion protein antibodies were investigated, PrP 6H4 antibody 
which recognises the amino acid sequence DYEDRYYRE at residues 144-152, and PrP 
SAF32 antibody, which recognises the sequence 
GWGQPHGGSWGQPHGGSWGQPHGGGWGQGGGT at residues 63-94 (Figure 3.6). 
Both antibodies were tested on naive hippocampal homogenates. Figure 3.7 shows that 
whilst PrP 6H4 antibody staining intensity from the methanol treated membrane 
exhibited a 25% reduction in signal and the SYPRO Ruby membrane a 50% reduction 
when compared to the control membrane (F(2, 6) = 10.81, p= 0.01), PrP SAF32 
antibody staining intensity revealed a 50% reduction in signal in methanol treated 
membranes and a 75% decrease in signal in SYPRO Ruby treated membranes. This 
result indicates that SYPRO Ruby differentially affects the binding of antibodies to 
different epitopes found on the same protein.  
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Figure 3.6. Diagrammatic representation of the prion protein showing the epitope locations for PrP 6H4 and SAF32 antibodies.  
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Figure 3.7. Representative blots for PrP 6H4 and PrP Saf32 antibody staining of 
hippocampal protein homogenate from naive animals. 
Blots show that PrP 6H4 and PrP SAF32 antibody staining intensity decreased after 
SYPRO Ruby staining of membranes (bottom) compared to control membranes (top). 
The quantification shows that SYPRO Ruby staining of membranes differentially 
affected antibody binding to different epitopes. 
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3.4   Discussion 
SYPRO Ruby protein detection has been discussed as a way of normalising 
against differences in protein loading. However, there are emerging reports that suggest 
that SYPRO Ruby affects the efficiency of quantifying protein expression. We 
investigated the use of SYPRO Ruby staining, in protein homogenates from naive and 
ME7-animals, as a method of optimising quantification of neuronal protein expression 
in disease tissue. My results showed that SYPRO Ruby affects antibody binding and 
subsequent quantification of antibody staining intensity. The effect may be to increase 
the antibody staining intensity, as seen by the GFAP antibody, to decrease the antibody 
staining intensity, as was seen with the PrP antibody, or to have no effect on the 
antibody staining intensity.  
These observations provide an important caution when using SYPRO Ruby to 
normalise against differences in protein loading, especially if a clinically relevant 
protein, like prion protein, is under investigation. Furthermore, comparing SYPRO 
Ruby staining to Coomassie staining, as a measure of protein loading, showed that 
SYPRO Ruby staining was not as sensitive as Coomassie staining and showed a more 
precipitous saturation at high concentrations of loaded protein. Since linearity of signal 
across a broad range of proteins is important this again cautions for careful preliminary 
consideration when using SYPRO ruby for normalization. 
SYPRO Ruby was promoted as being one of the most sensitive dyes available 
for protein detection, with the added advantage of being fully compatible with 
subsequent immunoblotting (Berggren et al., 1999). However, our data demonstrate this 
is not always the case. Staining of nitrocellulose membranes with SYPRO Ruby for 
total protein normalisation caused a decrease in signal detection when membranes were 
subsequently probed with PrP 6H4, PrP SAF32, SY38 10HS and PSD95 antibodies, an 
increase in GFAP signal, and no difference in NR1 and syntaxin signals. The isoelectric 
point (pI) was calculated, using the Compute pI/Mw calculator from ExPASy 
(http://www.expasy.ch/tools/pi_tool.html) to determine whether there was a relationship 
between pI and the effect of SYPRO Ruby which could explain why some antibody 
staining intensities were affected, and some were not. Table 3.2 lists the pI and 
molecular weights (Mw) of each of the proteins analysed, along with the effect of 
SYPRO Ruby. There was no relationship between Mw or pI and the effect of SYPRO 
Ruby on the antibody staining intensity. This alone demonstrates that users need to be 
cautious when using SYPRO Ruby to normalise, especially when normalisation is only  
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carried out once per protein sample (which often occurs to save on time) rather than for 
every membrane, as SYPRO Ruby would cause a mismatch in the data recorded 
between SYPRO Ruby and non-SYPRO Ruby stained membranes. 
A further problem identified was the use of SYPRO Ruby normalisation when 
comparing diseased and non-diseased samples. SYPRO Ruby differentially affects 
antibody binding in naive and diseased tissue (Figure 3.5). The graphs showed that there 
was a 20% decrease in the signal intensity of PrP 6H4 antibody binding to hippocampal 
protein homogenates derived from ME7-animals in SYPRO Ruby stained membranes 
when compared to PrP 6H4 antibody binding to hippocampal protein homogenates from 
naive animals. Whilst this might not be as important if one was only making qualitative 
assessments in diseases like ME7 prion disease, in which there is a large increase in PrP 
protein, it will however become more problematic for studies in which changes in 
protein levels are not large and there is a need to quantify the protein levels. Also, if 
SYPRO Ruby differentially affects antibody binding per se as well as detection in naive 
and diseased tissue it will be difficult to quantify changes in protein levels.   
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Table 3.2. Examining the relationship between a protein's isoelectric point (pI) and the effect of SYPRO Ruby on antibody staining intensity. 
The table shows that there does not seem to be a correlation between a protein‟s pI and the effect of SYPRO Ruby staining on the antibody staining 
intensity. In addition, there is also no relationship between the molecular weight of the protein and the effect of SYPRO Ruby staining.
Protein  Localisation  Mw (kDa)  Isoelectric point 
 
Effect of SYPRO Ruby on antibody staining intensity  UniProt ID 
Prion   Membrane bound  23  9.56  Decrease  P04925 
Synaptophysin  Presynaptic vesicle 
membrane  34  4.82  Decrease  Q62277 
PSD95  Postsynaptic membrane  80  5.56  Decrease  Q62108 
GFAP  Astrocytes  50  5.28  Increase  P03995 
Syntaxin  Presynaptic membrane  33  5.14  No change  O35526 
NR1 
Subunit of NMDA 
receptor of postsynaptic 
membrane 
103  9.01  No change  P35438  
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A third problem connected with the use of SYPRO Ruby as a method of 
normalising for differences in protein loading on gels was the finding that SYPRO Ruby 
differentially affected different epitopes on the same protein. This effect would only 
cause concern if a user quantified a protein using two different antibodies. This may be 
due to the fact that SYPRO Ruby non-covalently binds to the basic amino acids 
arginine, histidine and lysine; therefore if the epitope recognised by the antibody had a 
significant number of these basic amino acids then SYPRO Ruby may have more of an 
effect in altering antibody binding. This may provide a reason for the difference in PrP 
6H4 and PrP SAF32 signal reduction: the PrP 6H4 antibody epitope contains two 
arginine residues, whilst the PrP SAF32 antibody epitope contains three histidine 
residues. The one additional basic amino acid in the PrP SAF32 epitope may cause 
SYPRO Ruby to block a greater number of antibody binding sites. 
Some variation between membranes was seen in the quantification of protein 
expression after SYPRO Ruby treatment. This may have been caused by differences in 
the amount of SYPRO Ruby used for normalisation, the length of time the membrane 
was exposed to light after staining, and whether SYPRO Ruby had been re-used. The 
manufacturer‟s data sheets for SYPRO Ruby state that it can be re-used with no 
difference in results, however this was not tested. We tried to limit these variations by 
using an excess of SYPRO Ruby, compared to the membrane, minimising the exposure 
to light and never re-using SYPRO Ruby. 
These results taken together suggest that SYPRO Ruby, although generally a 
validated method for protein normalisation in western blotting, should be used with 
caution. Users would first need to check what effect SYPRO Ruby staining of 
membranes had on antibody detection, and then only use SYPRO Ruby when no 
difference in signal intensity between SYPRO Ruby stained and non-SYPRO Ruby 
stained membranes was seen. Not only is this more complicated, but it is not cost 
efficient, since SYPRO Ruby is more expensive than colloidal Coomassie Blue stain.  
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Chapter 4:  The Role of the Classical Complement Protein 
C1q in Synaptic Degeneration in the ME7 Model 
of Prion Disease 
4.1  Introduction 
Synaptic degeneration is an early event in the progression of many 
neurodegenerative diseases (Heinonen et al., 1995; Cunningham et al., 2003; Gray et 
al., 2009), often occurring before the loss of neurones in a pre-symptomatic stage of the 
disease (section 1.2.2). Models of synaptic degeneration allow investigation of the 
different pathways that could lead to synaptic degeneration. The ME7 model of prion 
disease is a model of chronic degeneration with a synaptic degeneration component 
(Cunningham et al., 2003). Synaptic degeneration begins in the stratum radiatum at 13 
weeks p.i, (~30% loss) which precedes CA1 neuronal loss that follows at 16 weeks p.i. 
The mechanisms that contribute to the synaptic degeneration are poorly understood. 
Conceptually the selective loss of a synapse suggests a tagging mechanism in 
which synapses that are to be lost are marked out. Each neurone can have many 
thousands of synapses indicating that a mechanism exists that ensures that only 
selective synapses are loss. An appealing hypothesis is that the neurone cell body can 
synthesise and secrete a protein which could bind to specific synapses signalling their 
removal. Recent data has suggested that proteins of the complement cascade (section 
1.6) are secreted during specific developmental periods and during disease to opsonise, 
or „tag‟, unwanted or degenerating synapses leading to selective removal. C1q, the 
initiator protein of the classical complement cascade, has been implicated in the 
synaptic degeneration that occurs in the developing and degenerating CNS.  
The aim of this chapter was to investigate the role played by C1q during the 
evolution of slow neurodegeneration characterised by the early loss of synapses. A 
combination of transcript profiling and biochemical protein analysis was used to 
characterise the expression of C1q across disease. In particular behavioural measures of 
disease progression were used as a template to investigate how disease progression 
correlated with changing C1q expression. Further, these behavioural measures were 
used to investigate the disease time course across mice lacking C1q on the assumption 
that if C1q was involved in the synaptic loss by „tagging‟ synapses, then the absence of 
C1q would translate to a decrease in synaptic degeneration.   
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Results showed a late-stage induction of C1q in wildtype mice which argues 
against a role of C1q in the synaptic dysfunction, degeneration and loss, as this process 
already occurs prior to the increase in complement synthesis. Mice with a genetic 
deletion of C1q showed no difference in the expression of examined synaptic associated 
proteins, this suggests that C1q did not contribute to the phase of the disease associated 
with synapse loss, and argues that in this disease model it is not a major determinant of 
the synaptic dysfunction, which is an early event in disease progression. 
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4.2  Methods 
4.2.1  Quantitative real time PCR of 13 and 20 week p.i CA1, CA3 and DG 
cDNA 
800ng of RNA extracted from 13 week and 20 week p.i  hippocampal tissue 
from NBH- and ME7-animals (CA1, CA3 and DG) was reverse transcribed into cDNA 
(section 2.6.2).  
 
4.2.2  Generation of C1qA-/- Mice 
Ten C57BL/6 C1qA-/- mice and eighteen BALB/C C1qA-/- mice were kindly 
provided by Dr Mark Cragg, (Tenovus, Southampton General Hospital). Mice were 
generated by targeted disruption of the C1qA gene using a neomycin cassette (Figure 
4.1). Mice with a genetic deficiency of C1qA are unable to assemble or secrete 
functional C1q (Botto et al., 1998).  
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Figure 4.1. Targeted disruption of C1qA Gene. 
Diagrammatic representation of the C1qA gene, the targeting vector and the structure of 
the disrupted gene containing the neomycin cassette (Botto et al., 1998).
C1qA gene 
Targeting vector 
Targeted gene 
probes  
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4.3  Results 
4.3.1  Transcriptional Induction of C1q in the late-stage of ME7 Prion Disease 
rt-PCR was used to measure the C1qA, C1qB and C1qC mRNA levels in the 
CA1, CA3 and DG from late-stage hippocampal tissue from NBH- and ME7-animals. 
The mRNA expression of C1q was also quantified in naive sex- and age-matched mice, 
which had not undergone any surgery to ensure that the stress from the surgical 
procedure did not cause induction of C1q.  Melting curves were checked to ensure no 
primer dimers were present, and to ensure no genomic contamination was amplified. 
Figure 4.2 showed an example of the raw data obtained from the Opticon Monitor 
software. The quantitation curve provides evidence for the induction of C1qA in 
hippocampal tissue from ME7-animals, compared to hippocampal tissue from NBH-
animals, as evidenced by the separation of the sigmoid curves for NBH- and ME7-
animals. The lower the Ct value the greater the transcript level of the gene of interest. 
The quantitation curve also showed that the surgical procedure did not induce C1qA 
induction, as shown by the overlap of the sigmoid curves for naive and NBH-animals. 
A large induction of C1qA, C1qB and C1qC mRNA was evident in late-stage 
hippocampal tissue from ME7-animals, compared to naïve and NBH-animals (CA1, 
CA3 and DG (n=6)) (Figure 4.3). The graphs represent the mean values alongside a 
scatter plot of mRNA from individual animals showing a clear separation between 
NBH- and ME7-animals. The induction seems to be most pronounced in the CA1 and 
DG. Comparison of the levels of C1q in hippocampal tissue from naive and NBH-
animals confirmed that the surgical procedure did not up-regulate C1q expression, and 
the up-regulation of C1q, seen in hippocampal tissue, from ME7-animals was a 
consequence of the establishment of prion disease. A one-way ANOVA with Tukey‟s 
post-hoc comparison test was used, after the data was normalised to GAPDH (section 
2.8.2.1), to analyse whether there was a significant difference in the means and in which 
area of the hippocampus the up-regulation was significant. C1qA was significantly up-
regulated in the CA1 and DG regions of the hippocampus of ME7- compared to NBH-
animals (F (8, 45) = 12.61, p<0.0001). C1qA induction was not significant in the CA3 
region of the hippocampus of ME7-animals. C1qB was significantly up-regulated in the 
CA1 region of the hippocampus of ME7-animals (F (8, 45) = 4.246, p=0.0007), but not 
in the CA3 or DG regions. C1qC was significantly up-regulated in CA1 and DG of 
ME7-animals compared to NBH-animals (F (8, 45) = 12.93, p<0.0001), but not in the  
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CA3. All three chains of C1q showed a greater than 10-fold induction in the CA1, 5-
fold in the CA3 and 7-fold in the DG of ME7-animals compared to NBH-animals. 
 
4.3.2  Induction of C1q and Disease-Associated Proteins in Late-Stage Disease 
C1q protein levels were investigated to determine whether there was an 
induction of C1q mRNA in the hippocampus translated into an induction of C1q 
protein. In order to confirm the presence of disease, the induction of GFAP, and 
induction of the prion protein, were used as independent markers of disease. Protein 
bands from hippocampal protein homogenates from NBH- and ME7- animals were 
quantified as described in section 2.12.8, and the fold change between ME7- and NBH-
animals calculated. Two–tailed unpaired t-tests were used to analyse the data. 
Representative blots showed the induction of GFAP, PrP, and C1q (Figure 4.4), 
alongside their fold increase in the microdissected hippocampus of late-stage 
hippocampal protein homogenates from NBH- and ME7-animals. The induction of PrP 
immunoreactivity confirmed that the mice were infected with prion disease, had an 
accumulation of prion protein, including the appearance of high molecular weight 
aggregates in the lanes loaded with hippocampal protein homogenates from ME7-
animals, which was not present in the hippocampal protein homogenate from NBH-
animals. A ~4 fold induction in the CA1 (p = 0.009), ~10 fold induction in the CA3 (p = 
0.042), and ~15 fold induction in the DG (p = 0.022) was seen. This result was 
consistent with the previous knowledge that initial PrP accumulation occurs in the DG, 
at 8 weeks p.i, and spreads to the CA3 and CA1 by 20 weeks p.i (Cunningham et al., 
2003). There was a significant induction of GFAP in the hippocampus of ME7-
compared to NBH-animals; ~20 fold in the CA1 (p = 0.0002), ~10 fold in the CA3 (p = 
0.0098) and ~15 fold in the DG (p < 0.0001). The representative blot showed the 
induction of GFAP, and a cleavage product, in the hippocampus of ME7-animals 
compared to NBH-animals. The induction of GFAP, together with the induction of PrP, 
confirmed the presence of prion disease. 
The transcriptional induction of C1q in the hippocampus of ME7-animals 
(Figure 4.3) was translated into a protein induction of C1q (Figure 4.4). The induction 
of C1q was significant in the CA1 (p = 0.028) and DG (p = 0.029) regions, but not in 
the CA3 (p = 0.28) region of the hippocampus of late-stage ME7-animals.   
99 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.2. Quantitation and melting curve from rt-PCR of C1qA on late-stage 
hippocampal cDNA extracted from naive, NBH- and ME7-animals. 
A – Quantitation curve from hippocampal cDNA extracted from naive, NBH- and ME7- 
animals (n=3/ treatment) showing a clear separation between ME7- animals and NBH- 
and naive animals. Hippocampal samples from ME7-animals have a lower Ct valve 
indicating a greater abundance of C1qA compared to NBH- and naive animals. 
Overlapping of the sigmoid curves from NBH- and naive animals confirms that the 
surgical procedure did not cause an up-regulation of C1q. 
B – Melting curve from samples in the quantitation curve (n=3/ treatment). The single 
smooth peak showed that no primer dimers or genomic contamination were present. 
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Figure 4.3. Induction of C1q mRNA in the hippocampus of late-stage hippocampus 
of ME7-animals. 
rt-PCR showed an induction of all three chains of C1q in the hippocampus of late-stage 
ME7-animals (n=6/ treatment).  The induction seemed to be most obvious in the CA1 
and DG (*p ≤0.05). Comparison of C1q levels in naive and NBH-hippocampal tissue 
confirmed that intracranial injection of NBH- or ME7-homogenate did not cause 
upregulation of C1q. 
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This late-stage transcriptional and translational up regulation of C1q in the 
hippocampus of ME7-animals provides evidence for a potential role of C1q in clearing 
cellular debris, or contributing to the inflammatory response leading to neuronal death. 
In order to determine whether C1q may be contributing to the synaptic degeneration, 
which occurs in the ME7 model of prion disease, transcriptional analysis of C1q in the 
mid-stage of disease, a time point at which significant synaptic degeneration (30% loss 
in the CA1) has been previously confirmed (Cunningham et al., 2003), was assessed. 
C1q may be involved in the process by directly tagging synapses, and then by binding 
to the C1q receptor found on astrocytes and microglia and signalling that the synapse is 
degenerating. 
 
4.3.3  Transcriptional Analysis of C1q in the mid-stage of ME7 Prion Disease 
rt-PCR was used to quantify C1qA, C1qB and C1qC mRNA levels in 
microdissected hippocampal (CA1, CA3 and DG) protein homogenate from mid-stage 
NBH- (n=5) and ME7-animals (n=6). Naive (n=6) age-matched animals were used as a 
control for the surgical procedure. Statistical analysis was carried out by one-way 
ANOVA with Bonferroni‟s post-hoc comparison test using GraphPad Prism 5. 
In comparison to the melting curve from 20 week rt-PCR (Figure 4.2) there was 
no separation between the sigmoid curves from NBH- and ME7-animals (Figure 4.5), 
indicating a lack of C1q induction at 13 weeks p.i. 
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Figure 4.4. Induction of PrP, GFAP and C1q in late-stage hippocampal protein 
homogenate from ME7-animals. 
Fold increase in the protein levels of PrP, GFAP and C1q, alongside representative blots 
from late stage CA1 hippocampal protein homogenate from ME7- and NBH-animals. 
Late stage microdissected hippocampus was homogenised and prepared as described in 
section 2.12, and 20µg protein sample was separated on 10% resolving gels, altering 
conditions of transfer (Table 2.3) according to the primary antibody used (*p≤0.05). 
High molecular weight bands in the C1q blot indicate non-specific binding of the 
antibody. 
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Figure 4.5. Quantitation and melting curves for C1qC of hippocampal cDNA 
extracted from NBH- and ME7-animals at 13 weeks post-disease initiation. 
A – Quantitation curve for C1qC in hippocampal cDNA extracted from 13week p.i 
NBH- and ME7-animals, and naive age-matched animals (n=3/ treatment). Note there 
was no longer a separation between the curves for NBH- and ME7-animals, indicating 
there was no induction of C1qC in the hippocampus at 13 weeks p.i. 
B – Melting curve for 13week p.i hippocampus of NBH-, ME7-, and naive age-matched 
animals. The single peaks indicate there were no primer dimers or genomic 
contamination. 
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Figure 4.6. Transcriptional analysis of C1q in the hippocampus of mid-stage NBH- 
and ME7-animals. 
rt-PCR showed there was no significant induction of C1q in the hippocampus of ME7-
animals (n=6/ treatment).  Comparison of C1q levels in naive and NBH-hippocampal 
tissue confirms that intracranial injection of NBH- or ME7-homogenate did not cause 
an up-regulation of C1q.   
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Figure 4.6 shows the transcript levels of C1qA, C1qB and C1qC in the CA1, 
CA3 and DG regions of the hippocampus from mid-stage NBH- and ME7-animals. The 
graphs represent the mean values alongside a scatter plot of the data showing that there 
was no difference between NBH- and ME7-animals. 
One-way ANOVA revealed a significant induction of C1qA protein in the DG 
of ME7-animals compared to naive animals (F(8, 42) = 2.373, p = 0.033). There was no 
significant induction of C1qB (F(8, 42) = 1.554, p = 0.16) in the hippocampus of ME7-
animals. C1qC was significantly induced in the CA1 region of ME7-animals compared 
to naive animals (F(8, 42) = 3.398, p = 0.004). Overall there was a slight trend to an 
increase of C1q levels in ME7-animals compared to NBH-animals, but it was not 
significant. 
 
4.3.4  Investigating the Role of C1q in Prion Disease 
The lack of induction of C1q in the CA1 of ME7-animals suggests that C1q is 
unlikely to serve in the selective removal of synapses in the ME7 model of prion 
disease. The small induction of C1q seen in the DG of ME7-animals compared to naive 
animals indicates that C1q may be responding to the PrP
Sc plaques deposition, as this is 
the region in which the first plaques appear in the ME7 model. 
To investigate whether C1q affects prion disease progression C1qA knockout 
mice were injected with ME7 prion agent and the disease progression monitored to see 
whether it deviated from the previously well characterised disease progression 
(Cunningham et al., 2003).  Since we recorded a large induction of C1q in the late-stage 
hippocampus of ME7-animals, and a modest induction in the mid-stage, C1qA 
knockout mice were injected with either NBH or ME7 prion agent and the progression 
of the disease assayed using burrowing, glucose consumption and the inverted screen 
behavioural tests. 
Ten C57BL/6 C1qA+/+, Ten C57BL/6 C1qA -/-, eleven BALB/C C1qA+/+ and 
eighteen BALB/C C1qA -/- mice were injected with either NBH or ME7 brain 
homogenate, and their burrowing, glucose consumption, and inverted screen behaviours 
analysed (section 2.3), to determine whether there was any deviation in the onset of 
disease (Cunningham et al., 2003). Overnight burrowing, glucose consumption (Figure 
4.7), inverted screen and mouse body weights (Figure 4.8) were recorded weekly from 
week 9 post-injection until week 20, after which mice were sacrificed for subsequent  
106 
 
analysis. All data was analysed by two-way repeated measures ANOVA with 
Bonferroni‟s post-test using GraphPad Prism 5. 
 
4.3.4.1  Overnight Burrowing 
After the initial 2 week group burrow (section 2.3.1), mice were tested 
individually on a weekly basis (Figure 4.7). Statistical analysis of these observations 
showed, as predicted, that C57BL/6 C1qA +/+ mice injected with ME7 prion agent 
showed a decline in burrowing from week 12 onwards (P≤0.05). In contrast, C57BL/6 
C1qA-/- mice injected with ME7 showed a decline from 14 weeks (P≤0.05) onwards, 
revealing a difference of two weeks in the onset of burrowing deficiencies. NBH-
animals from both C57BL/6 C1qA +/+ and C1qA-/- showed no decrease in the amount 
burrowed between weeks 9-20. In comparison to C57BL/6 mice, the BALB/C C1qA+/+ 
and BALB/C C1qA-/- ME7-animals showed no difference in the onset of burrowing 
deficiency, with both showing a decline in burrowing from week 16 (P≤0.05). 
Comparing C57BL/6 C1qA+/+ and BALB/C C1qA+/+ ME7-injected mice revealed a 
strain difference in the decline of burrowing behaviour. C57BL/6 C1qA+/+ ME7 mice 
declined, as expected, at week 12 (P≤0.05), whereas BALB/C C1qA+/+ ME7 mice 
declined at week 16 (P≤0.05) showing a four week difference in the onset of behaviour. 
 
4.3.4.2  Glucose Consumption 
As predicted, C57BL/6 C1qA+/+ ME7-animals showed a decline in glucose 
consumption from week 12 (P≤0.05), and C57BL/6 C1qA-/- ME7-animals showed a 
decline from 14 weeks (P≤0.05), a 2 week delay compared to C57BL/6 C1qA+/+ ME7-
animals (Figure 4.7). NBH-animals for both C57BL/6 C1qA+/+ and C57BL/6 C1qA-/- 
showed no decline in glucose consumption, apart from the sudden unexplained dip at 
week 16 for C57BL/6 C1qA-/- NBH-animals. BALB/C C1qA+/+ and BALB/C C1q-/- 
showed the same amount of glucose consumption throughout the weeks tested. A strain 
difference can also be seen in glucose consumption. C57BL/6 mice consumed around 
15g of glucose, whereas BALB/C mice drank around 5g. BALB/C ME7- and NBH-
animals showed no decline in glucose consumption.  
 
4.3.4.3  Inverted Screen 
Inverted screen assays were performed for C57BL/6 C1qA+/+, C57BL/6 C1qA-
/- and BALB/C C1qA+/+ mice (Figure 4.8). C57BL/6 C1qA+/+ and C57BL/6 C1qA-/-  
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ME7-animals showed a progressive decline in the length of time they remained 
suspended upside down from 18 weeks post disease initiation (P≤0.05). BALB/C 
C1qA+/+ ME7-animals showed a decline from week 20 (P≤0.05), once again showing a 
strain difference between C57BL/6 and BALB/C mice in the onset of the disease-
dependent behavioural dysfunction. There was no difference in the time spent 
suspended upside down between NBH-animals.  
 
4.3.4.4  Mouse Body Weight 
Mice were weighed once a week (Figure 4.8) before the inverted screen test. 
There was no difference in the body weights of NBH- and ME7-animals for C57BL/6 
C1qA+/+ and C57BL/6 C1qA-/- mice. In comparison, BALB/C C1qA+/+ mice showed 
a significant difference in the weights ME7-animals compared to NBH-animals from 
week 16 (P≤0.05).  
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Figure 4.7. Burrowing and glucose consumption tests on C1qA+/+ and C1qA-/- mice to assess any differences in the progression of disease. 
Ten C57BL/6 C1qA+/+, ten C57BL/6 C1qA -/-, eleven BALB/C C1qA+/+ and eighteen BALB/C C1qA-/- mice were injected with either NBH or 
ME7 brain homogenate and their burrowing and glucose consumption behaviours measured weekly from week 9 post injection until week 20 when 
mice were sacrificed for subsequent analysis (*p≤0.05). 
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Figure 4.8. Inverted screen test and body weight from C1qA+/+ and C1qA-/- mice. 
Ten C57BL/6 C1qA+/+, ten C57BL/6 C1qA-/-, and eleven BALB/C C1qA+/+ mice were injected with either NBH or ME7 brain homogenate and 
their strength and weight measured weekly from week 9 post injection until week 20 when mice were sacrificed for subsequent analysis, to determine 
whether C1q had an effect of disease progression (*p≤0.05).  
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4.3.5  Transcriptional Analysis of C1q in Wildtype and C1qA Knockout Mice 
Injected with ME7 Prion Agent 
Real-time PCR was used to quantify C1q mRNA and cytokine levels in the 
hippocampus of wildtype or C1qA knockout mice injected with ME7 prion agent (n=5), 
or NBH (n=5/6). All statistical analysis was carried out by one-way ANOVA with 
Bonferroni‟s post-hoc comparison test using GraphPad Prism 5. The graphs represent 
the mean values alongside a scatter plot of the data revealing any differences in levels of 
mRNA. Transcriptional analysis revealed an induction of C1qB and C1qC in both 
wildtype and C1qA knockout ME7-animals. There was an induction of C1qA in 
wildtype ME7-animals but not C1qA knockout ME7-animals (Figure 4.9), confirming 
the absence of C1qA in knockout mice. One-way ANOVA showed a significant 
induction of C1qA between wildtype NBH-animals and wildtype ME7-animals for both 
C57BL/6 and BALB/C mouse strains (F(7, 33) = 157.6, p < 0.0001). The induction of 
C1qA was greater in C57BL/6 WT ME7-animals compared to BALB/C WT ME7-
animals. C1qB (F(7,33) = 140.9, p <  0.0001) and C1qC (F(7,33) = 107.2, p< 0.0001) 
induction was seen in all ME7-animals regardless of background indicating that C1qB 
and C1qC mRNA were made in the absence of C1qA, although functional C1q protein 
could not be assembled (Botto et al., 1998). C1q induction was greater in C57BL/6 WT 
mice compared to BALB/C WT mice. 
Next the induction of the classical complement serine proteases were analysed 
(Figure 4.10). C1r (F(7, 33) = 17.56, p < 0.0001) and C1s (F(7, 33) = 24.48, p < 0.0001) 
were significantly induced in C57BL/6 WT ME7-animals and BALB/C KO ME7-
animals. BALB/C KO ME7-animals had a greater induction of C1r, and C1s, compared 
to BALB/C WT ME7-animals.  
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Figure 4.9. Induction of C1q mRNA in the hippocampus of late-stage hippocampus 
of ME7-animals from wildtype and C1q knockout mice. 
rt-PCR shows an induction of C1qB and C1qC in the hippocampus of late-stage ME7-
animals (n=5/ treatment). Induction of C1qA occurs only in wildtype mice confirming 
the knockout of C1qA (*p ≤0.05).   
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Figure 4.10. Transcriptional changes of the C1q serine proteases, C1r and C1s. 
rt-PCR shows a selective induction of C1r and C1s in the hippocampus of late-stage 
ME7-animals (n=5/ treatment) (*p ≤0.05). 
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4.3.6  Cytokine Profiles of C1q Sufficient and Deficient Mice  
C57BL/6 and BALB/C mice have different genetic backgrounds. C57BL/6 mice 
have a predominantly Th-1 response, whilst BALB/C mice have a predominantly Th-2 
response (Watanabe et al., 2004). To determine whether the genetic background of the 
mouse affects the inflammatory profile, which could possibly affect disease 
progression, we investigated the transcriptional expression of commonly secreted 
cytokines. We concentrated on the expression of cytokines in the late-stage of prion 
disease as this was when the predominant up-regulation of C1q, and its associated 
serine proteases, was seen.  
Analysis of both pro-inflammatory and anti-inflammatory cytokines was 
assessed to determine whether there was a difference in inflammatory status between 
C57BL/6 and BALB/C strains of mice. Analysis of the pro-inflammatory cytokine IL-
1β (Figure 4.11) showed no significant induction in ME7-animals (F(7,33) = 2.173, p = 
0.0628), compared to NBH-animals, however, there was a significant induction of 
mRNA for TNFα (F(7, 31) = 16.61, p < 0.0001) in ME7-animals compared to NBH-
animals (Figure 4.11). The induction of TNFα was significantly lower in C57BL/6 KO 
mice compared to C57BL/6 WT mice. The induction was the same for all BALB/C 
mice. Analysis of the anti-inflammatory cytokine IL-10 (Figure 4.12) revealed no 
induction in ME7-animals compared to NBH-animals (F(7, 33) = 1.24, p = 0.323) and 
there was no effect of mouse strain. Similarly, there was no significant induction of IL-6 
in either strain (F(7, 33) = 1.432, p = 0.2261)(Figure 4.12). This indicated that the strain 
of the mouse had no effect on the inflammatory profile. 
Analysis of disease-associated proteins was undertaken to determine whether the 
absence of C1q affected the disease profile. 
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Figure 4.11. Transcriptional analysis of IL-1β and TNFα in C1q sufficient and 
deficient mice. 
Transcriptional analysis of IL-1β and TNFα in the late-stage hippocampus revealed an 
induction of TNFα in ME7-injected mice compared to NBH-injected mice. No 
difference in the expression of IL-1β was found. 
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Figure 4.12. Transcriptional analysis of IL-10 and IL-6 in wildtype and C1qA 
knockout mice. 
rt-PCR revealed that there was no induction of the antinflammatory cytokine IL-10 and 
proinflammatory cytokine IL-6 in C1q sufficient or deficient mice. 
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4.3.7  Optimisation of C1q Antibody 
In order to analyse hippocampal protein samples from C1q sufficient and 
deficient mice for the presence/absence of C1q, the binding sites of the C1q antibody to 
be used were determined to assess whether the antibody binds to epitopes on a single 
chain or on multiple chains of C1q. C1q is made up of three different chains, C1qA, 
C1qB, and C1qC, which assemble to form the mature C1q protein (Arlaud et al., 2001).  
Purified Human C1q (Quidel) was separated on a 10% SDS resolving gel alongside 
20ug protein samples from C1q sufficient (WT) and C1q deficient (KO) NBH- and 
ME7-animals. When separated under reducing conditions, bands representative of 
C1qA (29kDa), C1qB (26kDa), and C1qC (22kDa) were clearly visible (Figure 4.13). 
The antibody preferentially binds to epitopes on C1qA, followed by C1qB and C1qC as 
seen by the difference in C1q antibody staining intensity between the three chains.  
Protein samples from wildtype NBH- and ME7-animals showed the expected induction 
of C1q in ME7-animals. Faint bands were also seen in C1qA KO NBH- and ME7-
animals showing that in mice that lacked C1qA, the antibody bound to epitopes on 
C1qB and C1qC. This suggests that in the absence of C1qA, C1qB and C1qC were still 
synthesised, even though functional C1q was not assembled (Botto et al., 1998). 
 
4.3.8  Biochemical Analysis of Disease-Associated Markers 
Biochemical analysis of disease-associated markers was undertaken, firstly to 
determine whether the absence of C1q affects the disease profile, and secondly to 
establish whether the genetic background of the mouse affects the disease progression. 
All statistical analysis was carried out by one-way ANOVA with Bonferroni‟s post-hoc 
comparison test using GraphPad Prism 5. 
As expected there was an induction of PrP in ME7-animals compared to NBH-
animals (F(7, 24) = 59.19, p < 0.0001). Interestingly, the induction of PrP in C1qA KO 
mice was significantly lower than the induction seen in WT mice. There was a ~10 fold 
increase of PrP in C57BL/6 WT mice versus a ~6 fold increase in C57BL/6 KO mice, 
and a ~5 fold increase of PrP in BALB/C WT mice versus a ~4 fold increase in 
BALB/C KO mice (Figure 4.14 and Figure 4.15). 
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Figure 4.13. Optimisation of C1q antibody 
10µg of purified C1q protein was separated on a 10% SDS gel alongside 20µg of 
protein samples from C1q sufficient (WT) and C1q deficient (KO) NBH- and ME7-
animals. Human C1q is made up of three chains; C1qA (29kDa), C1qB (26kDa), and 
C1qC (22kDa). The antibody preferentially binds to epitopes on C1qA, followed by 
C1qB and C1qC. An induction of C1q can be seen in WT ME7-animals compared to 
NBH-animals. In the absence of C1qA (KO NBH and KO ME7) the C1q antibody will 
bind to epitopes on C1qB and C1qC giving rise to faint bands in C1q deficient mice. 
   
C1qA  
C1qB 
C1qC 
W
T
 
M
E
7
 
K
O
 
N
B
H
 
W
T
 
N
B
H
 
K
O
 
M
E
7
 
C
1
q
 
P
r
o
t
e
i
n
  
118 
 
There was a prominent astrogliosis associated with the establishment of prion 
disease. A large ~11 fold induction in GFAP (F(7, 24) = 51.84, p < 0.0001) was 
revealed in ME7-animals compared to NBH-animals in both WT and KO mice in 
C57BL/6 and BALB/C mouse strains (Figure 4.14 and Figure 4.15).  
The expression of synaptic proteins was analysed to determine whether there 
was a difference in synapse loss in ME7-animals in the absence of C1q (Figure 4.14 and 
Figure 4.15). There was a significant ~2 fold decrease in the staining intensity of SY38 
in BALB/C KO ME7-animals compared to BALB/C KO NBH-animals (F(7, 34) = 
4.957, p = 0.0006). There was no significant difference in SY38 staining intensity in 
C57BL/6 ME7-animals and BALB/C WT mice. There was a significant ~2 fold 
decrease in staining intensity of syntaxin in C57BL/6 KO ME7-animals and BALB/C 
WT ME7-animals (F(7, 34) = 8.813, p < 0.0001), but no significant difference in 
C57BL/6 WT ME7-animals and BALB/C KO ME7-animals. PSD95 was analysed to 
determine postsynaptic loss. There was a significant ~2 fold decrease in PSD95 in 
C57BL/6 WT and KO ME7-animals and BALB/C KO ME7-animals (F(7, 34) = 5.089, 
p = 0.0005), but a no significant difference in BALB/C WT ME7-animals. 
The transcriptional induction of C1q in the hippocampus of C57BL/6 and 
BALB/C WT ME7-animals was translated into a protein induction of C1q (Figure 4.14) 
(F(7, 34) = 16.25, p < 0.0001). As expected there was no C1q in NBH-animals or in KO 
mice from both genetic backgrounds, confirming that C1q was not assembled even 
though C1qB and C1qC transcript were up-regulated (Figure 4.9). 
    
119 
 
PrP
C57 WT NBH
C57 WT ME7
C57 KO NBH
C57 KO ME7
BALB/C WT NBH
BALB/C WT ME7
BALB/C KO NBH
BALB/C KO ME7
0
100
200
300
I
n
t
e
n
s
i
t
y
*
*
*
*
*
*
*
GFAP
C57 WT NBH
C57 WT ME7
C57 KO NBH
C57 KO ME7
BALB/C WT NBH
BALB/C WT ME7
BALB/C KO NBH
BALB/C KO ME7
0
50
100
150
200 *
*
*
*
SY38
C57 WT NBH
C57 WT ME7
C57 KO NBH
C57 KO ME7
BALB/C WT NBH
BALB/C WT ME7
BALB/C KO NBH
BALB/C KO ME7
0
100
200
300
400
500
I
n
t
e
n
s
i
t
y *
PSD95
C57 WT NBH
C57 WT ME7
C57 KO NBH
C57 KO ME7
BALB/C WT NBH
BALB/C WT ME7
BALB/C KO NBH
BALB/C KO ME7
0
5
10
15
20 *
*
*
Syntaxin
C57 WT NBH
C57 WT ME7
C57 KO NBH
C57 KO ME7
BALB/C WT NBH
BALB/C WT ME7
BALB/C KO NBH
BALB/C KO ME7
0
200
400
600
800
I
n
t
e
n
s
i
t
y
*
*
*
*
C1q
C57 WT NBH
C57 WT ME7
C57 KO NBH
C57 KO ME7
BALB/C WT NBH
BALB/C WT ME7
BALB/C KO NBH
BALB/C KO ME7
0
1
2
3
4
5
*
*
*
*
 
Figure 4.14. Biochemical analysis of disease-associated markers in the late-stage 
hippocampal protein homogenate from ME7-animals in C1q sufficient and 
deficient mice 
Protein staining intensity for PrP, GFAP, SY38, PSD95, syntaxin, and C1q from 
hippocampal protein homogenate from NBH- and ME7-animals, in both C57BL/6 and 
BALB/C backgrounds (p≤0.05). Late-stage hippocampus was homogenised and 
prepared as described in section 2.12. 20µg protein homogenate was separated on 10% 
resolving gels, altering conditions of transfer according to the primary antibody used 
(Table 2.3).  
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Figure 4.15. Fold change of disease-associated markers in late-stage hippocampal 
homogenate from C1q deficient and sufficient mice 
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4.4  Discussion 
In this chapter, the work examined the role of C1q, the initiator protein of the 
classical complement cascade as a contributor to prion disease. In particular we took 
advantage of the well defined spatial and temporal synapse loss in the ME7 model of 
prion disease to assess whether C1q was labelling degenerating synapses. Initiating 
disease in genetic backgrounds lacking C1q allowed the investigation of the molecular 
correlates of synaptic loss, misfolded protein and debris clearance, all of which are 
indicators of the neuroinflammatory response associated with prion disease. 
 
4.4.1  Synaptic Tagging 
Data published from Stevens et al (2007) showed that C1q expression was up-
regulated in a developing retina and brain during a period of synaptic pruning of 
supernumerary synapses, and that secreted C1q was selectively localised to synaptic 
terminals (Figure 1.1). In addition, it was proposed that C1q was localised to the adult 
retinal synapse in a DBA/2J glaucoma mouse, at a stage of the disease before any 
neuronal loss could be detected. The localisation of C1q suggested that the classical 
complement cascade could mediate synapse loss in glaucoma and by extension other 
CNS neurodegenerative diseases. Based on this, a hypothesis was formed indicating that 
C1q could be involved in the synaptic loss that characterises the early stages of many 
neurodegenerative diseases (Table 1.2) (Cunningham et al., 2003; Gray et al., 2009). 
Synaptic degeneration in the ME7 model of prion disease occurs at 13weeks p.i 
in the stratum radiatum of the hippocampus, and is independent of neuronal cell body 
loss (Cunningham et al., 2003). We therefore studied whether C1q was upregulated in 
the hippocampus of 13 and 20 week p.i ME7-animals. In addition to the astrocytes, it is 
possible that the CA1 pyramidal neurones or CA3 pyramidal neurones secrete C1q, in 
response to an unknown stimulus (Barnum, 1995), which could then opsonise the 
dysfunctional synapses for selective removal. Results showed that C1q was not 
upregulated in the hippocampus of ME7-animals (except in the DG of ME7-animals 
relative to naive animals) at 13 weeks p.i. This finding indicates that C1q was not 
expressed by neurones, to prune synapses, by secreting induced C1q to „tag‟ their own 
sub-compartments to mediate synaptic removal. Data in support of this finding includes 
a lack of C1q immunoreactivity in 13 week p.i hippocampal brain sections from ME7-
animals (Katie Restall, unpublished); confirming that C1q was not upregulated in the 
hippocampus of ME7-animals at 13weeks p.i. My results indicate that C1q was not  
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involved in the early stage events which contribute to, or cause, synaptic degeneration. 
This data provides further evidence that in the ME7-model of prion disease C1q does 
not modulate synapse loss by „tagging‟ dysfunctional synapses. Furthermore, our 
analysis of synaptic markers in the late stage hippocampus of ME7-animals showed 
that, in general, the absence of C1q did not affect synapse loss, as evidenced by the 
similar fold decreases in the expression of synaptic proteins  
The localisation of C1q in ME7-animals was investigated (Katie Restall, 
unpublished data). Hippocampal sections from late-stage ME7- and NBH-animals were 
double immunostained with antibodies against C1q and GFAP, or a neuronal process 
marker, MAP-5. C1q positive staining co-localised with GFAP throughout the 
hippocampus, but failed to colocalise with MAP-5. This implies that C1q was not 
localised to neuronal processes in the late stages of prion disease. This data suggests 
that astrocytes are the main source of C1q in prion disease and is consistent with 
previous investigations in the CNS (Paul, 2008). The profound induction of C1q 
confirmed in the late stage, coupled with no induction at 13 weeks, and no differences 
in synaptic loss, indicates that C1q does not contribute to synaptic loss in the ME7 
model. The large late stage induction could imply that C1q contributes, or is a 
consequence of, neuronal loss, or some other facet of the disease. 
 
4.4.2  Clearance of Plaques or Cellular Debris 
One possible role for the large induction of C1q, seen in the hippocampus of 
late-stage ME7-animals, could be to aid in the clearance of prion plaques, or the cellular 
debris caused by the neuronal death which occurs at around 16wks p.i. 
Induction of C1q in the DG of 13 week p.i ME7-animals could indicate that C1q 
is upregulated in prion disease to aid in the clearance of accumulated prion plaques, as 
is seen in other neurodegenerative diseases such as Alzheimer's disease (Alexander et 
al., 2008). C1q has been shown to bind to immobilised PrP and scrapie amyloid fibrils 
(SAF) (Sim et al., 2006). Cunningham et al (2003) report that at 13 weeks p.i PrP
Sc 
accumulation is initially seen in the hilus and mossy fibres of the hippocampus of ME7-
animals, the site of injection, therefore it is possible that C1q opsonises plaques and 
recruits macrophages to ingest them.  
C1q mRNA and protein were significantly upregulated in the hippocampus of 
late-stage ME7-animals but not NBH-animals, and the induction seemed to be greater in 
the CA1 region of the hippocampus (Figure 4.3 and Figure 4.4). C1q could be  
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opsonising the neurones and aiding their clearance, via the recruitment of phagocytes, or 
activation of the classical complement cascade leading to the insertion of the MAC into 
the neurone membrane. Studies have shown that neurones are able to bind C1q and 
activate the complement cascade leading to neuronal cell lysis (Singhrao et al., 2000). 
Studies in preclinical Alzheimer's disease patients have shown the presence of C1q in 
the hippocampus, associated both with neurones and Aβ plaques. Synthesis of C1q has 
been shown in pyramidal neurones and glial cells in Alzheimer's disease as well as other 
injury models (Fonseca et al., 2004a) (section 1.6.2). It is also possible that the 
downstream complement component C3b binds to neurones, or cellular debris, and 
activates C3 receptors on microglia leading to elimination by phagocytosis. De novo 
synthesis of C1q in the brain has been shown in rat brain slices after kainic acid (KA) 
treatment or deafferenting lesions, this increase was similar for all three chains of C1q 
and was thought to originate from neurones, microglia, astrocytes and macrophages, all 
of which contained C1q mRNA (Goldsmith et al., 1997). To determine whether 
complement C1q was involved in the clearance of plaques or cellular debris, or aiding 
in the apoptosis of neurones, C1qA knockout mice were injected with ME7 prion agent 
and their disease progression analysed. 
BALB/C C1qA+/+, BALB/C C1qA-/-, C57BL/6 C1qA+/+ and C57BL/6 C1qA-
/- mice were injected with either NBH or ME7 prion agent, and the disease progression 
was monitored by behavioural tests. Burrowing behaviour and glucose consumption in 
ME7-animals begins to decrease from week 11 compared to NBH mice. Data from the 
behavioural studies (Figure 4.7 and Figure 4.8) showed a differential effect based on the 
strain of the mouse. Whilst C57BL/6 mice showed a 2 week delay in the decrease of 
burrowing between C1qA+/+ and C1qA-/- mice, BALB/C mice did not show a 
difference between C1qA+/+ and C1qA-/- mice. In addition, the predicted decrease in 
burrowing seen at 12 weeks in the C57BL/6 C1qA+/+ ME7-animals was delayed by 4 
weeks in BALB/C C1qA+/+ ME7-animals showing a strain-specific effect of prion 
disease progression.  
This observation was unexpected because the progression of prion disease, and 
incubation times, are thought to be controlled by the Prnp gene allele. The Prnp gene of 
mice has two well characterised alleles, Prnp
a and Prnp
b. The Prnp
a allele differs to 
Prnp
b allele by only two amino acid at codons 108 (L108F) and 189 (T189V), resulting 
in a longer incubation period in mice with the Prnp
b allele (Brown et al., 2000). Both 
BALB/C and C57BL/6 mice have the Prnp
a/a (short incubation period) allele, and  
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therefore should have the same incubation times (Kingsbury, 1990), although the 
disease may spread through the brain differently and impact different brain structures 
differentially. It is possible that the difference in the mice‟s genetic background could 
contribute to the slight differences in the progression of prion disease, which translated 
into a difference in the onset of burrowing between C57BL/6 and BALB/C mice, 
however this did not translate into a difference in synaptic profile.  
The inverted screen assays showed no difference in C57BL/6 C1qA+/+ and 
C1qA-/- indicating that C1q had no effect in the later stages of prion disease in 
C57BL/6 mice. It is possible that the absence of C1q in C57BL/6 mice in the earlier 
stages of disease was protective, shown by the two week delay in burrowing and 
glucose consumption, but once the disease had advanced, the absence of C1q had no 
effect. Mabbot et al (2001) reported that intracranial injection of ME7 prion agent into 
C57BL/6 C1qA-/- mice showed no difference in the incubation period of disease or 
spongiform pathology within the brain. However, intraperitoneal injection of ME7 prion 
agent into C57BL/6 C1qA-/- mice caused a delay in the onset of disease symptoms 
compared to C1qA+/+ controls. C1q may be involved, to a limited extent, in the 
migration of PrP into the CNS, by possibly opsonising PrP and aiding its uptake into 
follicular dendrite cells, before invading the CNS. This effect was only seen with 
limited amounts of injected ME7 homogenate, because injection of high doses of ME7 
agent did not affect pathogenesis in C1qA-/- mice (Mabbott et al., 2001). In addition, 
even after injection of limited doses of PrP, all mice eventually succumbed to prion 
disease, indicting that C1q does not play a critical role (Mabbott et al., 2001), therefore 
it was necessary to examine disease progression in the C1qA knockout background with 
markers of cell loss, astrocytosis, microglia activation, and PrP
Sc accumulation. 
Markers of disease progression were analysed biochemically to determine 
whether the absence of C1q affected disease progression. Interestingly, the 
accumulation of PrP was reduced in C1q deficient mice compared to C1q sufficient 
mice, and BALB/C KO ME7-animals mice had significantly less PrP accumulation 
compared to C57BL/6 KO ME7-animals (Figure 4.14). It is interesting to note that even 
though BALB/C KO ME7-animals showed no delay on the onset of burrowing 
deficiencies, there was a decreased accumulation of PrP. This implied that the absence 
of C1q led to a decreased accumulation of PrP. However, this decreased accumulation 
did not impact on the synaptic profile, as there were no changes in the synaptic markers 
examined between C1q sufficient and deficient mice (Figure 4.14). This result also  
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implied that PrP was not involved in the clearance of PrP plaques, as evidenced by the 
decrease of PrP in the absence of C1q, and not an increase. Instead it was possible that 
C1q was involved in the proliferation of PrP, and therefore in the absence of C1q, there 
was a decreased PrP accumulation. 
 
4.4.3  Immunoregulatory Role of C1q 
Transcriptional analysis of C1q sufficient and deficient mice on a C57BL/6 and 
BALB/C background (section 4.3.1) was undertaken to determine whether a lack of 
C1q affected previously characterised genes: the transcriptional analysis of the pro-
inflammatory cytokines IL-1β, IL-6, and TNFα, and the anti-inflammatory cytokine IL-
10 was also assessed to determine whether the absence of C1q affected the 
inflammatory profile. Any strain differences were also noted. As expected, there was no 
C1qA induction in C57BL/6 KO ME7-animals and BALB/C KO ME7-animals; 
however, there was still an induction of C1qB and C1qC in these mice, albeit to a lesser 
extent, indicating that the induction of C1qB and C1qC are not dependent on C1qA, 
even though functional C1q protein cannot be assembled without all three chains 
((Botto et al., 1998). A strain-specific difference in the induction of C1qA, C1qB and 
C1qC was seen in C57BL/6 WT ME7-animals and BALC/C WT ME7-animals, with 
BALB/C WT ME7-animals showing a significantly smaller induction compared to 
C57BL/6 WT ME7-animals (Figure 4.9). This indicates that the extent of C1q 
induction, in response to prion disease pathogenesis, was dependent on the strain of the 
mouse.  This was also true for the induction of the C1q serine proteases (Figure 4.10). 
There was a significant induction of C1r and C1s in BALB/C KO ME7-animals, but not 
C57BL/6 KO ME7-animals. Previous transcriptional analysis of pro-inflammatory and 
anti-inflammatory cytokines revealed a small but significant induction of IL-1β, TNFα, 
IL-10, IL-13 and TGFβ in the brains of late-satge  ME7-animals (Thackray et al., 2004; 
Cunningham et al., 2005). Similar analysis was carried out in C1q sufficient and 
deficient mice, which revealed a significant induction of TNFα, but not IL-1β, IL-6 or 
IL-10 (Figure 4.11 and Figure 4.12). There was no difference in the cytokine levels 
between BALB/C and C57BL/6 indicating that the strain of the mouse has no effect on 
the cytokine profile in prion disease. The ME7 prion agent induced a cytokine response 
that was modified by the lack of C1q, in respect to TNFα. It is possible that C1q acts up 
stream of TNFα. Studies conducted by Veerhuis et al (2004) found that C1q increased 
microglia activation induced by synthetic prion peptides, leading to an acceleration of  
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fibrillation of PrP and accumulation of PrP. The absence of C1q in the C57BL/6 C1q 
knockout mice could have led to a decrease in microglia activation, which led to a 
decrease in cytokine synthesis and expression (as seen by the decrease in TNFα and IL-
10). This could have caused the decrease in PrP accumulation that in turn could have 
lead to the two week delay in the onset of burrowing behaviour.  
 
4.4.4  Final Conclusions 
Despite the clear induction of C1q within prion disease, the temporal and spatial 
distribution of complement suggests that C1q was not „tagging‟ synapses in this model 
of chronic neurodegeneration. The late stage activation of C1q suggests that 
components of the classical complement cascade are unlikely to contribute to synaptic 
loss. Based on the time course and the cellular basis of upregulation, C1q was acting as 
an opsin to coat cellular debris from dying synapses and neurones, aiding in their 
clearance (Nadeau and Rivest, 2001; Zipfel, 2009).   
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Chapter 5:  Hippocampal Synaptic Degeneration in the CSPα 
Knockout Model of Synaptic Degeneration 
5.1  Introduction 
Cysteine string protein alpha (CSPα) is a 34kDa member of the J protein family, 
with an N-terminal J-domain, a linker domain and a central cysteine rich domain 
(Figure 5.1).  
Mice with a genetic deletion of CSPα die prematurely and exhibit a progressive 
neurological phenotype associated, with synaptic degeneration and loss (section 1.3.5). 
Knockout mice begin to die from postnatal week 3 and no mice survive beyond 3 
months of age (Figure 5.2). CSPα+/+, and CSPα+/-, mice develop normally and show 
no difference in mortality and weight gain indicating that CSPα is haplo-sufficient 
(Fernández-Chacón et al., 2004).  
We initiated work to gain an insight into the mechanisms of synaptic 
dysfunction, degeneration and loss. In contrast to the ME7 model of prion disease, the 
CSPα KO model allows the investigation into mechanisms of synaptic dysfunction, and 
loss, without the added complexity of accumulated misfolded protein (Fernández-
Chacón et al., 2004). In order to do this, the synaptic degeneration in the hippocampus 
was characterised, and associated cellular changes investigated. Multiple synaptic 
markers were used to assess whether a synaptic loss could be detected in CSP -/- mice. 
Initially, SY38 and PSD95 antibodies were used to determine whether we could detect 
gross loss of synapses. SY38 and PSD95 are found on the majority of synapses within 
the hippocampus, but evidence suggests that only a subpopulation of inhibitory 
synapses is degenerating within the hippocampus (Garcia-Junco-Clemente et al., 2010). 
Therefore, hippocampal protein expression of neuroligin 1 (NL1) and neuroligin 2 
(NL2) were examined to determine whether there was a difference in the number of 
excitatory or inhibitory synapse. Neuroligin 1is a postsynaptic protein thought to be 
specific for excitatory synapses, whereas neuroligin 2 is a postsynaptic protein thought 
to be specific for inhibitory synapses (Chih et al., 2005). The initial analysis involved 
investigating whether C1q was involved in the synaptic degeneration previously 
reported to occur in this model (Garcia-Junco-Clemente et al., 2010). 
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Figure 5.1. Schematic representation of CSPα.  
CSPα has an N-terminal J-domain, a linker domain, a central cysteine rich domain, and 
a variable C-terminal domain. Adapted from Swayne et al., (2006) and Chamberlain and 
Burgoyne, (2000). 
    
129 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.2. Characterisation of CSPα KO mice. 
Mice with a genetic deletion of CSPα stop gaining weight at P14, and by P30 mice enter 
a lethargic state. CSPα KO mice started to die in the third postnatal week, and none 
survive beyond 3 months (Fernández-Chacón et al., 2004). 
 
    
130 
 
    
131 
 
5.2  Results 
5.2.1  Characterisation of CSPα +/+, CSPα +/- and CSPα -/- mice 
Hippocampal protein expression of CSPα was determined to ensure that the 
genotyping of mice used in the experiments was correct. CSPα +/- mice expressed half 
the amount of CSPα compared to CSPα+/+ mice, and CSPα -/- mice expressed no CSPα 
(Fernández-Chacón et al., 2004).  
Figure 5.3 shows the normalised protein levels for CSPα. The representative blot 
for CSPα clearly showed that CSPα +/- mice had significantly less CSPα compared to 
CSPα +/+ mice, and CSPα -/- mice had no detectable levels of CSPα (F(2, 14) = 96.99, 
p <0.0001). This confirms that the genotyping was correct and therefore any subsequent 
hippocampal protein analysis was comparing protein levels of CSPα +/+, +/- and -/- 
mice. CSPα can also exist as a dimer of 54kDa (Gundersen et al., 2010), which was also 
reduced in CSPα +/- mice and nonexistent in CSPα -/- mice. Analysis was carried out 
by one-way ANOVA with Bonferroni‟s post-hoc multiple comparisons test using 
GraphPad Prism 5. 
 
5.2.2  Hippocampal Protein Expression in P28 CSPα Wild-Type, Heterozygous, 
and Knock-Out Mice. 
Figure 5.3 shows that hippocampal protein levels of synaptophysin, a 
presynaptic vesicle membrane protein, were not significantly different between CSPα 
+/+, +/- and -/- mice (F(2, 14) = 0.48, p = 0.63), indicating that there was no widespread 
presynaptic terminal loss in the hippocampus of P28 CSPα -/- mice. The level of 
PSD95, a scaffolding protein found on postsynaptic densities of neurones, was 
examined to detect whether there was any loss of postsynaptic terminals (Figure 5.4).     
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Figure 5.3. Graphical representation of normalised western blot data from CSPα 
wild-type, heterozygous, and knockout mice. 
Coomassie normalised data of hippocampal protein homogenate from CSPα +/+, +/- 
and -/- (n=5/genotype) for CSP and SY38, and representative blots (before 
normalisation). CSPα blots show that CSPα +/- mice had ~half as much as CSPα +/+ 
mice and CSPα -/- mice did not have any detectable levels of CSP, as shown by the lack 
of CSP immunoreactivity in the blots. Expression of SY38 shows no significant 
difference in the expression between CSPα +/+, +/- and -/- mice indicating there was no 
presynaptic degeneration (*p≤0.05). 
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There was no significant difference in the level of PSD95 between CSPα +/+, 
+/- and -/- mice (F(2, 14) = 0.55, p = 0.59), showing that there was no gross loss of 
postsynaptic terminals within the hippocampus. There was no significant difference in 
the levels of NL1 (F(2, 14) = 0.50, p = 0.62) and NL2 (F(2, 14) = 0.61, p = 0.56), 
suggesting that there was no significant difference in the number of inhibitory or 
excitatory synapses within the hippocampus (Figure 5.4). There was no significant 
difference in the NL1/NL2 ratios (Figure 5.5), as tested using an unpaired t-test, 
between CSPα +/+ (M=6.65, SD= 0.30) and CSPα -/- (M=7.70, SD=1.99) mice 
(t(8)=1.161, p=0.28), indicating that there was no difference in the numbers of either 
excitatory or inhibitory synapses between CSPα wildtype and knockout mice. The small 
increase in the ratio could indicate a loss of GABAergic synapses. 
The analysis of synaptic markers suggests that there was no widespread synaptic 
loss in the hippocampus up to P28. In addition, Nissl staining of CSP-/- mice does not 
suggest overt degeneration on cortex or sub-cortical regions. Unfortunately, due to some 
technical problems we were unable to optimise a parvalbumin (Synaptic Systems) 
antibody (data not shown), which would have identified whether there was a loss of 
PV+ GABAergic synapse, and a synaptotagmin-2 (znp-1; ZIRC Antibodies) (data not 
shown) antibody. Synaptotagmin-2 is a presynaptic marker of a subpopulation of 
hippocampal basket cell terminals. Synaptotagmin-2-positive GABAergic synapses 
have been shown to degenerate in CSPα -/- mice (Garcia-Junco-Clemente et al., 2010).  
To extend this analysis we investigated whether there was an inflammatory 
event which could suggest there was some synaptic dysfunction we were unable to 
detect. Expression of GFAP, an astrocyte marker, was used to determine the presence of 
pathology at P28.  The ME7 model of prion disease is characterised by an astrogliosis 
(section 4.3.2) associated with the synaptic pathology; therefore we investigated 
whether there was an astrogliosis in the hippocampus of CSPα +/- and CSPα -/- mice, 
which could indicate synaptic dysfunction. There was a significant induction of GFAP 
in the hippocampus of CSPα-/- mice (F(2, 14) = 12.95, p = 0.001), showing there was a 
mild gliosis in CSP-/- mice at P28 (Figure 5.6). The induction of GFAP provides 
evidence for a change in the hippocampal environment that is detected by the astrocytes, 
possibly synaptic dysfunction. Although this induction is small compared to the 
induction in prion disease, it supports the investigation of neuroinflammatory markers. 
Analysis was carried out by one-way ANOVA with Bonferroni‟s post-hoc multiple 
comparisons test using GraphPad Prism 5.  
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Figure 5.4. Graphical representation of normalised western blot data for different 
synaptic proteins from CSPα wild-type, heterozygous, and knockout mice. 
Coomassie normalised data of P28 CSPα +/+, +/- and -/- (n=5/genotype) for PSD95, 
neuroligin 1 (NL1) and neuroligin 2 (NL2), and representative blots (before 
normalisation). Results showed that there was no significant difference in the levels of 
the synaptic proteins indicating that there was no gross loss of excitatory or inhibitory 
synapses. 
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Figure 5.5. NL1/NL2 ratio from CSPα wild-type and knockout mice. 
A difference in NL1/NL2 ratios would show whether there was a loss of either 
glutamatergic or GABAergic synapses within the hippocampus. Results showed that 
there was no significant difference in the NL1/NL2 ratio between CSPα +/+ and CSPα -
/- mice (t(8)=1.161, p=0.28), determined using an unpaired t-test. 
 
 
 
 
 
 
 
 
 
 
Figure 5.6. Induction of GFAP in CSPα -/- mice. 
Normalised data shows a significant induction of GFAP in the hippocampus of CSPα -/- 
mice compared to CSPα +/+ and CSPα +/- mice (P≤0.05) at P28. 
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5.2.3   Transcriptional Analysis of P28 Wild-Type, Heterozygous, and Knockout 
Hippocampus 
Rt-PCR was used to assess whether C1q was upregulated in this second model 
of synaptic degeneration, in the absence of accumulated prion protein plaques. 
Hippocampal cDNA was generated from CSPα WT (+/+) (n=2), HZ (+/-) (n=2) and KO 
(-/-) (n=6) mice (P25-28), as described in section 2.6, and rt-PCR performed as 
described in section 2.8.2. The quantitation and melting curves were examined to assess 
the quality of the PCR and whether there were any primer dimers, misaligned primer 
products or genomic contamination. Statistical analysis was carried out using One-way 
ANOVA with Bonferroni‟s post-hoc multiple comparisons test with GraphPad Prism 5. 
Figure 5.7 shows a typical quantitation and melting curve obtained for the rt-
PCR performed on hippocampal cDNA from CSPα +/+, +/- and -/- mice, in this case for 
C1qB. The quantitation curve showed that the standard curve (10
14 – 10
9 plasmids/ µl) 
had a good separation between the standard curve dilutions, and that the hippocampal 
samples lie within the linear range of the standard curve. The melting curve showed a 
single peak suggesting that there were no primer dimers, misaligned primer 
amplification products, or genomic contamination in the PCR reaction.  
Data from rt-PCRs showed that there was no induction of any C1q genes in 
CSPα KO mice compared to WT mice (Figure 5.8). One-way ANOVA showed no 
statistical difference between CSPα +/+, +/- and -/- mice for C1qA (F(2, 9) = 1.706, p= 
0.25), C1qB (F(2, 9) = 0.703, p = 0.53), or C1qC (F(2, 9) = 2.565, p = 0.15), although 
there was a very small trend towards an increase in the levels of C1q. This data would 
indicate that C1q was not upregulated in response to the activation of astrocytes (Figure 
5.6). In order for activation of the classical complement cascade, whether by antibody 
dependent- or independent C1q binding, C1q needs to be part of the fully formed C1 
complex, which is made up of one C1q molecule (six C1qA chains, six C1qB chains 
and six C1qC chains) two C1r serine proteases, and two C1s serine proteases. 
Therefore, the transcript levels of C1r and C1s were analysed to determine whether the 
possibility of a functional C1q complex exists. Again, a small trend towards an increase 
was seen between CSPα KO and WT mice (Figure 5.8), however one-way ANOVA 
showed no significant difference between CSPα +/+, +/- and -/- mice for either C1r 
(F(2, 9) = 0.361, p = 0.71) or C1s (F(2, 9) = 0.623, p = 0.56).  
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Figure 5.7. CSP wild-type, Heterozygous, and homozygous rt-PCR for C1qB. 
Hippocampal cDNA generated from wild-type (n=2), heterozygous (n=2) and 
homozygous knockout mice (n=6) (P25-28) was amplified by rt-PCR. The quantitation 
curve (A) showed the plasmid standard curve (10
14 – 10
9 plasmids/ µl), with equal 
separation between dilutions, and the CSPα +/+, +/- and -/- samples falling within the 
linear range of the standard curve. The melting curve (B) showed a single peak 
indicating that there was no amplification of primer dimers, or genomic contamination. 
   
B 
A  
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This result indicates that there was no assembly of the fully formed C1 complex, and 
therefore no activation of the classical complement cascade, although activation of the 
other two arms of the cascade cannot be excluded.   
Activation of astrocytes in the hippocampus would indicate the presence of an 
inflammatory event occurring, similar to that in the ME7 model of prion disease. 
Transcript levels of the pro-inflammatory cytokines IL-1β and TNFα were analysed to 
determine whether an inflammatory process was active. These cytokines can be released 
by microglia and astrocytes and would provide evidence for an inflammatory event, 
possibly due to synaptic degeneration (Barnum, 1995; Kim and Nagai, 2010). 
Results from rt-PCRs on hippocampal cDNA generated from CSPα+/+, +/-, and 
-/- mice for IL-1β, IL-6, IL10, and TNF-α showed that there was no significant 
difference between CSPα WT, HZ and KO mice (Figure 5.8). One-way ANOVA 
confirmed that there was no significant difference in the levels of the pro-inflammatory 
cytokines IL-1β (F(2, 9) = 0.024, p = 0.98), TNFα (F(2, 9) = 0.50, p = 0.63), or IL-6 
(F(2,14) = 0.969, p = 0.41) and the anti-inflammatory cytokine IL-10 (F(2, 14) = 0.744, 
p = 0.50)  indicating the lack of an inflammatory event.  
In order to investigate whether there was a microglia activation and to confirm 
astrocyte activation, hippocampal sections from wild type and CSP KO mice were 
stained with an antibody against GFAP and Tomato Lectin (for microglia staining) 
(section 2.13) and quantified to determine whether there was a glial activation and 
whether this was restricted to a particular hippocampal region. 
 
5.2.4  Activation of astrocytes in CSPα KO mice  
Hippocampal sections from CSPα wild type and knockout mice from P23, P25 
and P26 mice were stained with an antibody against Glial fibrillary acidic protein 
(GFAP). GFAP is an intermediate filament protein that is specific for astrocytes in the 
CNS (Baba et al., 1997).  
Qualitative analysis of the images taken showed a decrease in GFAP staining in 
the CA1 (Figure 5.9), CA3 (Figure 5.10), and DG (Figure 5.11) at P23 in CSPα KO 
mice compared to CSPα WT mice. At P25, there was a similar amount of GFAP 
staining; however, the astrocytes appeared to be more branched in CSPα KO mice 
compared to CSPα WT mice in all areas of the hippocampus, indicating an activation of 
astrocytes in response to an unknown event, possibly synaptic dysfunction that could 
not be detected by the synaptic markers analysed.  
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Figure 5.8. Graphical representation of rt-PCR of CSPα +/+, +/- and -/- mice. 
Hippocampal cDNA generated from CSPα +/+, and -/- mice was amplified by rt-PCR, 
using specific primers (Table 2.1), and normalised against GAPDH. Data shows that 
there was no significant changes in the mRNA expression between CSPα +/+, +/- and -
/- mice for any of the genes analysed.  
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The activation of astrocytes was more apparent at P26 in all areas of the hippocampus. 
Although it was difficult to determine whether there was an increase in the number of 
astrocytes in CSPα KO mice, it was easy to see that the astrocytes were highly branched 
in all areas of the hippocampus of CSPα KO mice compared to CSPα WT mice. 
 
5.2.5  Activation of microglia in CSPα KO mice 
Hippocampal sections from CSPα WT and KO mice from P23, P25 and P26 
mice were stained with Tomato Lectin. Tomato Lectin is a sugar-binding glycoprotein 
that has a specific affinity for poly-N-acetyl lactosamine residues present on the surface 
membranes of microglia and endothelial cells (Rodriguez et al., 2010). The activation of 
microglia would be evidence for an innate immune response or neuroinflammation. 
Qualitative analysis of Tomato Lectin staining showed no morphological 
evidence of activation of microglia until P26 in the brains of CSPα KO mice compared 
to CSPα WT mice. In the CA1 of CSPα knockout mice, no Tomato Lectin staining was 
evident at P23 or P25, however, staining of the vasculature could be seen (Figure 5.12). 
At P26, microglia staining was visible in the neuropil either side of the CA1 pyramidal 
cell layer of CSPα knockout mice. Again staining of the vasculature could be seen.  In 
the CA3 of CSPα KO mice, microglia staining was not evident until P26 (Figure 5.13), 
where they surrounded the pyramidal cell layer. There was no microglia activation in 
the DG of CSPα KO mice at P23 or P25. At P26, microglia activation was evident 
around and within the granule cell layer (Figure 5.14), as well as staining of the 
vasculature. No staining for microglia could be seen in the CA1, CA3 or DG of CSPα 
WT mice at P23, P25, or P26, however vasculature staining was evident. 
    
141 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.9. Astrocyte staining in the CA1 of CSPα WT and KO mice at P23, P25, 
P26. 
10µm wax sections of the hippocampus were stained for GFAP (n=3/time point). 
Arrowheads highlight the increased branching of astrocytes in the CA1 of CSPα KO 
mice at P26. Images were taken at X20 magnification for analysis. Scale bar 50µm. 
WT  KO 
P23 
P25 
P26  
142 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.10. Astrocyte staining in the CA3 of CSPα WT and KO mice at P23, P25, 
P26. 
10µm wax sections of the hippocampus were stained for GFAP (n=3/time point). 
Arrowheads highlight the increased branching of astrocytes in the CA3 of CSPα KO 
mice at P26. Images were taken at X20 magnification for analysis. Scale bar 50µm. 
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Figure 5.11. Astrocyte staining in the DG of CSPα WT and KO mice at P23, P25, 
P26. 
10µm wax sections of the hippocampus were stained for GFAP (n=3/time point). 
Arrowheads highlight the increased branching of astrocytes in the DG of CSPα KO 
mice at P26. Images were taken at X20 magnification for analysis. Scale bar 50µm. 
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Figure 5.12. Microglia staining in the CA1 of CSPα WT and KO mice at P23, P25, 
P26. 
10µm wax sections of the hippocampus were stained for Tomato Lectin (n=3/time 
point). Arrowheads highlight the activation of microglia in the CA1 of CSPα KO mice 
at P26.  Images were taken at X20 magnification for analysis. Scale bar 50µm. 
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Figure 5.13. Microglia staining in the CA3 of CSPα WT and KO mice at P23, P25, 
P26. 
10µm wax sections of the hippocampus were stained for Tomato Lectin (n=3/time 
point). Arrowheads highlight the activation of microglia in the CA3 of CSPα KO mice 
at P26. Images were taken at X20 magnification for analysis. Scale bar 50µm. 
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Figure 5.14. Microglia staining in the DG of CSPα WT and KO mice at P23, P25, 
P26. 
10µm wax sections of the hippocampus were stained for Tomato Lectin (n=3/time 
point). Arrowheads highlight the activation of microglia in the DG of CSPα KO mice at 
P26. Images were taken at X20 magnification for analysis. Scale bar 50µm. 
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5.2.5.1  Quantitative analysis of GFAP and Tomato Lectin staining in CSPα WT and 
CSPα WT mice. 
In order to confirm the 1.5 fold induction of GFAP shown by the biochemical 
data (Figure 5.6), and to determine whether there was any microglia activation in this 
model of synaptic degeneration, the number of astrocytes and microglia for each of the 
hippocampal regions (CA1, CA3 and DG) were quantified to determine whether there 
was an induction of glial cells in CSPα KO mice (section 2.13.3). The number of glial 
cells were normalised to the total cell count for the rectangle and plotted on a graph. 
Quantification showed that there was no induction of GFAP between CSPα KO 
and CSPα WT mice at P23 in any of the hippocampal regions analysed (P>0.05). 
Instead a small non-significant decrease in the number of astrocytes was seen in CSPα 
KO mice compared to CSPα WT mice (Figure 5.15A).  At P25, there was a small non-
significant increase in the number of astrocytes in the CA1 and DG of CSPα KO mice 
compared to CSPα WT mice (P>0.05). At P26 there was a non-significant increase in 
the number of astrocytes in the CA1 and DG of CSPα KO mice compared to CSPα WT. 
In the CA3 of CSPα KO mice there was a significant three-fold increase in the number 
of astrocytes (P<0.05) compared to CSPα WT mice, confirming the induction of GFAP 
seen in the biochemical data (Figure 5.6).  
Analysis of Tomato Lectin staining (Figure 5.15B) revealed a similar pattern of 
induction to GFAP. At P23 there was no significant induction of microglia in the CA1, 
CA3 or DG regions of the hippocampus (p>0.05), with no more than 2 microglia 
identified in any rectangle in either CSPα WT or CSPα KO mice.  The same was true 
for P25 mice.  
At P25 there was no significant increase in the number of microglia in any of the 
hippocampal regions analysed between CSPα WT and CSPα KO mice (P>0.05). At 
P26, there was a non-significant induction in the number of microglia in CSPα KO mice 
compared to CSPα WT mice in the CA1 region of the hippocampus (P>0.05). There 
was a significant increase in the number of microglia in the CA3 (P<0.001) and DG 
(P<0.01) of CSPα KO mice compared to CSPα WT mice.  This confirms that there was 
an innate immune response to as yet unidentified pathology but possibly the 
degeneration of PV+ interneurones, previously reported (Garcia-Junco-Clemente et al., 
2010).  
148 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.15. Quantification of astrocyte and microglia staining in CSPα WT and CSPα KO mice at three different time points. 
Each region of the hippocampus was overlaid with 5 boxes and the number of astrocytes (A) or microglia (B) normalised to the total cell count for that 
box, and an average of all five boxes obtained. Two-way ANOVA showed that there was an increase in the number of astrocytes in the CA3 region of 
CSPα KO mice at P26, and an increase in microglia in the CA3 and DG regions of the hippocampus of CSPα KO mice at P26 (*p<0.05).
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5.3   Discussion 
CSPα is an abundant synaptic vesicle protein that contains an N-terminal DNA-J 
domain, which is involved in the interaction with chaperone proteins of the 
Hsp70/Hsc70 family, and a central cysteine-rich domain made up of 20 cysteine 
residues (residues 113-136) which can be palmitoylated on up to 14 cysteine residues, 
and anchor the protein to synaptic vesicle and other regulated secretory vesicle 
membranes (Chamberlain and Burgoyne, 1997; Evans et al., 2003; Fernández-Chacón 
et al., 2004; Greaves et al., 2008). One of the functions of CSPα is as a presynaptic 
chaperone involved in maintaining the integrity of synapses in a use-dependent fashion 
(Fernández-Chacón et al., 2004). CSPα may prevent neurodegeneration when normal 
synaptic function places a burden on the protein machinery involved, by preventing the 
accumulation of non-native, potentially toxic molecules, and recycling damaged 
components of the release machinery, through the formation of a catalytically active 
complex made up of CSPα, Hsc70 and SGT (Fernández-Chacón et al., 2004; Bronk et 
al., 2005). 
 
5.3.1  Biochemical Analysis of Synaptic Integrity in CSPα Knockout Mice 
Mice with a genetic knockout of CSPα develop a severe age-dependent 
phenotype resulting in death before P60 (Figure 5.2). Until very recently, synaptic 
degeneration within the hippocampus or cortex of CSPα KO mice had not been 
reported. García-Junco-Clemente et al (2010) showed that fast firing PV+, 
synaptotagmin 2-expressing GABAergic synapses, but not glutamatergic synapses, 
were vulnerable to synaptic degeneration in CSPα KO mice. 
Synaptic degeneration within the hippocampus was examined using broad 
synaptic markers. Synaptophysin (SY38), a presynaptic vesicle glycoprotein, was used 
for quantification of synapses due to its ubiquitous expression in synapses (Calhoun et 
al., 1996), and PSD95, a postsynaptic scaffolding protein involved in anchoring 
synaptic proteins at glutamatergic synapses (Sheng and Sala, 2001). Western blot 
analysis showed no significant difference in the hippocampal protein expression of 
these two proteins between CSPα WT and CSPα KO mice at P28. Due to the abundant 
and widespread expression of these two proteins at hippocampal synapses, using them 
to detail synaptic degeneration and loss of minor subsets of selective synapses might be 
difficult. Indeed, parvalbumin positive (PV+) GABAergic interneurones cannot be 
detected using antibodies to ubiquitously expressed synaptic proteins. PV+ GABAergic  
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interneurones make up 20-50% of the interneurones within the hippocampus, which 
make up 5-10% of all neurones (Jones and Yakel, 1999; Fuchs et al., 2007). To try to 
detect loss of these synapses, that make up <5% of total synapses in the hippocampus, 
the ratio and number of glutamatergic (NL1) and GABAergic (NL2) synapses were 
examined to determine whether there was any loss of GABAergic synapses. 
Results showed that there was no difference in the number of glutamatergic or 
GABAergic synapses, as seen by the hippocampal protein expression of NL1 and NL2 
respectively (Song et al., 1999; Varoqueaux et al., 2004). In addition, there was no 
difference in the ratio between NL1/NL2 synapses, which would indicate that there was 
no loss of glutamatergic or GABAergic synapses. It is possible that NL1 and NL2 
protein expression within the hippocampus was too broad, and therefore unable to 
detect PV+ GABAergic synaptic loss.  
Fernández-Chacón et al reported that most CSPα -/- mice die in the second 
postnatal month and none survive past three months (Fernández-Chacón et al., 2004). 
We were unable to keep KO mice beyond the first postnatal month (approximately) due 
to Home Office Licence limitations, which state that CSPα KO mice must be sacrificed 
once their body weight drops to 80% of littermate body weights. Garcia-Junco-
Clemente et al reported an approximate 50% loss of synaptotagmin-2 and parvalbumin 
expression between P28-P32 (Garcia-Junco-Clemente et al., 2010). Mice used in the 
biochemical and histological analysis of synaptic and pathological markers were no 
older than P28, therefore it may have been slightly too early to detect any widespread 
synaptic degeneration, thus it may be necessary to look beyond P28 to detect synaptic 
degeneration with the markers used in this report.    
 
5.3.2  Histochemical Analysis of Glial Activation  
There was no gross synaptic loss (with the markers analysed), and no difference 
in the overall ratio of glutamate and inhibitory synapses, as shown by the NL1:NL2 
ratio. Despite this, GFAP shows a clear up-regulation and supports a dysfunctional and 
potential degeneration in the hippocampus. Activation of GFAP at P28 may indicate 
that analysing mice at P25 and P26 may be critical in investigating synaptic 
degeneration. The activation of astrocytes and microglia supports a role of the innate 
immune response and non-neuronal cells in CSPα-mediated degeneration. Cellular 
investigation of the activation of astrocytes and microglia showed morphological 
activation of glial cells in the hippocampus of CSPα KO mice.  
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Immunohistochemical analysis of hippocampal tissue from CSPα WT and CSPα 
KO mice revealed an induction of GFAP and Tomato Lectin at P26 in CSPα KO, 
consistent with the biochemical induction of GFAP seen in the hippocampus of CSPα 
KO mice at P28. The lack of induction of glia in the hippocampus of CSPα KO mice at 
P23 or P25 shows that the innate immune response is a late-stage event that occurs close 
to death (sacrificed due to Home Office limitations). The induction of GFAP is limited 
to the CA3 of CSPα KO mice; however, there appeared to be no specific location for 
this induction. Astrocytes were found both within the pyramidal cell layer and 
surrounding it. The same is true for the localisation of microglia within the CA3 and 
DG of CSPα KO mice. There was very little presence of microglia until P26, once again 
indicating a glia response to a late stage event. Results published by Chandra et al 
(2005) showed that there was widespread GFAP expression in the hippocampus of 
CSP-/- mice at 6 weeks of age, and there was also slight GFAP expression in the spinal 
cord of CSP-/- mice at P10, indicating that GFAP induction is an early stage event that 
increases with ensuing pathology (Chandra et al., 2005). 
Whilst we have been unable to show a decrease in PV protein, previously 
reported by Garcia-Junco-Clemente et al (2010), we investigated mechanisms which 
could contribute to, or be a consequence of, PV+ interneurone dysfunction and/or 
degeneration. Firstly, a transcriptional analysis of C1q was undertaken to determine 
whether C1q could be associated with the induction of astrocytes and microglia seen in 
the hippocampus of CSPα KO mice. 
 
5.3.3  Transcriptional Analysis of C1q in CSPα Knockout Mice 
rt-PCR of hippocampal cDNA from CSPα WT, HZ and KO mice showed that 
there was no induction of any of the three chains of C1q, or its associated serine 
proteases, C1r and C1s, within the hippocampus of P28 CSPα KO mice, a time point at 
which degeneration of a subpopulation of GABAergic synapses within the hippocampus 
has been shown (Garcia-Junco-Clemente et al., 2010). This result confirms that C1q is 
not involved in synaptic degeneration. 
 
5.3.4  Final Conclusions 
Astrocytes and microglia are sensitive to changes in the neural environment and 
often respond with cellular activations that precede identifiable pathological changes of 
neuronal degeneration or protein deposition. These are often associated with the  
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production of neuroinflammatory mediators that act as a protective signal. This is not 
always the case but the activation of astrocytes and microglia are a common feature of 
many neurodegenerative diseases and in particular mark out early stages (Betmouni et 
al., 1996). In CSPα WT, HZ and KO mice, biochemical induction of GFAP provided 
the first clue that there was a change in the brains of the CSP -/- brains. Western blot 
analysis of hippocampal protein homogenate extracted from CSPα WT, HZ and KO 
mice revealed a significant 1.5 fold induction of GFAP. Cellular investigation of the 
localisation of these activated astrocytes, and microglia, showed that glial activation 
was most obvious in the CA3 and DG of CSPα KO mice at P26 only. Data published on 
the expression of GABAergic synapses in the hippocampus has shown that GABAergic 
neurone expression throughout the hippocampal formation is homogeneous (Seress and 
Ribak, 1988), indicating that if we were able to analyse CSPα-/- mice at ages later than 
P28, the GFAP induction we saw could have spread throughout the whole 
hippocampus, as was reported by Chandra et al (2005) in 6 week old CSPα-/- mice 
(Chandra et al., 2005). Figure 5.6 showed that there was no significant difference in the 
levels of GFAP between CSPα WT and HZ mice indicating that expression of CSPα to 
50% of normal levels was enough to prevent activation of astrocytes and microglia, 
suggesting no degeneration of synapses. In addition, CSPα HZ mice have the same 
weight gain and life expectancy of CSPα WT mice (Fernández-Chacón et al., 2004). 
To determine whether the activation of astrocytes and microglia led to a pro-
inflammatory or anti-inflammatory response, the levels of different cytokines were 
examined. Results showed that there was no induction of the proinflammatory cytokines 
IL-1β, IL-6, and TNFα, and no induction of the antinflammatory cytokine IL-10 
between CSPα WT, HZ and KO mice. Due to the small induction of astrocytes and 
microglia seen in CSPα KO mice, it is possible that our techniques were not sensitive 
enough to indentify small changes in cytokine levels. 
Results showed that the classical complement protein C1q was not upregulated 
in CSPα KO mice compared to CSPα WT and CSPα HZ mice, even though there was a 
modest 1.5 fold induction of GFAP, and an activation of microglia. A gross look into 
synaptic degeneration revealed no difference in protein expression of SY38, PSD95, 
NL1 and NL2, however expression of PV and synaptotagmin 2 could not be established.    
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Chapter 6:  General Discussion and Future Work 
  The incidence of chronic neurodegenerative diseases such as Alzheimer's 
disease are increasing due to the increasing average age of the general population 
(Hebert et al., 1995). The pathological changes seen at the end stages of disease are 
unlikely to be critical to disease progression, and therefore investigation into the earlier 
stages of disease are more likely to yield mechanisms which affect disease progression 
(Selkoe, 2002). Synaptic degeneration is an early discernable event in the pathology of 
many neurodegenerative diseases including Alzheimer's disease (Wishart et al., 2006; 
Arendt, 2009), Huntington disease (Li et al., 2003; Rozas et al., 2010), motor neurone 
disease (Wishart et al., 2006), Parkinson‟s disease (Bate et al., 2010) and prion disease 
(Jeffrey et al., 2000; Cunningham et al., 2003; Wishart et al., 2006).  
 
6.1  Modulators of Synaptic Degeneration 
The aim of this project was to examine the possible mechanisms that contribute 
to synaptic dysfunction, degeneration, and loss. The complement system has been 
implicated in disease progression of multiple neurodegenerative diseases (Klein et al., 
2001; Shen and Meri, 2003; Fonseca et al., 2004b; Stevens et al., 2007; Alexander et al., 
2008). Further it has emerged as a candidate for modulating the synaptic degeneration 
(Stevens et al., 2007).  
 
6.1.1  The Role of C1q as a Modulator of Synaptic Degeneration   
A role for C1q, the classical complement cascade protein, in the synaptic 
pruning that occurs within a development period within the visual system of postnatal 
mice has been suggested. During development, punctate C1q immunoreactivity was 
found enriched throughout the synaptic inner plexiform layer (IPL) and retinal ganglion 
cells (RGC) of postnatal developing retinas, co-localised with the synaptic markers 
PSD95 and SV2, and decreased in the mature retina (Stevens et al., 2007). The 
localization of C1q to developing synapses, and its physiological role in eliminating 
unwanted cells and cellular debris, suggested a role for C1q in mediating synapse 
elimination. Similar investigations were carried out in mice lacking function C1q (Botto 
et al., 1998), and results showed that in the absence of C1q there was a lack of eye 
specific segregation. C1q could be opsonising weaker, developing, synapses and aiding 
the synaptic pruning and refinement that occurs in the developing retina. It was also  
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suggested that C1q could be involved in the synaptic degeneration which occurs in other 
neurodegenerative diseases (Stevens et al., 2007). The role of C1q in synaptic 
degeneration was assessed using a mouse model of prion disease (ME7), in which 
synaptic degeneration (30% loss) precedes neuronal cell body loss, and in CSPα 
knockout mice, in which spontaneous genetic synaptic degeneration occurs in a use-
dependent manner (Garcia-Junco-Clemente et al., 2010). 
 
6.1.2  The Role of C1q in Prion Disease 
Results from mice injected with ME7 prion agent showed that there was a large 
late-stage induction of C1q in the hippocampus of ME7-animals compared to NBH-
animals, which was largest in the CA1 area of the hippocampus. This suggested that 
C1q was upregulated in the hippocampus of ME7-animals in the response to the 
disease. However, a similar induction was not detectable in the hippocampus from 
13week p.i ME7-animals. Since this is a time point at which a 30% loss of synapses has 
been shown (Cunningham et al., 2003), it showed that C1q was not involved in the 
synaptic degeneration that occurred in prion disease. In order to determine whether C1q 
contributes to the progression of prion disease, behavioural assays were undertaken to 
determine whether there were any differences in the onset of behaviours between C1q 
sufficient and deficient C57BL/6 and BALB/C mice. There was a two week delay in the 
onset of the decline of burrowing and glucose consumption behaviours, but only for 
C57BL/6 mice indicating a strain-specific effect of C1q deletion, showing that C1q is 
very unlikely to be a potent modifier of disease on its own and combined with the lack 
of differences in the late stage astrocyte activation and synaptic loss shows that C1q 
does not affect disease progression.  
 
6.1.3  The Role of C1q in the Synaptic Degeneration in CSPα Ko Mice 
Preliminary analysis of CSPα +/+, +/-, and -/- mice revealed that there was no 
induction of C1q mRNA within the hippocampus of CSPα deficient mice at P28, a time 
point at which a subset of inhibitory interneurones are degenerating (Garcia-Junco-
Clemente et al., 2010).  
Together, the data from the prion disease model and CSPα KO model, confirms 
that C1q was not involved in synaptic degeneration in these models and suggests that 
the role of C1q in synaptic degeneration is not conserved between different types of 
synaptic degeneration.  
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6.1.4  Late-Stage Role of C1q 
In a mouse model of Alzheimer's disease, absence of C1q led to less 
inflammation and decreased neuronal damage (Fonseca et al., 2004b). It is possible that 
in the ME7 model of prion disease, C1q could bind to PrP, as has been shown to occur 
in vitro (Erlich et al., 2010) and activate astrocytes and microglia which cause 
inflammation and contribute to neuronal damage. If this were the case, then analysis of 
C1q deficient and sufficient mice should reveal a difference in the status of 
inflammation and synaptic loss, which we did not see. 
Accumulating evidence shows that C1q is involved in the initial development of 
disease, and neuroinvasion of prion protein into the CNS. Mice deficient in C1q are 
resistant to infection when intraperitoneally injected with limited amounts of prion 
protein (Klein et al., 2001; Mabbott et al., 2001), however, the same is not true when 
mice were intracranially injected with PrP, indicating that C1q is involved in the 
migration of PrP from the periphery to the CNS, and the initial replication (Klein et al., 
2001; Mabbott et al., 2001; Flores-Langarica et al., 2009) in the early stages of prion 
infection, and is involved in the inflammatory process and clearance of cellular debris in 
the later stages of disease (Botto et al., 1998; Fonseca et al., 2004b). 
 
6.2  Future Work 
6.2.1  Induction of early ER stress markers  
Mechanistic insights into the early events of synapse loss are limited, and much 
of the data available suggests that synapse dysfunction and loss is a key intermediate of 
many neurodegenerative diseases. Little is known about upstream events that precede 
the observed synapse dysfunction. Some cellular pathways that may act in such a way 
include mitochondria (Siskova et al., 2009) and stress pathways. As the ME7 model 
provides a temporally defined chronic neurodegeneration, it would be possible to 
investigate candidate upstream pathways which act as markers in the earlier stages of 
disease.  It is predicted that these cell-body responses could correlate with synaptic 
dysfunction seen in the ME7 model. In a mouse model of familial amyotrophic lateral 
sclerosis (or motoneurone disease, FALS), it was found that a subset of motoneurones 
that were selectively vulnerable to synapse loss (the fast firing fatigable motoneurones), 
and subsequent neuronal loss, exhibited a temporally earlier activation of somatic ER 
stress and ubiquitination cascade markers. Chronically enhancing ER stress worsened 
the disease, whereas inhibition ameliorated disease (Saxena et al., 2009). It is interesting  
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to note that in both this mouse model of FALS, and in the CSPα-/- mouse model, it is 
the fast firing neurones that are more vulnerable to dysfunction. 
 
6.2.2  Upregulation of ER stress markers in the ME7 model 
Brains from 13week, 16week, and 19week NBH- and ME7-animals have been 
collected and fresh frozen embedded into OCT. Semi-thick, Bregma-matched positions, 
sections will be cut and the CA1, CA3, and DG regions microdissected out, and the 
RNA extracted, and analysed to determine whether there are any protein markers which 
are upregulated/down-regulated and could act as an early marker of synaptic 
dysfunction. Brain sections, of matched Bregma position, from NBH- and ME7-animals 
will be cut to determine the localisation of these markers. Initially, an antibody against 
eukaryotic initiation factor 2α (eIF2α) will be used, a marker of ER-stress and the 
unfolded-protein response that has been shown to be upregulated in vulnerable 
motoneurones at an early stage of disease, before pathology (Saxena et al., 2009).  
 
6.2.2.1  Upregulation of ER stress markers in the CSPα model 
If eIF2α is upregulated in the early stages of both the ME7 strain of prion 
disease and in CSPα -/- mice it could provide a conserved early marker of synaptic 
dysfunction. Brain sections from CSPα +/+, CSPα +/- and CSPα -/- mice would be 
analysed, and it would be predicted that if ER stress is an early event which precedes 
synaptic dysfunction and loss then an increase of eIF2α would be seen. 
    
157 
 
6.3  Final Thoughts 
Neurodegenerative diseases, such as Alzheimer‟s disease, often have a 
presymptomatic stage of the disease, therefore, diagnosis does not usually occur until 
clinical symptoms appear, and by this stage it is often too late to delay the disease 
progression. In order to try to find a treatment for these diseases, the initial mechanisms 
which cause dysfunction need to be determined. This involves defining the initial insult 
and downstream cascades. Most diseased, post-mortem, human tissue available for the 
analysis of disease mechanisms has been obtained from patients who were at the end 
stages of disease. The disease has often been established for decades which make it 
difficult to study what mechanisms are involved in the initial stages of disease. Mouse 
models are commonly used to explore the potential causes and/or treatments of human 
diseases.  
Synaptic degeneration is an early event which occurs in many neurodegenerative 
diseases (Cunningham et al., 2003; Arendt, 2009; Gray et al., 2009), often before the 
onset of clinical symptoms, therefore studying mechanisms which cause synaptic 
dysfunction may lead to therapeutic targets which can delay the progression of disease.  
Mice injected with the ME7 prion agent, or mice with a genetic deletion of 
CSPα both develop synaptic degeneration within the hippocampus. Using these two 
mouse models it was possible to investigate specific mechanisms which could 
contribute to synaptic dysfunction and degeneration. Experiments conducted here have 
shown that the classical complement system, and in particular C1q, was not involved in 
the synaptic degeneration occurring in the ME7 model of prion disease, nor was it 
associated with the activation of astrocytes in CSPα knockout mice. This indicates that 
C1q is not a conserved mechanism of synaptic degeneration and loss. 
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Chapter 7:  Appendix 
7.1  Example calculation of the number of plasmids. 
Plasmid Copies per µl 
Size of plasmid + Insert 
  C1qA: 4326bp 
  C1qB: 4354bp 
  C1qC: 4370bp 
 
Moles = mass/molecular weight   
Molecular weight = 660 x no. bp 
Mass = concentration  
Plasmids per µl = moles x 6.022x10
23 
 
Plasmid C1qA: 
Concentration: 1891.25ng/µl 
Mw: 60 x 4326 = 2855160g/l (2.855160g/µl) 
Moles = 1891.25x10
-9/ 2.855160 = 6.62x10
-7 moles 
Plasmids per µl: 6.62x10
-7 x 6.022x10
23 = 3.99x10
17 copies per µl 
 
This was then diluted using nuclease free water (Ambion, UK) to create a plasmid 
standard curve.  
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7.2  Agarose Gel Electrophoresis 
7.2.1  50x Tris Acetate (TAE) 
100ml 0.5M EDTA (pH8.0) 
0.2M TrisBase 
57.1ml Glacial Acetic Acid 
(Made up to 1L in ddH2O) 
 
7.2.2  6X Loading Buffer 
0.025g Bromophenol blue 
0.025g Xylene cyanol FF 
3ml 100% Glycerol 
7ml ddH2O 
 
7.3  Western Blot 
7.3.1  Reagents for different % resolving gels 
% Separation 
gel 
Stacker 
sol
n 
30% Acryl 
amide 
3M TRIS 
(pH8.8) 
10% 
APS 
10% 
SDS 
dH2O  TEMED 
15  -  5ml  1.25ml  50µl  100µl  Up  10µl 
12.5  -  4.2ml  1.25ml  50µl  100µl  To  10µl 
10  -  3.3ml  1.25ml  50µl  100µl  10  10µl 
7.5  -  2.5ml  1.25ml  50µl  100µl  mls  10µl 
Stacking Gel  5ml  -  -  50µl  -  -  10µl 
Table 7.1. Volume of reagents required to make different % SDS-PAGE gels.  
The TEMED was added last before casting the gel. Isopropanol was overlaid on to the 
resolving gel to eliminate air bubbles and was removed prior to casting of the stacking 
gel.  
 
7.3.2  Stacker Solution 
15ml 30% Acrylamide 
37.5ml 0.25M TRIS HCL (pH6.8) 
1ml 10% SDS 
(made up to 100ml in ddH2O) 
 
7.3.3  10X Laemmli Buffer 
0.25M TRIS 
1.92M Glycine 
10%w/v SDS  
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7.3.4  Coomassie Destain 
25% Methanol 
10% Glacial acetic acid 
65% ddH2O 
 
7.3.5  Overnight Transfer Buffer 
20% Methanol 
10% 10X Laemmli buffer 
70% ddH2O 
 
7.3.6  2 Hour Transfer Buffer 
14g Glycine (192mM) 
3.03g TRIS (25mM) 
200ml Methanol (20%) 
0.5ml 10% SDS (0.02%) 
(up to 1L with ddH2O) 
 
7.3.7  SYPRO Ruby Destain 
10% Methanol 
7% Glacial acetic acid 
83% ddH2O 
 
7.3.8  TBS-Tween 
3.03g TRIS 
8.18g NaCl 
0.37g KCl  
1ml 50% Tween 
pH8 with ~1.5ml HCl 
(made up to 1L with ddH2O) 
    
163 
 
7.4  Quality of 13 and 20 week p.i CA1, CA3 and DG RNA 
7.4.1  20 week p.i RNA Quality and Concentration 
  Concentration (ng/µl)  260/280 ratio 
ME7 
ZS41 
CA1  138.29  2.09 
CA3  133.77  2.09 
DG  130.76  2.08 
ZS44 
CA1  129.76  2.09 
CA3  76.03  2.06 
DG  111.43  2.10 
ZS46 
CA1  155.41  2.09 
CA3  161.10  2.09 
DG  105.88  2.08 
ZS47 
CA1  106.35  2.07 
CA3  81.55  2.05 
DG  121.75  2.07 
ZS98 
CA1  60.70  2.04 
CA3  125.51  2.08 
DG  100.26  2.07 
ZS99 
CA1  127.35  2.08 
CA3  95.67  2.06 
DG  102.85  2.05 
NBH 
ZS32 
CA1  115.82  2.05 
CA3  127.74  2.06 
DG  128.47  2.07 
ZS35 
CA1  60.22  2.03 
CA3  86.05  2.06 
DG  99.11  2.07 
ZS36 
CA1  120.27  2.08 
CA3  123.91  2.07 
DG  82.15  2.05 
ZS39 
CA1  105.25  2.08 
CA3  69.41  2.07 
DG  66.43  2.07 
ZS108 
CA1  77.95  2.06 
CA3  122.19  2.08 
DG  79.92  2.05 
ZS109 
CA1  66.54  2.05 
CA3  78.88  2.09 
DG  74.24  2.08 
The table shows that the RNA extract is pure based on the 260-280 ratio≥1.8.  
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7.4.2  13 week p.i RNA Quality and Concentration 
  Concentration (ng/µl)  260/280 ratio 
ME7 
ZS16 
CA1  105.79  2.09 
CA3  70.63  2.09 
DG  90.19  2.09 
ZS21 
CA1  155.58  2.10 
CA3  53.77  2.14 
DG  78.37  2.10 
ZS24 
CA1  123.15  2.09 
CA3  94.93  2.08 
DG  104.01  2.07 
ZS25 
CA1  107.81  2.11 
CA3  124.10  2.12 
DG  90.82  2.11 
ZS92 
CA1  93.20  2.10 
CA3  128.27  2.11 
DG  93.67  2.11 
ZS93 
CA1  57.26  2.12 
CA3  93.05  2.13 
DG  94.40  2.12 
NBH 
ZS12 
CA1  77.56  2.12 
CA3  109.03  2.10 
DG  98.29  2.10 
ZS15 
CA1  61.01  2.06 
CA3  63.77  2.04 
DG  65.50  2.01 
ZS28 
CA1  90.15  2.08 
CA3  78.56  2.07 
DG  95.74  2.10 
ZS62 
CA1  88.69  2.11 
CA3  123.56  2.10 
DG  82.67  2.11 
ZS63 
CA1  94.08  2.13 
CA3  131.57  2.11 
DG  95.21  2.09 
ZS65 
CA1  92.70  2.08 
CA3  97.47  2.11 
DG  74.81  2.09 
The table shows that the RNA extract is pure based on the 260-280 ratio≥1.8. 
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7.5  Example of Plasmid and Insert Alignment for C1qA 
Sequence of the C1qA plasmid and C1qA forward primer showing the location 
of the forward primer (yellow) within the plasmid sequence (blue), and the insert 
(green).  
GGTTCCGAGGTTTTAAGGAGACCCAGGGGAATCTGGCCCCCCTGGCAAACCTGGCAATGTG
GGGCTCCCAGGTCCCAGTGGTCCCCTGGGGGACAGCGGCCCCCAAGGACTGAAGGGCGTGA
AAGGCAATCCAGGCAAAGCCGAATTCTGCAGATATCCATCACACTGGCGGCCGCTCGAGCA
TGCATCTAGAGGGCCCAATTCGCCCTATAGTGAGTCGTATTACAATTCACTGGCCGTCGTTTT
ACAACGTCGTGACTGGGAAAACCCTGGCGTTACCCAACTTAATCGCCTTGCAGCACATCCCC
CTTTCGCCAGCTGGCGTAATAGCGAAGAGGCCCGCACCGATCGCCCTTCCCAACAGTTGCGC
AGCCTGAATGGCGAATGGACGCGCCCTGTAGCGGCGCATTAAGCGCGGCGGGTGTGGTGGT
TACGCGCAGCGTGACCGCTACACTTGCCAGCGCCCTAGCGCCCGCTCCTTTCGCTTTCTTCCC
TTCCTTTCTCGCCACGTTCGCCGGCTTTCCCCGTCAAGCTCTAAATCGGGGGCTCCCTTTAGG
GTTCCGATTTAGTGCTTTACGGCACCTCGACCCCAAAAAACTTGATTAGGGTGATGGTTCAC
GTAGTGGGCCATCGCCCTGATAGACGGTTTTTCGCCCTTTGACGTTGGAGTCCACGTTCTTTA
ATAGTGGACTCTTGTTCCAAACTGGAACAACACTCAACCCTATCTCGGTCTATTCTTTTGATT
TATAAGGGATTTTGCCGATTTCGGCCTATTGGTTAAAAAATGAGCTGATTTAACAAAAATTT
AACGCGAATTTTAACAAAATTCAGGGCGCAAGGGCTGCTAAAGGAAGCGGAACACGTAGAA
AGCCAGTCCGCAGAAACGGTGCTGACCCCGGATGAATGTCAGCTACTGGGCTATCTGGACA
AGGGAAAACGCAAGCGCAAAGAGAAAGCAGGTAGCTTGCAGTGGGCTTACATGGCGA 
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Sequence of the C1qA plasmid and C1qA reverse primer showing the location 
of the reverse primer (yellow) within the plasmid sequence (blue), and the insert 
(green). 
CCCAGGGGACCACTGGGACCTGGGAGCCCCACATTGCCAGGTTTGCCAGGGGGGCCAGATT
CCCCTGGGTCTCCTTTAAAACCTCGGATACCAGTCCGGATGCCAGCAGCTCCTGGCTCCCCTC
TCTCTCCTTTGAAAGCCGAATTCCAGCACACTGGCGGCCGTTACTAGTGGATCCGAGCTCGG
TACCAAGCTTGATGCATAGCTTGAGTATTCTATAGTGTCACCTAAATAGCTTGGCGTAATCAT
GGTCATAGCTGTTTCCTGTGTGAAATTGTTATCCGCTCACAATTCCACACAACATACGAGCC
GGAAGCATAAAGTGTAAAGCCTGGGGTGCCTAATGAGTGAGCTAACTCACATTAATTGCGTT
GCGCTCACTGCCCGCTTTCCAGTCGGGAAACCTGTCGTGCCAGCTGCATTAATGAATCGGCC
AACGCGCGGGGAGAGGCGGTTTGCGTATTGGGCGCTCTTCCGCTTCCTCGCTCACTGACTCG
CTGCGCTCGGTCGTTCGGCTGCGGCGAGCGGTATCAGCTCACTCAAAGGCGGTAATACGGTT
ATCCACAGAATCAGGGGATAACGCAGGAAAGAACATGTGAGCAAAAGGCCAGCAAAAGGC
CAGGAACCGTAAAAAGGCCGCGTTGCTGGCGTTTTTCCATAGGCTCCGCCCCCCTGACGAGC
ATCACAAAAATCGACGCTCAAGTCAGAGGTGGCGAAACCCGACAGGACTATAAAGATACCA
GGCGTTTCCCCCTGGAAGCTCCCTCGTGCGCTCTCCTGTTCCGACCCTGCCGCTTACCGGATA
CCTGTCCGCCTTTCTCCCTTCGGGAAGCGTGGCGCTTTCTCATAGCTCACGCTGTAGGTATCT
CAGTTCGGTGTAGGTCGTTCGCTCCAAGCTGGGCTGTGTGCACGAACCCCCCGTTCAGCCCG
ACCGCTGCGCCTTATCCGGTAACTATCGTCTTGAGTCCAA 
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Alignment of forward and reverse plasmid sequence and the location of the 
C1qA forward and reverse primers (highlighted in yellow). The resulting insert size was 
the expected 163 (Table 2.1). 
 
FWD     ---------------------------------------------GGTTCCGAGGTTTTA 
REV     
TCAAAGGAGAGAGAGGGGAGCCAGGAGCTGCTGGCATCCGGACTGGTATCCGAGGTTTTA 
 
 
FWD     A-
GGAGACCCAGGGGAATCTGGCCCCCCTGGCAAACCTGGCAATGTGGGGCTCCCAGGTC 
REV     
AAGGAGACCCAGGGGAATCTGGCCCCCCTGGCAAACCTGGCAATGTGGGGCTCCCAGGTC 
 
 
FWD     
CCAGTGGTCCCCTGGGGGACAGCGGCCCCCAAGGACTGAAGGGCGTGAAAGGCAATCCAG 
REV     CCAGTGGTCCCCTGGG-------------------------------------------- 
 
 
FWD     GCA 
REV     ---  
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1 
2 
3 
4 
5 
6 
7 
8 
7.6  Ear Tagging for Identification 
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7.7  Microscope Settings for Staining of Hippocampal Sections with 
Tomato Lectin  
   
  Magnification  Setting  Value 
Tomato Lectin   
X5 
Exposure  8.3ms 
Gain  2.3x 
Lamp  8.24% 
 
X10 
Exposure  8.3ms 
Gain  4.0x 
Lamp  14.90% 
 
X20 
Exposure  1.8ms 
Gain  3.9x 
Lamp  29.80% 
 
X40 
Exposure  5.1 ms 
Gain  4x 
Lamp  14.90% 
 
X63 
Exposure  2.3ms 
Gain  4.4% 
Lamp  39.61%  
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7.8  Microscope Settings for Staining of Hippocampal Sections with 
GFAP 
 
  Magnification  Setting  Value 
GFAP   
X5 
Exposure  5.1ms 
Gain  4.0x 
Lamp  8.24% 
 
X10 
Exposure  6.9ms 
Gain  4.1x 
Lamp  15.69% 
 
X20 
Exposure  1.8ms 
Gain  4.1x 
Lamp  29.80% 
 
X40 
Exposure  6.2 ms 
Gain  4.1x 
Lamp  14.90% 
 
X63 
Exposure  1.6ms 
Gain  4.4x 
Lamp  39.61%  
174 
 
    
175 
 
Chapter 8:  References 
AGUZZI, A., BAUMANN, F. & BREMER, J. 2008. The prion's elusive reason for 
being. Annual Review of Neuroscience, 31, 439-477. 
ALEXANDER, J. J., ANDERSON, A. J., BARNUM, S. R., STEVENS, B. & 
TENNER, A. J. 2008. The complement cascade: Yin-yang in neuroinflammation 
- neuro-protection and -degeneration. Journal of Neurochemistry, 107, 1169-
1187. 
ARAQUE, A., PARPURA, V., SANZGIRI, R. P. & HAYDON, P. G. 1999. Tripartite 
synapses: Glia, the unacknowledged partner. Trends in Neurosciences, 22, 208-
215. 
ARENDT, T. 2009. Synaptic degeneration in alzheimer‟s disease. Acta 
Neuropathologica, 118, 167-179. 
ARLAUD, G. J., GABORIAUD, C., THIELENS, N. M., ROSSI, V., BERSCH, B., 
HERNANDEZ, J.-F. & FONTECILLA-CAMPS, J. C. 2001. Structural biology 
of c1: Dissection of a complex molecular machinery. Immunological Reviews, 
180, 136-145. 
ARNOLD, C., REISCH, N., LEIBOLD, C., BECKER, S., PRUFERT, K., SAUTTER, 
K., PALM, D., JATZKE, S., BUCHNER, S. & BUCHNER, E. 2004. Structure-
function analysis of the cysteine string protein in drosophila: Cysteine string, 
linker and c terminus. J Exp Biol, 207, 1323-1334. 
AVIRUTNAN, P., MEHLHOP, E. & DIAMOND, M. S. 2008. Complement and its role 
in protection and pathogenesis of flavivirus infections. Vaccine, 26, I100-I107. 
BABA, H., NAKAHIRA, K., MORITA, N., TANAKA, F., AKITA, H. & IKENAKA, 
K. 1997. Gfap gene expression during development of astrocyte. Developmental 
Neuroscience, 19, 49-57. 
BALLATORE, C., LEE, V. M. Y. & TROJANOWSKI, J. Q. 2007. Tau-mediated 
neurodegeneration in alzheimer's disease and related disorders. Nat Rev 
Neurosci, 8, 663-672. 
BARNUM, S. R. 1995. Complement biosynthesis in the central nervous system. 
Critical Reviews in Oral Biology & Medicine, 6, 132-146. 
BATE, C., GENTLEMAN, S. & WILLIAMS, A. 2010. Alpha-synuclein induced 
synapse damage is enhanced by amyloid-beta(1-42). Molecular 
Neurodegeneration, 5, 55. 
BEAL, M. F. 1998. Mitochondrial dysfunction in neurodegenerative diseases. 
Biochimica et Biophysica Acta (BBA) - Bioenergetics, 1366, 211-223. 
BELL, J. E. & IRONSIDE, J. W. 1993. Neuropathology of spongiform 
encephalopathies in humans. British Medical Bulletin, 49, 738-777. 
BENN, C. L., FOX, H. & BATES, G. P. 2008. Optimisation of region-specific 
reference gene selection and relative gene expression analysis methods for pre-
clinical trials of huntington's disease. Molecular Neurodegeneration, 3, 17-34. 
BERGGREN, K., STEINBERG, T. H., LAUBER, W. M., CARROLL, J. A., LOPEZ, 
M. F., CHERNOKALSKAYA, E., ZIESKE, L., DIWU, Z., HAUGLAND, R. P. 
& PATTON, W. F. 1999. A luminescent ruthenium complex for ultrasensitive 
detection of proteins immobilized on membrane supports. Analytical 
Biochemistry, 276, 129-143. 
BERGGREN, K. N., SCHULENBERG, B., LOPEZ, M. F., STEINBERG, T. H., 
BOGDANOVA, A., SMEJKAL, G., WANG, A. & PATTON, W. F. 2002. An 
improved formulation of sypro ruby protein gel stain: Comparison with the 
original formulation and with a ruthenium ii tris (bathophenanthroline 
disulfonate) formulation. Proteomics, 2, 486-498.  
176 
 
BETMOUNI, S., DEACON, R. M. J., RAWLINS, J. N. P. & FERRY, V. H. 1999. 
Behavioral consequences of prion disease targeted to the hippocampus in a 
mouse model of scrapie. Psychobiology, 27, 63-71. 
BETMOUNI, S., PERRY, V. H. & GORDON, J. L. 1996. Evidence for an early 
inflammatory response in the central nervous system of mice with scrapie. 
Neuroscience, 74, 1-5. 
BLANQUET-GROSSARD, F., THIELENS, N. M., VENDRELY, C., JAMIN, M. & 
ARLAUD, G. J. 2005. Complement protein c1q recognizes a conformationally 
modified form of the prion protein†. Biochemistry, 44, 4349-4356. 
BOBBA, A., PETRAGALLO, V. A., MARRA, E. & ATLANTE, A. 2010. Alzheimer's 
proteins, oxidative stress, and mitochondrial dysfunction interplay in a neuronal 
model of alzheimer's disease. Int J Alzheimers Dis, 2010. 
BOTTO, M., DELL'AGNOLA, C., BYGRAVE, A., THOMPSON, E., COOK, H., 
PETRY, F., LOOS, M., PANDOLFI, P. & WALPORT, M. 1998. Homozygous 
c1q deficiency causes glomerulonephritis associated with multiple apoptotic 
bodies. Nat Genet, 19, 56 - 59. 
BRAHMACHARI, S., FUNG, Y. K. & PAHAN, K. 2006. Induction of glial fibrillary 
acidic protein expression in astrocytes by nitric oxide. J. Neurosci., 26, 4930-
4939. 
BRONK, P., NIE, Z. P., KLOSE, M. K., DAWSON-SCULLY, K., ZHANG, J. H., 
ROBERTSON, R. M., ATWOOD, H. L. & ZINSMAIER, K. E. 2005. The 
multiple functions of cysteine-string protein analyzed at drosophila nerve 
terminals. Journal of Neuroscience, 25, 2204-2214. 
BROWN, D. R., IORDANOVA, I. K., WONG, B.-S., VÉNIEN-BRYAN, C., HAFIZ, 
F., GLASSSMITH, L. L., SY, M.-S., GAMBETTI, P., JONES, I. M., CLIVE, C. 
& HASWELL, S. J. 2000. Functional and structural differences between the 
prion protein from two alleles prnp(a) and prnp(b) of mouse. European Journal 
of Biochemistry, 267, 2452-2459. 
BUÉE, L., BUSSIÈRE, T., BUÉE-SCHERRER, V., DELACOURTE, A. & HOF, P. R. 
2000. Tau protein isoforms, phosphorylation and role in neurodegenerative 
disorders. Brain Research Reviews, 33, 95-130. 
BUELER, H., AGUZZI, A., SAILER, A., GREINER, R. A., AUTENRIED, P., 
AGUET, M. & WEISSMANN, C. 1993. Mice devoid of prp are resistant to 
scrapie. Cell, 73, 1339-1347. 
BUTLER, D., BENDISKE, J., MICHAELIS, M. L., KARANIAN, D. A. & BAHR, B. 
A. 2007. Microtubule-stabilizing agent prevents protein accumulation-induced 
loss of synaptic markers. European Journal of Pharmacology, 562, 20-27. 
CALABRESE, V., LODI, R., TONON, C., D'AGATA, V., SAPIENZA, M., 
SCAPAGNINI, G., MANGIAMELI, A., PENNISI, G., STELLA, A. M. G. & 
BUTTERFIELD, D. A. 2005. Oxidative stress, mitochondrial dysfunction and 
cellular stress response in friedreich's ataxia. Journal of the Neurological 
Sciences, 233, 145-162. 
CALHOUN, M., JUCKER, M., MARTIN, L., THINAKARAN, G., PRICE, D. & 
MOUTON, P. 1996. Comparative evaluation of synaptophysin-based methods 
for quantification of synapses. Journal of Neurocytology, 25, 821-828. 
CENTONZE, D., MUZIO, L., ROSSI, S., CAVASINNI, F., DE CHIARA, V., 
BERGAMI, A., MUSELLA, A., D'AMELIO, M., CAVALLUCCI, V., 
MARTORANA, A., BERGAMASCHI, A., CENCIONI, M. T., DIAMANTINI, 
A., BUTTI, E., COMI, G., BERNARDI, G., CECCONI, F., BATTISTINI, L., 
FURLAN, R. & MARTINO, G. 2009. Inflammation triggers synaptic alteration  
177 
 
and degeneration in experimental autoimmune encephalomyelitis. J. Neurosci., 
29, 3442-3452. 
CHAMBERLAIN, L. H. & BURGOYNE, R. D. 1997. The molecular chaperone 
function of the secretory vesicle cysteine string proteins. Journal of Biological 
Chemistry, 272, 31420-31426. 
CHANDRA, S., GALLARDO, G., FERNANDEZ-CHACON, R., SCHLUTER, O. M. 
& SUDHOF, T. C. 2005. Alpha-synuclein cooperates with csp alpha in 
preventing neurodegeneration. Cell, 123, 383-396. 
CHIH, B., ENGELMAN, H. & SCHEIFFELE, P. 2005. Control of excitatory and 
inhibitory synapse formation by neuroligins. Science, 307, 1324-1328. 
COLEMAN, M. P. & RIBCHESTER, R. R. 2004. Programmed axon death, synaptic 
dysfunction and the ubiquitin proteasome system. Current Drug Targets - CNS 
& Neurological Disorders, 3, 227-238. 
CUNNINGHAM, C., DEACON, R., WELLS, H., BOCHE, D., WATERS, S., DINIZ, 
C. P., SCOTT, H., RAWLINS, J. N. P. & PERRY, V. H. 2003. Synaptic 
changes characterize early behavioural signs in the me7 model of murine prion 
disease. European Journal of Neuroscience, 17, 2147-2155. 
CUNNINGHAM, C., WILCOCKSON, D., BOCHE, D. & PERRY, V. 2005. 
Comparison of inflammatory and acute-phase responses in the brain and 
peripheral organs of the me7 model of prion disease. Journal of Virology, 79, 
5174-5184. 
D'AMELIO, M., CAVALLUCCI, V., MIDDEI, S., MARCHETTI, C., PACIONI, S., 
FERRI, A., DIAMANTINI, A., DE ZIO, D., CARRARA, P., BATTISTINI, L., 
MORENO, S., BACCI, A., AMMASSARI-TEULE, M., MARIE, H. & 
CECCONI, F. 2011. Caspase-3 triggers early synaptic dysfunction in a mouse 
model of alzheimer's disease. Nat Neurosci, 14, 69-76. 
D'ANDREA, M., COLE, G. & ARD, M. 2004. The microglial phagocytic role with 
specific plaque types in the alzheimer disease brain. Neurobiol Aging, 25, 675 - 
683. 
DAUER, W. & PRZEDBORSKI, S. 2003. Parkinson's disease: Mechanisms and 
models. Neuron, 39, 889-909. 
DAWSON, H. N., CANTILLANA, V., JANSEN, M., WANG, H., VITEK, M. P., 
WILCOCK, D. M., LYNCH, J. R. & LASKOWITZ, D. T. 2010. Loss of tau 
elicits axonal degeneration in a mouse model of alzheimer's disease. 
Neuroscience, 169, 516-531. 
DE VOS, K. J., GRIERSON, A. J., ACKERLEY, S. & MILLER, C. C. J. 2008. Role of 
axonal transport in neurodegenerative diseases. Annual Review of Neuroscience, 
31, 151-173. 
DEFRANCO, A. L., LOCKSLEY, R. M. & ROBERTSON, M. 2007. Immunity: The 
immune response in infectious and inflammatory disease, London, New Science 
Press. 
DOBLE, A. 1999. The role of excitotoxicity in neurodegenerative disease: Implications 
for therapy. Pharmacology & Therapeutics, 81, 163-221. 
DUNCKLEY, T., COON, K. D. & STEPHAN, D. A. 2005. Discovery and development 
of biomarkers of neurological disease. Drug Discovery Today, 10, 326-334. 
DZIEDZIC, T., METZ, I., DALLENGA, T., KÖNIG, F. B., MÜLLER, S., 
STADELMANN, C. & BRÜCK, W. 2010. Wallerian degeneration: A major 
component of early axonal pathology in multiple sclerosis. Brain Pathology, 20, 
976-985.  
178 
 
ECKERT, A., KEIL, U., MARQUES, C. A., BONERT, A., FREY, C., SCHÜSSEL, K. 
& MÜLLER, W. E. 2003. Mitochondrial dysfunction, apoptotic cell death, and 
alzheimer's disease. Biochemical Pharmacology, 66, 1627-1634. 
ERLICH, P., DUMESTRE-PÉRARD, C., LING, W. L., LEMAIRE-VIEILLE, C., 
SCHOEHN, G., ARLAUD, G. J., THIELENS, N. M., GAGNON, J. & 
CESBRON, J.-Y. 2010. Complement protein c1q forms a complex with 
cytotoxic prion protein oligomers. Journal of Biological Chemistry, 285, 19267-
19276. 
EVANS, G. J. O., MORGAN, A. & BURGOYNE, R. D. 2003. Tying everything 
together: The multiple roles of cysteine string protein (csp) in regulated 
exocytosis. Traffic, 4, 653-659. 
FAN, R. & TENNER, A. 2004. Complement c1q expression induced by abeta in rat 
hippocampal organotypic slice cultures. Exp Neurol, 185, 241 - 253. 
FERGUSON, R. E., CARROLL, H. P., HARRIS, A., MAHER, E. R., SELBY, P. J. & 
BANKS, R. E. 2005. Housekeeping proteins: A preliminary study illustrating 
some limitations as useful references in protein expression studies. Proteomics, 
5, 566-571. 
FERNÁNDEZ-CHACÓN, R., WÖLFEL, M., NISHIMUNE, H., TABARES, L., 
SCHMITZ, F., CASTELLANO-MUÑOZ, M., ROSENMUND, C., 
MONTESINOS, M., SANES, J. & SCHNEGGENBURGER, R. 2004. The 
synaptic vesicle protein csp prevents presynaptic degeneration. Neuron, 42, 
237–251. 
FISCHER, B., SCHMOLL, H., RIEDERER, P., BAUER, J., PLATT, D. & POPA-
WAGNER, A. 1995. Complement c1q and c3 mrna expression in the frontal 
cortex of alzheimer's patients. J Mol Med, 73, 465 - 471. 
FLORES-LANGARICA, A., SEBTI, Y., MITCHELL, D. A., SIM, R. B. & 
MACPHERSON, G. G. 2009. Scrapie pathogenesis: The role of complement 
c1q in scrapie agent uptake by conventional dendritic cells. Journal of 
Immunology, 182, 1305-1313. 
FONSECA, M., KAWAS, C., TRONCOSO, J. & TENNER, A. 2004a. Neuronal 
localization of c1q in preclinical alzheimer's disease. Neurobiol Dis, 15, 40 - 46. 
FONSECA, M. I., ZHOU, J., BOTTO, M. & TENNER, A. J. 2004b. Absence of c1q 
leads to less neuropathology in transgenic mouse models of alzheimer's disease. 
Journal of Neuroscience, 24, 6457-6465. 
FORNAI, F., FERRUCCI, M., GESI, M., DI POGGIO, A. B., GIORGI, F. S., 
BIAGIONI, F. & PAPARELLI, A. 2006. A hypothesis on prion disorders: Are 
infectious, inherited, and sporadic causes so distinct? Brain Research Bulletin, 
69, 95-100. 
FRANK-CANNON, T., ALTO, L., MCALPINE, F. & TANSEY, M. 2009. Does 
neuroinflammation fan the flame in neurodegenerative diseases? Molecular 
Neurodegeneration, 4, 47. 
FREUND, T. F. & BUZSAKI, G. 1996. Interneurons of the hippocampus. 
Hippocampus, 6, 347-470. 
FUCHS, E. C., ZIVKOVIC, A. R., CUNNINGHAM, M. O., MIDDLETON, S., 
LEBEAU, F. E. N., BANNERMAN, DAVID M., ROZOV, A., 
WHITTINGTON, M. A., TRAUB, R. D., RAWLINS, J. N. P. & MONYER, H. 
2007. Recruitment of parvalbumin-positive interneurons determines 
hippocampal function and associated behavior. 53, 591-604. 
GARCIA-JUNCO-CLEMENTE, P., CANTERO, G., GOMEZ-SANCHEZ, L., 
LINARES-CLEMENTE, P., MARTINEZ-LOPEZ, J. A., LUJAN, R. & 
FERNANDEZ-CHACON, R. 2010. Cysteine string protein-alpha prevents  
179 
 
activity-dependent degeneration in gabaergic synapses. Journal of Neuroscience, 
30, 7377-7391. 
GARCIA-VALENZUELA, E., SHAREEF, S., WALSH, J. & SHARMA, S. C. 1995. 
Programmed cell death of retinal ganglion cells during experimental glaucoma. 
Experimental Eye Research, 61, 33-44. 
GILLINGWATER, T. H., INGHAM, C. A., PARRY, K. E., WRIGHT, A. K., HALEY, 
J. E., WISHART, T. M., ARBUTHNOTT, G. W. & RIBCHESTER, R. R. 2006. 
Delayed synaptic degeneration in the cns of wlds mice after cortical lesion. 
Brain, 129, 1546-1556. 
GOLDSMITH, S., WALS, P., ROZOVSKY, I., MORGAN, T. & FINCH, C. 1997. 
Kainic acid and decorticating lesions stimulate the synthesis of c1q protein in 
adult rat brain. J Neurochem, 68, 2046 - 2052. 
GRAY, B. C., SISKOVA, Z., PERRY, V. H. & O'CONNOR, V. 2009. Selective 
presynaptic degeneration in the synaptopathy associated with me7-induced 
hippocampal pathology. Neurobiology of Disease, 35, 63-74. 
GREAVES, J., SALAUN, C., FUKATA, Y., FUKATA, M. & CHAMBERLAIN, L. H. 
2008. Palmitoylation and membrane interactions of the neuroprotective 
chaperone cysteine-string protein. Journal of Biological Chemistry, 283, 25014-
25026. 
GREER, S., HONEYWELL, R., GELETU, M., ARULANANDAM, R. & RAPTIS, L. 
2010. Housekeeping genes; expression levels may change with density of 
cultured cells. Journal of Immunological Methods, In Press, Corrected Proof. 
GUNDERSEN, C. B., KOHAN, S. A., SOUDA, P., WHITELEGGE, J. P. & 
UMBACH, J. A. 2010. Cysteine string protein beta is prominently associated 
with nerve terminals and secretory organelles in mouse brain. Brain Research, 
1332, 1-11. 
GUZIK, B. W. & GOLDSTEIN, L. S. B. 2004. Microtubule-dependent transport in 
neurons: Steps towards an understanding of regulation, function and 
dysfunction. Current Opinion in Cell Biology, 16, 443-450. 
HAGIWARA, M., KOBAYASHI, K.-I., TADOKORO, T. & YAMAMOTO, Y. 2009. 
Application of sypro ruby- and flamingo-stained polyacrylamide gels to western 
blot analysis. Analytical Biochemistry, 389, 171-173. 
HALL, G. F., CHU, B., LEE, G. & YAO, J. 2000. Human tau filaments induce 
microtubule and synapse loss in an in vivo model of neurofibrillary degenerative 
disease. Journal of Cell Science, 113, 1373-1387. 
HARRIS, D. A. & TRUE, H. L. 2006. New insights into prion structure and toxicity. 
Neuron, 50, 353-357. 
HEBERT, L. E., SCHERR, P. A., BECKETT, L. A., ALBERT, M. S., PILGRIM, D. 
M., CHOWN, M. J., FUNKENSTEIN, H. H. & EVANS, D. A. 1995. Age-
specific incidence of alzheimer's disease in a community population. JAMA, 
273, 1354-1359. 
HEGDE, A. N. & DIANTONIO, A. 2002. Ubiquitin and the synapse. Nat Rev Neurosci, 
3, 854-61. 
HEINONEN, O., SOININEN, H., SORVARI, H., KOSUNEN, O., PALJÄRVI, L., 
KOIVISTO, E. & RIEKKINEN, P. J. 1995. Loss of synaptophysin-like 
immunoreactivity in the hippocampal formation is an early phenomenon in 
alzheimer's disease. Neuroscience, 64, 375-384. 
HOOKS, B. M. & CHEN, C. 2006. Distinct roles for spontaneous and visual activity in 
remodeling of the retinogeniculate synapse. 52, 281-291.  
180 
 
INGRAM, G., HAKOBYAN, S., ROBERTSON, N. P. & MORGAN, B. P. 2009. 
Complement in multiple sclerosis: Its role in disease and potential as a 
biomarker. Clinical & Experimental Immunology, 155, 128-139. 
JEFFREY, M., HALLIDAY, W. G., BELL, J., JOHNSTON, A. R., MACLEOD, N. K., 
INGHAM, C., SAYERS, A. R., BROWN, D. A. & FRASER, J. R. 2000. 
Synapse loss associated with abnormal prp precedes neuronal degeneration in 
the scrapie-infected murine hippocampus. Neuropathology and Applied 
Neurobiology, 26, 41-54. 
JEFFREY, M., MARTIN, S., BARR, J., CHONG, A. & FRASER, J. R. 2001. Onset of 
accumulation of prpresin murine me7 scrapie in relation to pathological and prp 
immunohistochemical changes. Journal of Comparative Pathology, 124, 20-28. 
JONES, S. & YAKEL, J. 1999. Inhibitory interneurons in hippocampus. Cell 
Biochemistry and Biophysics, 31, 207-218. 
JUCKER, M. 2010. The benefits and limitations of animal models for translational 
research in neurodegenerative diseases. Nat Med, 16, 1210-1214. 
KALLIOPI STASI, D. N., XIAOYAN YANG, RONG-FANG WANG LIZHEN REN, 
STEVEN M. PODOS, THOM MITTAG, AND JOHN DANIAS 2006. 
Complement component 1q (c1q) upregulation in retina of murine, primate, and 
human glaucomatous eyes. Investigative Ophthalmology & Visual Science, 47, 
1024-1029. 
KERMAN, A., LIU, H.-N., CROUL, S., BILBAO, J., ROGAEVA, E., ZINMAN, L., 
ROBERTSON, J. & CHAKRABARTTY, A. 2010. Amyotrophic lateral 
sclerosis is a non-amyloid disease in which extensive misfolding of sod1 is 
unique to the familial form. Acta Neuropathologica, 119, 335-344. 
KIM, S. U. & NAGAI, A. 2010. Microglia as immune effectors of the central nervous 
system: Expression of cytokines and chemokines. Clinical and Experimental 
Neuroimmunology, 1, 61-69. 
KINGSBURY, D. T. 1990. Genetics of response to slow virus (prion) infection. Annual 
Review of Genetics, 24, 115-132. 
KLEIN, M. A., KAESER, P. S., SCHWARZ, P., WEYD, H., XENARIOS, I., 
ZINKERNAGEL, R. M., CARROLL, M. C., VERBEEK, J. S., BOTTO, M., 
WALPORT, M. J., MOLINA, H., KALINKE, U., ACHA-ORBEA, H. & 
AGUZZI, A. 2001. Complement facilitates early prion pathogenesis. Nature 
Medicine, 7, 488-492. 
KORHONEN, L. & LINDHOLM, D. 2004. The ubiquitin proteasome system in 
synaptic and axonal degeneration. The Journal of Cell Biology, 165, 27-30. 
KOVACS, G. G., GASQUE, P., STROBEL, T., LINDECK-POZZA, E., 
STROHSCHNEIDER, M., IRONSIDE, J. W., BUDKA, H. & GUENTCHEV, 
M. 2004. Complement activation in human prion disease. Neurobiology of 
Disease, 15, 21-28. 
KREUTZBERG, G. W. 1996. Microglia: A sensor for pathological events in the cns. 
Trends in Neurosciences, 19, 312-318. 
LAMONTE, B. H., WALLACE, K. E., HOLLOWAY, B. A., SHELLY, S. S., 
ASCANO, J., TOKITO, M., VAN WINKLE, T., HOWLAND, D. S. & 
HOLZBAUR, E. L. 2002. Disruption of dynein/dynactin inhibits axonal 
transport in motor neurons causing late-onset progressive degeneration. Neuron, 
34, 715-27. 
LANNE, B. & PANFILOV, O. 2005. Protein staining influences the quality of mass 
spectra obtained by peptide mass fingerprinting after separation on 2-d gels. A 
comparison of staining with coomassie brilliant blue and sypro ruby. Journal of 
Proteome Research, 4, 175-179.  
181 
 
LEE, H.-G., MOREIRA, P. I., ZHU, X., SMITH, M. A. & PERRY, G. 2004. Staying 
connected: Synapses in alzheimer disease. Am J Pathol, 165, 1461-1464. 
LEE, S., MALER, L. & DUNN, R. J. 2000. Differential expression of the psd-95 gene 
family in electrosensory neurons. The Journal of Comparative Neurology, 426, 
429-440. 
LI, J.-Y., PLOMANN, M. & BRUNDIN, P. 2003. Huntington's disease: A 
synaptopathy? Trends in Molecular Medicine, 9, 414-420. 
LIU, B. & HONG, J.-S. 2003. Role of microglia in inflammation-mediated 
neurodegenerative diseases: Mechanisms and strategies for therapeutic 
intervention. Journal of Pharmacology and Experimental Therapeutics, 304, 1-
7. 
LOEFFLER, D., CAMP, D. & CONANT, S. 2006. Complement activation in the 
parkinson's disease substantia nigra: An immunocytochemical study. Journal of 
Neuroinflammation, 3, 29. 
MABBOTT, N. A., BRUCE, M. E., BOTTO, M., WALPORT, M. J. & PEPYS, M. B. 
2001. Temporary depletion of complement component c3 or genetic deficiency 
of c1q significantly delays onset of scrapie. Nature Medicine, 7, 485-487. 
MARAGAKIS, N. J. & ROTHSTEIN, J. D. 2006. Mechanisms of disease: Astrocytes 
in neurodegenerative disease. Nat Clin Pract Neuro, 2, 679-689. 
MATTSON, M. & CHAN, S. 2002. Cysteine proteases, synaptic degeneration and 
neuroodegenerative disorders. In: LAJTHA, A. & BANIK, N. L. (eds.) Role of 
proteases in the pathophysiology of neurodegenerative diseases. Springer US. 
MATTSON, M. P. 2000. Apoptosis in neurodegenerative disorders. Nat Rev Mol Cell 
Biol, 1, 120-9. 
MATTSON, M. P. & DUAN, W. 1999. “apoptotic” biochemical cascades in synaptic 
compartments: Roles in adaptive plasticity and neurodegenerative disorders. 
Journal of Neuroscience Research, 58, 152-166. 
MCGEER, P. L. & MCGEER, E. G. 1995. The inflammatory response system of brain: 
Implications for therapy of alzheimer and other neurodegenerative diseases. 
Brain Research Reviews, 21, 195-218. 
MCMAHON, H. T., BOLSHAKOV, V. Y., JANZ, R., HAMMER, R. E., 
SIEGELBAUM, S. A. & SÜDHOF, T. C. 1996. Synaptophysin, a major 
synaptic vesicle protein, is not essential for neurotransmitter release. 
Proceedings of the National Academy of Sciences of the United States of 
America, 93, 4760-4764. 
MILLER, L. C., SWAYNE, L. A., CHEN, L., FENG, Z.-P., WACKER, J. L., 
MUCHOWSKI, P. J., ZAMPONI, G. W. & BRAUN, J. E. A. 2003. Cysteine 
string protein (csp) inhibition of n-type calcium channels is blocked by mutant 
huntingtin. Journal of Biological Chemistry, 278:, 53072-53081. 
NADEAU, S. & RIVEST, S. 2001. The complement system is an integrated part of the 
natural innate immune response in the brain. Faseb Journal, 15, 1410-1433. 
NAGAO, M., MISAWA, H., KATO, S. & HIRAI, S. 1998. Loss of cholinergic 
synapses on the spinal motor neurons of amyotrophic lateral sclerosis. Journal 
of Neuropathology & Experimental Neurology, 57, 329-333. 
NALEPA, G., ROLFE, M. & HARPER, J. W. 2006. Drug discovery in the ubiquitin-
proteasome system. Nat Rev Drug Discov, 5, 596-613. 
NATAF, S., CARROLL, S. L., WETSEL, R. A., SZALAI, A. J. & BARNUM, S. R. 
2000. Attenuation of experimental autoimmune demyelination in complement-
deficient mice. J Immunol, 165, 5867-5873.  
182 
 
NAUTA, A. J., ROOS, A. & DAHA, M. R. 2004. A regulatory role for complement in 
innate immunity and autoimmunity. International Archives of Allergy and 
Immunology, 134, 310-323. 
PAUL, W. E. 2008. Complement. In: PAUL, W. E. (ed.) Fundamental immunology. 
Sixth ed.: Wolters Kluwer. 
PEKNY, M. & NILSSON, M. 2005. Astrocyte activation and reactive gliosis. Glia, 50, 
427-434. 
PHAM-HUY, L. A., HE, H. & PHAM-HUY, C. 2008. Free radicals, antioxidants in 
disease and health. Int. J. Biomed. Sci., 4(2), 89-96. 
PORTER, A. G. & JANICKE, R. U. 1999. Emerging roles of caspase-3 in apoptosis. 
Cell Death Differ, 6, 99-104. 
RODRIGUEZ, J. J., WITTON, J., OLABARRIA, M., NORISTANI, H. N. & 
VERKHRATSKY, A. 2010. Increase in the density of resting microglia 
precedes neuritic plaque formation and microglial activation in a transgenic 
model of alzheimer's disease. Cell Death and Dis, 1, e1. 
ROSENTHAL, N. & BROWN, S. 2007. The mouse ascending: Perspectives for human-
disease models. Nat Cell Biol, 9, 993-999. 
ROSS, C. A. & POIRIER, M. A. 2004. Protein aggregation and neurodegenerative 
disease. Nature Reviews Neuroscience, S10-S17. 
ROZAS, J. L., GOMEZ-SANCHEZ, L., TOMAS-ZAPICO, C., LUCAS, J. J. & 
FERNANDEZ-CHACON, R. 2010. Presynaptic dysfunction in huntington's 
disease. Biochemical Society Transactions, 38, 488-492. 
RUBINSZTEIN, D. C. 2006. The roles of intracellular protein-degradation pathways in 
neurodegeneration. Nature, 443, 780-786. 
RUS, H., CUDRICI, C., DAVID, S. & NICULESCU, F. 2006. The complement system 
in central nervous system diseases. Autoimmunity, 39, 395-402. 
SALMINEN, A., OJALA, J., KAUPPINEN, A., KAARNIRANTA, K. & SUURONEN, 
T. 2009. Inflammation in alzheimer's disease: Amyloid-[beta] oligomers trigger 
innate immunity defence via pattern recognition receptors. Progress in 
Neurobiology, 87, 181-194. 
SANGHERA, N., WALL, M., VENIEN-BRYAN, C. & PINHEIRO, T. J. T. 2008. 
Globular and pre-fibrillar prion aggregates are toxic to neuronal cells and 
perturb their electrophysiology. Biochimica Et Biophysica Acta-Proteins and 
Proteomics, 1784, 873-881. 
SAXENA, S., CABUY, E. & CARONI, P. 2009. A role for motoneuron subtype-
selective er stress in disease manifestations of fals mice. Nat Neurosci, 12, 627-
636. 
SCALLET, A. C. & YE, X. 1997. Excitotoxic mechanisms of neurodegeneration in 
transmissible spongiform encephalopathies. Annals of the New York Academy of 
Sciences, 825, 194-205. 
SELKOE, D. J. 2002. Alzheimer's disease is a synaptic failure. Science, 298, 789-791. 
SERESS, L. & RIBAK, C. E. 1988. The development of gabaergic neurons in the rat 
hippocampal formation. An immunocytochemical study. Developmental Brain 
Research, 44, 197-209. 
SHEN, Y. & MERI, S. 2003. Yin and yang: Complement activation and regulation in 
alzheimer's disease. Progress in Neurobiology, 70, 463-472. 
SHENG, M. & SALA, C. 2001. Pdz domains and the organization of supramolecular 
complexes. Annual Review of Neuroscience, 24, 1-29. 
SIM, R. B., KISHORE, U., VILLIERS, C. L., MARCHE, P. N. & MITCHELL, D. A. 
Year. C1q binding and complement activation by prions and amyloids. In:  6th 
International Workshop on the First Component of Complement C1 and  
183 
 
Collectins, Jun 2006 Seeheim, GERMANY. Elsevier Gmbh, Urban & Fischer 
Verlag, 355-362. 
SIMONIAN, N. A. & COYLE, J. T. 1996. Oxidative stress in neurodegenerative 
diseases. Annual Review of Pharmacology and Toxicology, 36, 83-106. 
SIMPSON, R. J. 2006. Fluorescent staining of proteins with sypro ruby. Cold Spring 
Harb Protoc, 2006. 
SINGHRAO, S. K., NEAL, J. W., MORGAN, B. P. & GASQUE, P. 1999. Increased 
complement biosynthesis by microglia and complement activation on neurons in 
huntington's disease. Experimental Neurology, 159, 362-376. 
SINGHRAO, S. K., NEAL, J. W., RUSHMERE, N. K., MORGAN, B. P. & GASQUE, 
P. 2000. Spontaneous classical pathway activation and deficiency of membrane 
regulators render human neurons susceptible to complement lysis. Am J Pathol, 
157, 905-918. 
SISKOVA, Z., PAGE, A., O'CONNOR, V. & PERRY, V. H. 2009. Degenerating 
synaptic boutons in prion disease: Microglia activation without synaptic 
stripping. Am J Pathol, 175, 1610-1621. 
SONG, J.-Y., ICHTCHENKO, K., SÜDHOF, T. C. & BROSE, N. 1999. Neuroligin 1 is 
a postsynaptic cell-adhesion molecule of excitatory synapses. Proceedings of the 
National Academy of Sciences of the United States of America, 96, 1100-1105. 
SOTO, C. & CASTILLA, J. 2004. The controversial protein-only hypothesis of prion 
propagation. Nature Reviews Neuroscience, S63-S67. 
SPILLANTINI, M. G., SCHMIDT, M. L., LEE, V. M. Y., TROJANOWSKI, J. Q., 
JAKES, R. & GOEDERT, M. 1997. [alpha]-synuclein in lewy bodies. Nature, 
388, 839-840. 
STA, M., SYLVA-STEENLAND, R. M. R., CASULA, M., DE JONG, J. M. B. V., 
TROOST, D., ARONICA, E. & BAAS, F. 2011. Innate and adaptive immunity 
in amyotrophic lateral sclerosis: Evidence of complement activation. 
Neurobiology of Disease, 42, 211-220. 
STASI, K., NAGEL, D., YANG, X., WANG, R.-F., REN, L., PODOS, S. M., 
MITTAG, T. & DANIAS, J. 2006. Complement component 1q (c1q) 
upregulation in retina of murine, primate, and human glaucomatous eyes. Invest. 
Ophthalmol. Vis. Sci., 47, 1024-1029. 
STEVENS, B., ALLEN, N. J., VAZQUEZ, L. E., HOWELL, G. R., 
CHRISTOPHERSON, K. S., NOURI, N., MICHEVA, K. D., MEHALOW, A. 
K., HUBERMAN, A. D., STAFFORD, B., SHER, A., LITKE, A. M., 
LAMBRIS, J. D., SMITH, S. J., JOHN, S. W. M. & BARRES, B. A. 2007. The 
classical complement cascade mediates cns synapse elimination. Cell, 131, 
1164-1178. 
SWAYNE, L. A., BECK, K. E. & BRAUN, J. E. A. 2006. The cysteine string protein 
multimeric complex. Biochemical and Biophysical Research Communications, 
348, 83-91. 
TENNER, A. J. & PISALYAPUT, K. 2008. Central nervous system diseases and 
inflammation - the complement system in the cns: Thinking again, Springer. 
THACKRAY, A. M., MCKENZIE, A. N., KLEIN, M. A., LAUDER, A. & BUJDOSO, 
R. 2004. Accelerated prion disease in the absence of interleukin-10. Journal of 
Virology, 78, 13697-13707. 
TRAPP, B. D., WUJEK, J. R., CRISTE, G. A., JALABI, W., YIN, X., KIDD, G. J., 
STOHLMAN, S. & RANSOHOFF, R. 2007. Evidence for synaptic stripping by 
cortical microglia. Glia, 55, 360-368. 
VAROQUEAUX, F., JAMAIN, S. & BROSE, N. 2004. Neuroligin 2 is exclusively 
localized to inhibitory synapses. European Journal of Cell Biology, 83, 449-456.  
184 
 
VOGT, J., PAUL, F., AKTAS, O., MÜLLER-WIELSCH, K., DÖRR, J., DÖRR, S., 
BHARATHI, B. S., GLUMM, R., SCHMITZ, C., STEINBUSCH, H., RAINE, 
C. S., TSOKOS, M., NITSCH, R. & ZIPP, F. 2009. Lower motor neuron loss in 
multiple sclerosis and experimental autoimmune encephalomyelitis. Annals of 
Neurology, 66, 310-322. 
WAJANT, H., PFIZENMAIER, K. & SCHEURICH, P. 2003. Tumor necrosis factor 
signaling. Cell Death Differentiation, 10, 45-65. 
WALPORT, M. J. 2001. Advances in immunology: Complement (second of two parts). 
New England Journal of Medicine, 344, 1140-1144. 
WANG, J. & MALDONADO, M. A. 2006. The ubiquitin-proteasome system and its 
role in inflammatory and autoimmune diseases. Cell Mol Immunol, 3, 255-61. 
WATANABE, H., NUMATA, K., ITO, T., TAKAGI, K. & MATSUKAWA, A. 2004. 
Innate immune response in th1- and th2-dominant mouse strains. Shock, 22, 
460-466. 
WISHART, T. M., PARSON, S. H. & GILLINGWATER, T. H. 2006. Synaptic 
vulnerability in neurodegenerative disease. Journal of Neuropathology and 
Experimental Neurology, 65, 733-739. 
WOODRUFF, T. M., COSTANTINI, K. J., TAYLOR, S. M. & NOAKES, P. G. 2009. 
Role of complement in motor neuron disease: Animal models and therapeutic 
potential of complement inhibitors. In: LAMBRIS, J. D. (ed.) Current topics in 
complement ii. Springer New York. 
WOOF, J. M. & BURTON, D. R. 2004. Human antibody - fc receptor interactions 
illuminated by crystal structures. Nature Reviews Immunology, 4, 89-99. 
YAMADA, J., HAYASHI, Y., JINNO, S., WU, Z., INOUE, K., KOHSAKA, S. & 
NAKANISHI, H. 2008. Reduced synaptic activity precedes synaptic stripping in 
vagal motoneurons after axotomy. Glia, 56, 1448-1462. 
ZIPFEL, P. F. 2009. Complement and immune defense: From innate immunity to 
human diseases. Immunology Letters, 126, 1-7. 
 
 